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Abstract 
 
Rett syndrome (RTT), a disorder caused almost exclusively by mutations in the X-
linked gene, MECP2, has a clinical phenotype thought to be primarily of 
neurological origin. Disruption of Mecp2 in mice results in a prominent RTT-like 
phenotype and Mecp2 knock-out animal models provide an excellent platform for 
investigating the role of MeCP2 in the brain development. In this thesis, I used 
the Mecp2-stop mouse model to address the effects of MeCP2 deficiency in the 
central nervous system. First, I assessed the genotype-phenotype relationship at 
the level of the whole organism by detailed temporal mapping of the RTT-like 
neurological signs. I also addressed the genotype-phenotype relationship at the 
level of neuronal networks by assessing alterations in neuronal (cortical) density 
including potential alterations across morphologically discrete cell subtypes. 
Finally, I also investigated the genotype-phenotype relationship at the level of 
the synapse by assessing RTT-related changed in synaptic plasticity. 
Whole organism phenotyping using observational scoring revealed the male 
hemizygous Mecp2-mutant mice (Mecp2
stop/y) to show an early (from ~5 weeks) 
and aggressive onset of signs including locomotor and other general features. 
Correlated studies at the level of the synapse revealed the severity of gross 
organismal pathology to mirror a progressive decline in both short- and long-
term forms of synaptic plasticity as measured in the CA1 region of the 
hippocampus. Specifically, extracellular field recordings in acute hippocampal 
slices from strongly symptomatic Mecp2-stop mice showed long-term plasticity 
(LTP) at the Schaffer-collateral-to-CA1 pyramidal synapse to be 40.2 ± 1.6 % of 
age-matched wild-type littermate controls. In addition, putative presynaptic 
short-term forms of plasticity (post-tetanic potentiation (PTP) and paired-pulse 
facilitation (PPF)) were also decreased in the Mecp2-stop hippocampus (45 ± 
18.8 % and 78 ± 0.1 % of wild type for PTP and PPF respectively; all p<0.05). 
Moreover, the impairment in LTP was associated with symptom severity score 
whereby mice with a more ‘severe’ symptom score showed a more profound 
deficit in LTP.   
Refined axon stimulation protocols revealed evidence of pronounced LTP 
saturation in symptomatic Mecp2
stop/y mice, suggesting an LTP ‘ceiling’ effect. I 3 
therefore assessed the action of the weak NMDA receptor blocker memantine, 
shown previously to reverse LTP saturation-related LTP deficits, in the 
hippocampus of control and Mecp2-stop mice. Application of memantine (1μM), 
resulted in substantial reversal of short-term plasticity deficits in the Mecp2-
stop samples, without affecting plasticity in wild-type mice. However, systemic 
administration of memantine (30mg/Kg) in vivo did not have any observable 
effect on RTT-like phenotype at the organismal level including symptom onset, 
progression and survival.  
Utilising immunohistochemistry (NeuN) and histological staining (DAPI) to 
quantify cell density in layer five of the somatosensory cortex, I demonstrated 
that the symptomatic Mecp2-stop mouse had a higher cortical cell density 
compared to wild-type controls (1.28 times of whole cortical cell density and 
1.41 times of neuronal cell density). Detailed analyses of distinct neuronal 
subpopulations (parvalbumin-, somatostatin-, calretinin- and calbindin-
immunopositive cells) showed that calretinin (CR)- and somatostatin (SOM)- 
immunopositive cells had a lower cell density in Mecp2-stop mouse 
somatosensory cortex. However, the distribution patterns of different neuronal 
subtypes (using the same markers) in Mecp2-stop hippocampus were preserved 
and were grossly similar to those of WT brains.  
In summary, in this thesis, I demonstrated that the cell densities of CR- and 
SOM- positive neurons were altered in the somatosensory cortex in symptomatic 
Mecp2-stop mice. At the synaptic functional level, I showed both short-term and 
long-term plasticity deficits in the hippocampus of Mecp2-stop brains. 
Memantine, a clinically widely-used Alzheimer drug, partially restored the 
synaptic plasticity deficits in vitro. These data together supported that deficits 
in specific neuronal populations and progressive functional synaptic impairment 
may be key features in the RTT brain and also demonstrated the potential for 
the pharmacological restoration of synaptic plasticity function.4 
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1  Introduction 
1.1 General introduction 
Rett syndrome is a postnatal progressive neurological disorder that alters normal 
brain development during early childhood. Brain development is a complicated 
but highly organised process. It includes the processes that generate, shape, and 
reshape the nervous system, from the earliest stages of embryogenesis to the 
final years of life. At the embryonic stage, the brain emerges as the neural tube. 
The anterior part of the neural tube is the telencephalon, which later expands 
rapidly and eventually gives rise to the brain. Newly-generated neurons migrate 
to different parts of the developing brain and are organised into different brain 
structures. After neurons immigrate to their designated regions, they project 
axons and dendrites and connect with each other via synapses to form networks. 
The synaptic connection between neurons is the foundation of functional neural 
circuits that mediate sensory and motor processing and underlie behaviour. Most 
essential neurodevelopment occurs in the first five to ten years of human life. 
Therefore, it is not surprising that most prevalent neurodevelopmental disorders 
have early onsets, and symptoms can involve motor, sensory, autonomic or 
higher cognitive dysfunctions. Rett syndrome is a neurodevelopmental disorder 
and represents a significant cause of mental retardation in girls. Genetic studies 
have revealed that Rett syndrome is due to the mutation of MECP2 (Amir et al., 
1999), and knock-out animal models provide an excellent platform for 
investigating the role of MECP2 in brain development. In this thesis, I used the 
Mecp2-stop mouse model to assess the genotype-phenotype relationship and the 
progress patterns of symptoms. At the cellular level, I quantified alterations in 
neuronal subtype densities and their distributions in the brain, and finally 
evaluated synaptic functions in the RTT brain to further realise the pathologic 
mechanism which underlies Rett syndrome.     16 
1.2 Rett syndrome 
Rett syndrome (RTT; MIM 312750) was first identified by Dr Andreas Rett in 1966, 
after he observed twenty-two patients with similar unique symptoms (Rett, 
1966). The constellation of features that represent RTT became more widely 
recognized as a specific neurodevelopmental disorder after subsequent larger 
studies by Dr Bengt Hagberg (Hagberg et al., 1983). In 1999, Amir et al. 
discovered the genetic basis of RTT (>95% of cases of classical RTT) to be 
mutations in the gene MECP2 (Amir et al., 1999). A few years earlier, Dr Adrian 
Bird and his colleagues identified MeCP2 (methyl-CpG binding protein 2) as a 
novel protein that binds to methylated CpG dinucleotides within the mammalian 
genome (Lewis et al., 1992). Methylation of CpGs is associated with gene 
silencing and alterations in chromatin structure. Whilst the exact function of 
MeCP2 is still not known, it is an abundant nuclear protein and is considered 
likely to regulate gene expression, whether through the silencing or activation of 
specific genes or through more global regulation of transcriptional processes 
(Klose & Bird, 2006; Chahrour et al., 2008; Skene et al., 2010). 
An important feature in the aetiology of RTT is the fact that MECP2 is located on 
the X chromosome, Xq28 (Quaderi et al., 1994). Most mutations are sporadic and 
rarely inherited. Moreover, mutations in males typically result in severe infantile 
encephalopathy due to complete absence of functional MeCP2. In contrast, 
females are heterozygous for the mutation with, due to X chromosome 
inactivation, approximately half of the cells expressing the mutant MECP2 allele 
but with the other half expressing a functional allele. Thus, RTT is a disease that 
is almost exclusively seen in females. 
1.2.1 Clinical Features of RTT 
Rett syndrome is a predominantly neurological disorder and a primary cause of 
severe mental retardation in girls with an incidence of approximately 1 in 10,000 
female births (Neul et al., 2010). Patients with RTT appear to develop normally 
up to 6–18 months of age. They typically achieve normal 
neurodevelopmental milestones, from gross and fine motor functions to social 
communication skills. The head circumference of Rett girls is normal at birth; 
however, it begins to decelerate in its growth at 2 to 3 months of age (Schultz et     17 
al., 1993). Distinctive aspects contributing to the diagnosis include 
developmental regression, with accompanying loss of hand skills, mobility skills 
and speech, and stereotypical hand movements. As the syndrome progresses, 
social withdrawal and loss of language become apparent with features 
reminiscent of autism (Nomura, 2005). The onset of mental deterioration is 
accompanied by loss of motor coordination and the development of ataxia and 
gait apraxia. Associated features, such as microcephaly, respiratory/autonomic 
abnormalities (Julu et al., 2001), seizures, scoliosis, growth deficits and early 
hypotonia, are very prevalent. 
Among these symptoms, the most significant is seizure disorder, which ranges 
from simple convulsion to intractable epilepsy (Jian et al., 2006). 
Neurophysiological evaluations show cortical hyperexcitability on the 
electroencephalogram (EEG), which represents a loss of expected developmental 
features and the occurrence of rhythmic slow activity, primarily in the frontal-
central regions. However, most events presumed to be seizures are without EEG 
correlation during video-EEG recording (Percy, 2008). Other associated 
abnormalities during the post-regression phase include teeth grinding, night 
laughing or crying, screaming fits, low mood, and anxiety episodes elicited by 
distressful external events (Mount et al., 2001). Most girls with RTT lose mobility, 
and are often wheelchair-bound during their teenage years. Impairment of the 
autonomic nervous system in Rett syndrome is suggested by an increased 
incidence of long Q–T intervals during electrocardiographic recordings, and this 
can contribute to the higher incidence rate of sudden unexpected death in RTT 
patients. Other autonomic abnormalities include hypotrophy, cold blue feet, 
severe constipation, oropharyngeal dysfunction, and cardiac abnormalities, 
including tachycardia and sinus bradycardia. Even with high risk of sudden death 
due to respiratory and cardiac dysfunctions, several patients survive till the sixth 
or seventh decade of life with limited mobility (Hagberg, 2005). 
1.2.2 Genetic Basis of RTT 
RTT cases are usually the result of dominantly-acting sporadic mutations in the 
X-linked gene MECP2, which encodes methyl-CpG-binding protein 2 (MeCP2) 
(Amir et al., 1999). MeCP2 is expressed quite widely throughout the body, with 
notably high expression in postnatal neurons (LaSalle et al., 2001; Shahbazian et     18 
al., 2002; Zhou et al., 2006). However, the question remains as to why 
disruption of a ubiquitously expressed protein results in a predominantly 
neurological phenotype (Zhou et al., 2006). Most pathogenic mutations in MECP2 
cause RTT in heterozygous females, while mutations leading to other phenotypic 
outcomes are also known (Moretti & Zoghbi, 2006). Since most RTT cases are 
sporadic, it was difficult to map the disease locus by traditional linkage analysis. 
Instead, using information from families under the rare circumstances in which 
the mutant MECP2 is inherited, the Xq28 region was identified, and subsequent 
screening of candidate genes in RTT patients revealed mutations in MECP2 (Amir 
et al., 1999). Boys inheriting a mutant MECP2 allele are much more severely 
affected, presenting with infantile encephalopathy and usually not surviving 
infancy. Since most MECP2 mutations leading to RTT involve loss of function of 
the mutant allele, RTT can be modelled using gene knockout mice that 
recapitulate many of the key clinical signs that characterize RTT in humans 
(Chen et al., 2001; Guy et al., 2007). 
MECP2 is located on the X chromosome and is subject to X chromosome 
inactivation (XCI), such that in each cell in a heterozygous female RTT patient 
expresses only the normal or the mutant MECP2 allele. The XCI process is 
random and results in an approximately 50:50 phenotypic mixture of cells. 
Previous studies of the distribution pattern of brain cells expressing normal and 
mutant MECP2 alleles have revealed that MeCP2-negative cells tend not to be 
clustered and are well-mixed with MeCP2-positive cells in a mosaic pattern (Guy 
et al., 2007). However, a number of studies have reported that the skewing of 
XCI ratio is away from 50:50 in RTT patients (Knudsen et al., 2006; Schanen et 
al., 1997). It is well-known that several rare familial cases of RTT are attributed 
to that mothers of these patients carry the causative mutation, but are highly 
skewed towards expression of the normal allele (Villard et al., 2001). A study 
investigating the skewing phenomenon of XCI in sporadic RTT cases (Archer et 
al., 2007) revealed that most RTT patients had degrees of skewing towards 
expression of the normal allele and this phenomenon could partially explain the 
phenotypic variability of RTT. The tendency that MeCP2-positive cells are 
generated more or survive longer still needs to be verified since most skewing 
studies were conducted in peripheral tissues with a higher cell turnover rate 
rather than in brain regions.     19 
MeCP2 is a member of a family of proteins that bind regions of DNA enriched 
with methylated CpG regions (MBD family) (Hendrich & Bird, 1998). MeCP2 was 
initially identified in rat cells based on its ability to bind methylated DNA and 
was found to bind a single symmetrically methylated CpG independent of 
sequence context (Meehan et al., 1989; Lewis et al., 1992). MeCP2 RNA is 
ubiquitously transcribed in the whole body; however, protein expression shows 
tissue specificity. In the adult mouse, MeCP2 is highly abundant in the brain, 
lung and spleen, less abundant in the kidney and heart, and almost negligible in 
the liver, stomach and small intestine (Shahbazian et al., 2002). The 
quantification of MeCP2 in adult mouse brain has shown nearly 16 million 
molecules of MeCP2 per nucleus in neurons, with almost an order of magnitude 
less in glial cells and 30- fold less in liver cells (Skene et al., 2010). In mice, the 
neuronal MeCP2 level is low at birth and elevates significantly during the first 3 
weeks of life (Kishi & Macklis, 2004; Skene et al., 2010). 
MeCP2 contains six functional domains encoded by exon 3 and 4, including a 
methyl-CpG binding domain (MBD), two high mobility group protein-like domains 
(HMGD), a transcriptional repression domain (TRD) (Nan et al., 1993; Nan et al., 
1997), and two C-terminal domains (CTD) (see structure of MeCP2 and common 
mutation sites in RTT in figure 1.1). The MBD domain is necessary and sufficient 
to bind a single symmetrically methylated CpG in the major groove of DNA, 
covering a region of 12bp surrounding the methyl-CpG site (Nan et al., 1993). 
MeCP2 binds methylated DNA in vitro and in vivo, and is capable of binding to 
DNA in a nucleosomal context without targeted disruption of the nucleosome 
(Nan et al., 1997; Kudo, 1998). The domain responsible for conferring gene 
silencing was mapped to the middle of the protein and defined as the 
transcriptional repression domain (TRD). The TRD overlaps with a nuclear 
localisation signal and is capable of repressing transcription in vitro and in vivo 
(Nan et al., 1997). The C-terminal domain (CTD) could be divided into CTDα and 
CTDβ. The CTDβ contains the WW binding domain, which is involved in splicing 
factor interactions. MeCP2 was classically considered to be a methylation-
dependent transcriptional repressor (Nan et al., 1998). However, other studies 
suggest additional or alternative roles, including an enhancer of transcription 
(Chahrour et al., 2008), a global regulator of chromatin structure (Horike et al., 
2005) or a global dampener of transcriptional noise (Skene et al., 2010).     20 
 
Figure 1.1 Illustrated structure of MeCP2 and the location and frequency of common MeCP2 
mutations in RTT patients. 
R106W, arginine to tryptophan point mutation at residue 106; R133C, arginine to cysteine 
point mutation at residue 133; T158M, threonine to methionine point mutation at residue 158; 
R168X, arginine to stop codon at residue 168; R255X, arginine to stop codon at residue 255; 
R294X, arginine to stop codon at residue 294; R306C, arginine to cysteine point mutation at 
residue 306. Adopted and modified from Zlatanova et al., 2005 (Zlatanova et al., 2005). 
MeCP2 is expressed in a range of tissues but is especially abundant in post-
mitotic neurons. Mice lacking MeCP2 in neurons show overt RTT-like symptoms, 
whereas mice in which the expression of MeCP2 is driven in neurons alone are 
reported to show a normal phenotype (Luikenhuis et al., 2004). While MeCP2 is 
present at low levels in astrocytes, and MeCP2 deficiency in these cells may 
confer subtle non-cell autonomous actions on neuronal phenotype (Ballas et al., 
2009; Maezawa et al., 2009), a body of evidence points to the overt RTT-like 
symptoms being due mainly to MeCP2 deficiency in the nervous system and 
neurons in particular. 
1.2.3 Neuropathology in RTT patients 
The average one-year-old infant brain weight in RTT patients is 900 g. The 
weight of the Rett syndrome brain is significantly less than that of the brain of 
age-matched controls in autopsy studies (Armstrong, 2005). Observation of 
MeCP2 expression has shown that it is primarily distributed in post-mitotic 
neurons (Shahbazian et al., 2005). The weight of the Rett brain does not 
decrease significantly with age, so atrophy does not account for the small cell     21 
size (Armstrong, 2005). Instead, RTT is characterised by lack of brain growth 
which is not generalised, since some structures such as the cerebral hemispheres 
are affected more than other structures such as the cerebellum (Armstrong, 
2005). Alterations in volume mainly occur in prefrontal, posterior frontal, and 
anterior temporal regions, with preservation in the posterior temporal and 
posterior occipital regions (Reiss et al., 1993; Subramaniam et al., 1997). 
Neurochemical studies based on RTT patient data are relatively limited. 
Nevertheless, cerebrospinal fluid and brain tissues have been analysed with 
respect to levels of various transmitters, receptors, and additional trophic 
factors. Abnormalities have been reported in most systems, including in 
acetylcholine (Wenk & Mobley, 1996; Wenk, 1997; Wenk & Hauss-Wegrzyniak, 
1999), dopamine (Zoghbi et al., 1985; Brucke et al., 1987; Zoghbi et al., 1989; 
Lekman et al., 1990; Percy, 1992), serotonin (Segawa & Nomura, 1990; Segawa 
& Nomura, 1992), glutamate (Hamberger et al., 1992; Lappalainen & Riikonen, 
1996), substance P (Matsuishi et al., 1997; Deguchi et al., 2000), and nerve 
growth factor (Lappalainen et al., 1996; Riikonen & Vanhala, 1999). The age of 
the patient with Rett syndrome (Lekman et al., 1990) and the severity of the 
symptoms (Percy, 1992) influence measurements. The reduced levels of 
acetylcholine and cholinergic markers (Armstrong, 2005) are one of the most 
consistent findings (Wenk, 1997). 
1.2.4 Animal models of RTT 
Several mouse genetic models of RTT have been developed through interruption 
of murine Mecp2, and these models accurately recapitulate the cardinal signs 
that characterise RTT in humans (Chen et al., 2001; Guy et al., 2001; 
Shahbazian et al., 2002; Luikenhuis et al., 2004; Guy et al., 2007). RTT models 
are proving invaluable in helping understand the underlying pathology and 
neuronal dysfunction in RTT, as well as providing insights into the 
pathophysiology of neurodevelopmental disorders more generally. Mecp2-null 
male mice develop motor impairment, tremor, breathing abnormalities and limb 
stereotypies (Chen et al., 2001; Guy et al., 2001; Guy et al., 2007). In most of 
the models, the null males demonstrate apparently normal early development 
before the onset of overt signs at about 6 weeks of age, and progression is 
usually fairly aggressive, with death at about 16-20 weeks. Females     22 
heterozygous for Mecp2 show a more delayed onset of symptoms. The symptom 
severity increases over a period of weeks to months, as in human females; these 
then stabilise and the mice show an apparently normal lifespan. 
Three RTT models have been widely used. The first of these is the Jaenisch 
model (Chen et al., 2001), which utilised the cre-lox recombination system to 
delete Mecp2 exon 3 in this model. Normal development is observed in null 
model for the first five weeks, following which mice develop nervousness, body 
trembling, piloerection and occasional breathing abnormalities. Mice typically 
experience weight loss at 8 weeks and most die by 10 weeks. Reduced brain 
weight and neuronal size in hippocampus, cerebral cortex, and cerebellum have 
been reported. The second model is the Bird model (Guy et al., 2001), which 
was generated by targeted deletion of exons 3 and 4 of Mecp2 in embryonic 
stem cells to produce a complete null in terms of the production of MeCP2 
protein. Hemizygous males are normal till 3 to 8 weeks, but later develop stiff 
uncoordinated gait, hindlimb clasping, irregular breathing and uneven teeth 
wear. Symptoms progress rapidly after 10 weeks, with weight loss and death at 
around 12-16 weeks. In contrast, the heterozygous females develop inertia and 
hindlimb clasping at around 3 months, and breathing abnormalities (irregular 
breathing patterns) and decreased mobility after 6 months. They survive longer 
than males and are fertile. The Mecp2
308/y model (Shahbazian et al., 2002) is a 
milder model and was generated by insertion of a truncating Mecp2 mutation. A 
stop codon (after amino acid 308) produces a protein that is truncated yet 
retains the MBD, TRD domains and nuclear localisation signal motif. Males 
appear normal till 6 weeks and later develop tremors, motor impairment, 
hypoactivity, anxiety behaviour, seizures, kyphosis, and stereotypic forelimb 
motions. Survival is much longer than MeCP2 null models, with males living to 10 
months and being fertile. Females also survive and have milder symptoms than 
seen in the null (complete absence of protein) models. 
Most RTT model studies have focused on global deletion or truncation of Mecp2 
(Chen et al., 2001; Guy et al., 2001; Shahbazian et al., 2002; Pelka et al., 2006; 
Stearns et al., 2007). Behavioural studies in these mice have revealed altered 
gait and motor defects including hypoactivity, paw stereotypies and balance and 
swimming impairments. Such mice also display an anxiety phenotype including 
reduced exploration, increased thigmotaxis (movement toward or away from     23 
mechanical stimulus) and altered plus and zero maze behaviour. Motor 
dysfunction limits the application of certain cognitive tests, but impairments in 
fear conditioning and novel object recognition have been reported (Pelka et al., 
2006; Stearns et al., 2007). In the Mecp2
308/y model, which generates truncated 
MeCP2 and displays significantly milder symptoms, mice show impairments in 
hippocampal-dependent spatial memory as well as social memory (Moretti et al., 
2006).  
Like in RTT patients, Mecp2-mutant mice have smaller cortical neurons packed 
at a higher density than their wild-type littermates (Chen et al., 2001; Kishi & 
Macklis, 2004; Stearns et al., 2007). Moreover, pyramidal neurons in the cortex 
(Kishi & Macklis, 2004) as well as in hippocampal CA3 region, and granule cells of 
the dentate gyrus show reduced dendritic complexity (Ballas et al., 2009). 
Furthermore, Jaenisch Mecp2-mutant mice show a disorganised olfactory 
neuroepithelium indicative of delayed terminal differentiation (Matarazzo et al., 
2004). However, dendritic branching in layer III and V pyramidal neurons of the 
frontal cortex of male Mecp2
308/y mice was comparable to that in controls 
(Moretti et al., 2006). In the Bird model, pyramidal neurons from the 
somatosensory cortex of six-week-old mice show lower spine densities compared 
with wild-type controls (Fukuda et al., 2005). Newly generated granule cells in 
the dentate gyrus of eight-week-old Jaenisch model mutant mice also show 
impaired dendritic spine density and distribution (Smrt et al., 2007). In female 
heterozygous mice, the onset of this dendritic spine phenotype is delayed and 
more severe in Mecp2-lacking neurons than in Mecp2-expressing neurons, 
suggesting both cell autonomous and non-cell autonomous effects (Belichenko et 
al., 2009). The intensity of PSD-95 (an abundant postsynaptic protein) is also 
lower in layer V pyramidal neurons of the motor cortex of MeCP2-null mice 
(Tropea et al., 2009). As far as pre-synaptic terminals are concerned, the motor 
cortex of Bird model mice shows defects in axonal fasciculation (Belichenko et 
al., 2009). Moreover, the intensity of VGLUT1 (a pre-synaptic protein) is lower in 
the dendritic region of the hippocampal CA1 region from MeCP2-null mice; 
however, the post-synaptic dendritic marker MAP-2 was not different. The 
authors interpreted this as showing that Mecp2 deletion caused a reduction in 
the number of mature synapses in area CA1, consistent with their results from 
dissociated neuronal cultures (Chao et al., 2007).     24 
1.2.5 Synaptic Function Studies in RTT models 
Anatomical studies have shown changes in neuronal structure and synaptic 
connectivity (Armstrong et al., 1995; Belichenko et al., 1997; Armstrong et al., 
1998; Chao et al., 2007). For instance, the neuronal soma is smaller in the 
absence of MeCP2 (15-25% smaller in hippocampal CA2 region), and cells are 
more densely packed (Kaufmann & Moser, 2000; Chen et al., 2001; Armstrong, 
2005; Taneja et al., 2009). Mutation of MeCP2 is also associated with an 
abnormal number of axons (~33% increased in Mecp2-mutant mice) (Belichenko 
et al., 2009) and a defect in axonal targeting (Matarazzo et al., 2004; Palmer et 
al., 2008; Belichenko et al., 2009). These results indicate a decrease in the 
number of synapses in RTT brains, which has been confirmed for glutamatergic 
synapses in primary neuronal cultures (Chao et al., 2007). 
Electrophysiological studies in mice show subtle changes in neuronal electrical 
properties within cortical areas (Dani et al., 2005; Kline et al., 2010) and more 
pronounced changes in other regions such as the brain stem and locus ceruleus 
(Medrihan et al., 2008; Taneja et al., 2009). Overt changes in synaptic function 
include reduced synaptic plasticity (Asaka et al., 2006; Moretti et al., 2006; Guy 
et al., 2007; Nelson et al., 2008) and changes in basal inhibitory and excitatory 
synaptic transmission (Dani et al., 2005; Medrihan et al., 2008; Nelson et al., 
2008; D'Cruz et al., 2010; Kline et al., 2010; Maliszewska-Cyna et al., 2010). At 
the network level there is a shift in the balance of excitatory/inhibitory (E/I) 
currents, with increased excitatory and decreased inhibitory neurotransmission 
in the hippocampus and cortex (Dani et al., 2005; Nelson et al., 2006; Chao et 
al., 2007; Zhang et al., 2008; Wood & Shepherd, 2010). This is supported by data 
showing defects of GABAergic neurotransmission in the brainstem (Medrihan et 
al., 2008). Recently, the mouse model with MeCP2 deficiency solely in 
GABAergic neurons has recapitulated most of the phenotypic features displayed 
by Mecp2-null mice, including synaptic dysfunctions (Chao et al., 2010). 
Although GABAergic interneurons constitute only around 10% of the total 
neuronal population, GABA is the major inhibitory neurotransmitter in the brain 
and the GABAergic interneuron serves as the coordinator of the neuronal 
networks (Watanabe et al., 2002). As a result, defects in the inhibitory neurons 
are likely to affect most neuronal networks and mimic the phenotypes in the 
Mecp2-null mouse. This conclusion is in line with previous reports stating that     25 
the E/I balance is shifted, showing higher excitatory and lower inhibitory 
neurotransmission. Since GABAergic interneurons are a constellation of diverse 
neuron groups varying according to  their firing signatures, biochemical markers, 
morphologies, innervating patterns, and distributions (Ascoli et al., 2008; 
Klausberger & Somogyi, 2008), it is essential to assess the effect of MeCP2 
deficiency not only in total GABAergic interneurons but also in distinct subtypes. 
The synaptic dysfunction also has been shown by assessing the levels of 
neurotransmitters, and was in line with the RTT brain autopsy studies (see 
section 1.2.3). In mice, reduced levels of serotonin (5- hydroxytryptamine), 
adrenaline, and dopamine have been found in the Mecp2-null brain(Ide et al., 
2005; Samaco et al., 2009; Isoda et al., 2010; Santos et al., 2010). These are 
associated with regional defects in the expression of key rate-limiting enzymes 
tyrosine hydroxylase and tryptophan hydroxylase 2 in the brainstem, the 
substantia nigra, and the raphe nuclei (Viemari et al., 2005; Samaco et al., 2009; 
Taneja et al., 2009), and this conclusion suggests that restoration of the 
monoamine system may be one of the options for rescuing RTT phenotypes (see 
section 1.5.6). 
According to the studies of Mecp2-mutant mouse models, synaptic plasticity 
(long-term potentiation, LTP) appears to be normal in young Mecp2-mutant mice 
(Asaka et al., 2006; Guy et al., 2007; Dani & Nelson, 2009), but shows 
impairment when tested in older mice upon onset of overt RTT-like signs (Asaka 
et al., 2006; Guy et al., 2007). In addition, the degree of LTP impairment 
appears to correlate with the severity of the RTT-like neurological phenotype 
(Gadalla et al., 2011). Regarding the long-term depression (LTD), another form 
of NMDA-receptor-dependent long-lasting synaptic plasticity, it is considered to 
be essential during early development and has also been investigated in 
different Mecp2-mutant mouse models. In the Bird Mecp2 knockout model, low-
frequency afferent stimulation (LFS, 15 min at 1 Hz) induced a smaller or absent 
LTD in hippocampal CA1 region of symptomatic mutant mice (Asaka et al., 2006). 
Similarly, LTD induced in area CA1 by paired-pulse low-frequency stimulation of 
its afferent fibers was impaired in hippocampal slices from symptomatic 
Mecp2
308/Y mice (Moretti et al., 2006). In the same Mecp2
308/Y model, they also 
investigated LTD by exposing slices to the group I mGluR agonist DHPG (50µm) 
for 10 min. DHPG-induced LTD was similar in WT and Mecp2
308/Y mice, indicating     26 
that mutation of Mecp2 does not alter group I mGluR-induced signalling (Moretti 
et al., 2006). Moreover, in the symptomatic Mecp2-stop female (Guy et al., 
2007), the authors also attempted to assess LFS-induced LTD. However, since 
LTD is difficult to experimentally induce in vitro from tissue derived from older 
animals (Mecp2-stop females became symptomatic usually after 3 months old), 
the LTD data was absent and incomparable in both WT and symptomatic groups 
(Dr Jian Gan, personal communication). The precise mechanisms underlying the 
involvement of MeCP2 in regulating morphological and functional aspects of 
synaptic signalling are yet to be identified. However, synaptic plasticity deficits 
are one of the most consistent findings and may provide important insights into 
RTT-like pathogenesis as well as serve as a target system for therapeutic 
interventions. 
1.2.6 Therapeutic Approaches toward RTT 
It appears that lack of functional MeCP2 results in a nervous system primed to 
malfunction at a critical point during postnatal brain development. However, 
function can be restored (including normal plasticity) to a large degree by the 
reintroduction of MeCP2 (Guy et al., 2007). In the study by Guy and colleagues 
(Guy et al., 2007), endogenous Mecp2 was silenced by insertion of lox-stop 
cassette allowing the mice to develop symptoms (and plasticity deficits) before 
reintroducing MeCP2 into the brain by pharmacological reactivation of the gene. 
This reactivation resulted in a pronounced improvement in neurological signs and 
reduced mortality in the mice. Similar strategies to reintroduce or rebalance 
MeCP2 levels have been adopted by other groups using different genetic 
approaches, and these studies have demonstrated improvements in motor 
function and a reversal of brain weight and neuronal morphology deficits 
(Luikenhuis et al., 2004; Giacometti et al., 2007; Jugloff et al., 2008). Another 
genetic strategy has been to overexpress Bdnf, a potent modulator of synaptic 
plasticity/function that is dysregulated in MeCP2 mutant mice, which again 
reverses signs such as locomotor deficits (Martinowich et al., 2003). Whilst none 
of these studies represent a therapeutic strategy that can be applied to human 
patients, they nevertheless demonstrate the concept of phenotypic reversibility 
in mouse models of RTT and suggest that the Mecp2-mutant mice represent a 
viable platform for testing future pharmacological and genetic strategies that 
can be translated for clinical use.      27 
The most obvious strategy in RTT is one of gene therapy. This approach has been 
successful in disorders such as thalassemia (Perumbeti & Malik, 2010), sickle cell 
disease (Olowoyeye & Okwundu, 2010), cystic fibrosis (Davies & Alton, 2010), 
and some cancers (Voutsinas & Stravopodis, 2009; Al-Humadi et al., 2010; Sangro 
& Prieto, 2010; Vachani et al., 2010), but the application of gene therapy to CNS 
disorders is a particular challenge. Whilst conceptually straightforward, RTT 
being a monogenic disorder, the application of gene therapy in RTT is likely to 
be problematic on numerous counts. For instance, it is likely to be necessary to 
express MeCP2 in the correct cell types and at the correct levels since 
overexpression of MeCP2 is also known to be detrimental (Collins et al., 2004). A 
related complication is that females with RTT have a mosaic expression of 
MeCP2, with cells expressing the mutant allele and other cells expressing the 
normal allele and producing functional protein (Hoffbuhr et al., 2002). It is 
possible that a targeted strategy would be required, whereby the transgene is 
activated only in the ‘mutant’ cells and overexpression avoided in the cells with 
the ‘healthy’ allele, which are presumably functioning normally. This is an 
active current area of research but there is relatively little published literature 
as yet. Using lentiviral delivery of Mecp2 driven by the endogenous Mecp2 
promoter, Rastegar and colleagues achieved natural expression patterns of 
MeCP2 and concomitant reversal of dendritic maturation phenotypes in vitro, 
but this approach has not yet been tested in vivo (Rastegar et al., 2009).  
In contrast to the limited gene therapy literature, a significant number of 
studies have investigated pharmacological interventions in models of RTT.  
Several modulators of synaptic function / plasticity have been tested, including 
the AMPA receptor modulator CX546, the IGF-1 tripeptide, the monoamine 
reuptake inhibitor desipramine and the Alzheimer drug memantine. In addition 
to the pharmacological strategies targeting neuronal mechanisms downstream of 
the MeCP2 deficiency, another approach is to target the MeCP2 mutation itself. 
This may be applied to specific but common mutations in MeCP2 leading to 
premature stop codons. Gentamycin, a widely used antibiotic agent, has this 
capacity and can provide modest (10–22%) read-through of common nonsense 
mutations in Mecp2-mutant transfected HeLa cells (Brendel et al., 2009). 
Whether this approach can be successfully applied in vivo or indeed in the clinic 
remains to be established.     28 
The studies focusing on AMPA receptor modulators (the ampakine CX546) are 
based on the fact that levels of BDNF are considered to be regulated by MeCP2 
binding (Chen et al., 2003) and that aberrant levels of BDNF have concomitant 
effects on neurite outgrowth and synaptic maturation and maintenance. Mice 
treated with daily dosing of CX546 showed enhanced levels of BDNF and an 
improvement in the breathing phenotype (irregular breathing patterns) that is a 
prominent feature of RTT patients and seen in Mecp2-mutant mice (Nag et al., 
2009). 
In addition to BDNF (via ampakines), another growth factor that has received 
attention is IGF-1 (Insulin-like growth factor 1) which is a well-known regulator 
of synaptic maturation and plasticity. The activity of IGF-1 is regulated by a 
range of IGF binding proteins. One of these, IGFBP3, has a binding site for the 
MeCP2 (Chang et al., 2004) and MeCP2-null mice and RTT patients express 
aberrantly high levels of this protein which would be expected in turn to inhibit 
IGF-1 signalling (Itoh et al., 2007). An active tripeptide fragment of IGF-1 has 
been shown to enhance lifespan, improve locomotor function and breathing 
pattern and heart rate abnormalities in MeCP2-null mice (Tropea et al., 2009). 
At the cellular level, reversed structural and cortical plasticity deficits were also 
observed following IGF-1 tripeptide treatment (Tropea et al., 2009), and clinical 
trials using recombinant IGF-1 are now underway. 
For some time there has been an interest in monoamine systems with respect to 
RTT. There are consistent reports that levels of monoamine markers are reduced 
in the RTT brain and in MeCP2-null mice (Zoghbi et al., 1985; Zoghbi et al., 1989; 
Percy, 1992; Viemari et al., 2005). To counter these deficits, drugs such as 
desipramine (an inhibitor of monoamine uptake) have been tested in MeCP2-null 
mice (Roux et al., 2007; Zanella et al., 2008). Repeated administration of 
desipramine improves breathing and prolongs lifespan in RTT mice and at a 
cellular level, reverses the depletion in brain stem tyrosine hydroxylase (Roux et 
al., 2007).     29 
1.2.7 Limitations of RTT research 
For the past decade, RTT research shifted from the clinical observations to the 
molecular and cellular neuroscience levels. However, there are still questions 
that need to be addressed. 
Firstly, the symptom progress pattern is not compatible between human and 
mouse models. For the RTT patients, generally the symptom onset is 12 to 18 
months, and most symptoms occur in the early toddler stage (Chahrour & Zoghbi, 
2007). In contrast, the heterozygous females of Mecp2-null models normally 
develop symptoms only once they have reached the adult stage. Several previous 
reports offered species differences or effects of X chromosome inactivation ratio 
as explanations, but the exact link between mutant MeCP2 and phenotype 
development is not yet confirmed. This is worthy of further investigation since 
decoding of the genotype-phenotype relationship is essential for the 
understanding of the pathologic mechanism that underlies RTT. 
Seizures are one of the most prevalent symptoms of RTT (Chahrour & Zoghbi, 
2007). In RTT patients, seizures vary from the focal convulsion to intractable 
epilepsy (Jian et al., 2006). This observation is in line with a recent study 
demonstrating that deletion of MeCP2 exclusively in GABAergic inhibitory 
neurons recapitulated most RTT-like symptoms, particularly seizure disorder and 
hyperexcitable neuronal networks (Chao et al., 2010). In the brain, neurons are 
classified into two main groups. One is the excitatory neuron (glutamergic 
neuron), and the other is the inhibitory neuron (GABAergic neuron). Two 
hypotheses can fit the phenomenon observed in the RTT mouse model. The first 
of these is an imbalance between the excitatory and the inhibitory populations. 
The population imbalance could originate from imbalanced neurogenesis 
processes deriving embryonic neurodevelopment, or from the fact that inhibitory 
neurons are more vulnerable than excitatory neurons directly or indirectly 
influenced by the mutant MeCP2 protein. It is worth comparing the neuronal 
population change in distinct cell types to further determine whether MeCP2 is 
essential to the development or integrity of specific neuronal subtypes. 
The second hypothesis is that the electric property changes are associated with 
synaptic deficits in the Mecp2-null models. Synaptic dysfunctions have been     30 
reported in various anatomical and electrophysiological studies in RTT animal 
models (Asaka et al., 2006; Moretti et al., 2006; Guy et al., 2007; Nelson et al., 
2008). There are still several debates on the link between synaptic plasticity 
deficits and general phenotype development in RTT animals (Dani & Nelson, 
2009). To dissect the synaptic abnormalities in the RTT brain, it is necessary to 
adopt more accurate experimental schemes for synaptic functional assessment; 
this will be beneficial for further understanding of the synaptopathy in RTT and 
for future clinical treatment. 
In this thesis, my main focus is on the influence of MeCP2 dysfunction in the 
brain, especially in the cerebral cortex and the hippocampus. Therefore, in the 
following sections, general descriptions of the cerebral cortex and the 
hippocampus are included, followed by the introduction of the synapse, its 
structures and functions in the brain. 
 
 
1.3 Cerebral cortex 
The cerebral cortex is the neural tissue that lies as an outermost layer, 2 to 4 
mm thick, of the cerebrum in mammalian brains (Bentivoglio et al., 2003). It 
plays a key role in higher-level psycho-physical functions, such as memory, 
attention, perceptual awareness, thought, language, and consciousness. The 
phylogenetically more ancient part of the cerebral cortex, the hippocampus, has 
at most three cellular layers, and is divided into subfields (see section 1.3.5). 
The most phylogenetically recent part of the cerebral cortex is the neocortex, 
which is differentiated into six horizontal layers, each of which has a different 
composition of neurons and connectivity. 
1.3.1  Layer structures in the neocortex 
Different cortical layers each contain characteristic distributions of neuronal cell 
types and connections with other cortical regions. Staining cross-sections of the 
cortex has revealed the position of neuronal cell bodies and the intracortical 
axon tracts, which have allowed neuroanatomists to produce a detailed     31 
description of the laminar structure of the mammalian brain. After the work of 
Korbinian Brodmann, the neurons of the cerebral neocortex are grouped into six 
main layers (Bentivoglio et al., 2003), from the pial surface to the white matter 
(see figure 1.1).     32 
 
Figure 1.2 Illustration of layer structures in the neocortex. 
The diagram of cortical layers I to VI, and WM represents the white matter layer. Adopted 
and modified from Bentivoglio et al., 2003 (Bentivoglio et al., 2003). 
Layer I, the molecular layer, contains only a few scattered neurons and these 
are all inhibitory neurons. It also consists of extensions of apical dendritic tufts 
of pyramidal neurons located at layers II and III. Inputs to the apical tufts are 
thought to be essential for learning and attention functions. 
Layer II, the external granular layer, contains mainly small pyramidal neurons 
and inhibitory neurons, principally bipolar cells and double bouquet cells. It also 
contains apical dendrites from pyramidal cells whose cell bodies are found in 
layers V and VI.     33 
Layer III, the external pyramidal layer, contains mainly small and medium-size 
pyramidal neurons, and few non-pyramidal neurons with vertically-oriented 
intracortical axons. Layers I to III are the main targets of interhemispheric 
corticocortical afferents, and layer III is the principal source of corticocortical 
efferents. 
Layer IV, the internal granular layer, is the exclusive location of a class of small 
excitatory cells called spiny stellate cells. It also contains a variety of inhibitory 
cells, and is the main target of thalamocortical afferents from thalamus neurons. 
Layer V, the internal pyramidal layer, contains large pyramidal neurons. It is the 
principal source of subcortical efferents. Large pyramidal cells which send axons 
leaving the cortex and targeting the basal ganglia, the brain stem and the spinal 
cord can be observed in layer V. Chandelier cells, which are inhibitory cells that 
make synaptic connections only to the axons protruding from other neurons, are 
often found in layer V. 
Layer VI, the polymorphic layer, contains few large pyramidal neurons and many 
small spindle-like pyramidal and multiform neurons. Layer VI sends efferent 
fibres back to the thalamus, establishing the precise reciprocal interconnection 
between the cortex and the thalamus. Layer VI also contains a class of inhibitory 
neurons called Martinotti cells, whose axonal outputs make long projections 
across all layers of the neocortex. 
1.3.2 Cell types in the neocortex 
Neurons in the neocortex can be categorised as below (Connors & Gutnick, 1990), 
1. Pyramidal cells. Pyramidal cells consist of about 60-70% of all neurons in the 
neocortex. They are the only neurons that send signals out of their local areas to 
other regions of the brain. Most pyramidal cells belong to the regular spiking 
neuron group. The signalling-type classification was defined by experimental 
observations of the neuronal response when a pyramidal cell is injected with a 
constant excitatory current.     34 
2. Spiny Stellate Cells (SSCs). SSCs make up the other type of excitatory neurons 
in neocortex. They are found only in layer IV and fromabout 10% of the total 
population of neurons. SSCs are locally projecting interneurons only. SSCs belong 
to the regular spiking group as far as their signalling behaviour is concerned. 
3. Inhibitory interneurons. The remaining 20-30% of cortical neurons are 
inhibitory interneurons and can be further classified by electric properties 
(Connors & Gutnick, 1990). 50% of these neurons are classified as Class-I 
GABAergic cells. They are found in all cortical layers and belong to the fast-
spiking group. About 15% of inhibitory interneurons in the neocortex are Class-II 
GABAergic cells. These neurons exhibit a low spiking threshold and are known as 
low threshold spiking cells. Class-II cells are observed in layers II-VI of the 
neocortex. Class-III inhibitory interneurons make up another 15% of all inhibitory 
interneurons in the neocortex. They express VIP (vasoactive intestinal peptide) 
and display an irregular spiking pattern. There are also other inhibitory 
interneurons that cannot be classified; these account for 20% of all inhibitory 
interneurons in the neocortex. 
1.3.3 Classification of cortical inhibitory interneurons by 
expression of calcium-binding proteins 
Cortical inhibitory interneurons can be also classified into distinct classes on the 
basis of calcium-binding protein (CBP) expression. Parvalbumin (PV), calbindin 
(CB) and calretinin (CR) belong to the large family of CBPs, which are 
characterised by the presence of a variable number of helix-loop-helix motives 
binding calcium ions. The major function of these three CBPs is buffering of 
intracellular calcium. CB and CR are bound to cellular structures, while PV is 
freely mobile in axons, neuronal soma and nuclei. Data from different brain 
regions suggest that these proteins are involved in regulating calcium pools for 
synaptic plasticity functions (Schwaller et al., 2002; Schmidt et al., 2007; 
Mojumder et al., 2008). 
Previous analyses have demonstrated that neurochemical markers such as CBPs 
represent relevant tools to define the chemo-architecture of the neocortex and 
that they are observed in distinct neuronal subpopulations. Inhibitory neurons 
that express CBPs PV, CB and CR form three largely non-overlapping     35 
subpopulations. In the rat neocortex layer V, it has been demonstrated that 50% 
of all inhibitory cells express PV, 15% express CR and 30% express CB (Wonders & 
Anderson, 2006). The density of CB+ and CR+ neurons is greater in layers II–III, 
while PV+ interneurons were most often found in the middle cortical layers 
(Zaitsev et al., 2005). CB and CR expressing interneurons share many 
morphological similarities and are mainly bipolar, bi-tufted and double bouquet 
neurons. PV+ neurons are common in layers II–V and classified as basket cells and 
chandelier cells (DeFelipe, 1997; DeFelipe, 1999). In the majority of mammalian 
representatives, balanced representation of the three CBPs was demonstrated 
(Hof & Sherwood, 2005). 
1.3.4 Hippocampus 
The hippocampus is part of the limbic system in mammalian brains and is 
essential for memory formation as well as spatial navigation functions (Bliss & 
Collingridge, 1993; Wilson & McNaughton, 1993; Malenka & Bear, 2004; 
McNaughton et al., 2006). The clear laminated structures and highly organised 
excitatory and inhibitory input-output networks have made the hippocampus one 
of the most widely investigated regions in the brain. Therefore, the 
hippocampus is an excellent platform for experimental projects ranging from 
synaptic physiology, neural plasticity, spatial learning and memory to clinical 
conditions such as epilepsy, schizophrenia, Alzheimer’s disease, and autism 
(Bliss & Lomo, 1973; Best & White, 1999; Burke & Barnes, 2006; Boyer et al., 
2007). 
1.3.4.1  Structures of the hippocampus 
The hippocampus is shaped a sea-horse seated in the medial temporal lobe of 
the mammal’s brain, and consists of three main subdivisions: CA1, CA3 (CA: 
cornus ammonis) and the dentate gyrus (DG) (figure 1.2). In addition to these 
subdivisions, the hippocampus has three distinct cell layers. A single layer of 
pyramidal cells, the stratum pyramidale, has afferent fibres running transversely 
above (stratum oriens) and below (stratum radiatum and stratum lacunosum-
moleculare) them. The dentate gyrus also consists of three layers; a polymorphic 
layer (the hilus), a granular layer (stratum granulosum) and a molecular layer 
(stratum moleculare).    36 
 
Figure 1.3 Illustration of the hippocampus showing the excitatory trisynaptic pathway. 
Adapted and modified from classical illustration of hippocampal formation showing the 
excitatory trisynaptic pathway as drawn by Santiago Ramon y Cajal (Ramón y Cajal, 1952, 
1955). Insert shows the schematic representation of main excitatory pathways and the 
direction of information flow. Source: http://en.wikipedia.org/wiki/Hippocampus 
1.3.4.2  Cell types in the hippocampus 
The main neurons in the CA3 and CA1 regions of hippocampus are pyramidal 
neurons. There are approximately 210000 pyramidal cells in the rat hippocampal 
CA3 region, while in the CA1 nearly 320000 are observed (Boss et al., 1987). 
Pyramidal cells are mainly seated in the stratum pyramidale, sending out apical 
dendrites through the stratum radiatum to the stratum lacunosum-moleculare 
and basal dendrites through the stratum oriens. As for the dentate gyrus, the 
principal cells are granule cells, and there are an estimated 700000 of these in 
rat hippocampi (Boss et al., 1985; Boss et al., 1987). Interneurons, however, are 
inhibitory neurons that appear widely distributed throughout the hippocampus 
and can be found in the stratum oriens, pyramidale and radiatum. Several 
subtypes of these neurons exist in the hippocampus, including basket cells, axo-
axonic cells, bistratified cells, etc. All the inhibitory interneurons comprise 
around 10% of the total neuronal population, and are responsible for general 
inhibition and modulation of network activities (Freund & Buzsaki, 1996; Jonas 
et al., 2004; Ascoli et al., 2008; Klausberger & Somogyi, 2008).     37 
1.3.4.3  Neuronal circuits in the hippocampus 
The excitatory circuits in the hippocampus are characterised as conveying 
unidirectional flow of information through a well-characterised “trisynaptic” 
pathway (Bliss & Gardner-Medwin, 1973; Malenka & Nicoll, 1999) (see figure 1.2). 
Pyramidal cells in the entorihnal cortex (EC) layer II send axon projections into 
the DG (the perforant pathway). The perforant path serves as the major input of 
the hippocampus. Subsequently, the mossy fibre (MF) delivers information flows 
from the DG granule cells into the CA3 area of the hippocampus. The pyramidal 
cells in the CA3 then innervate the CA1 area of the hippocampus through long 
axon projections called Schaffer collaterals (SC) to allow signals to be 
transmitted from the CA3 into the CA1. Finally, the CA1 pyramidal cells project 
axons into subiculum, which directs projections back to the EC. As a relay, the 
information flows start from the superficial layers and finish in the deep layers 
of the entorhinal cortex (EC), and this is simply presented as the EC-DG-CA3-
CA1-EC pathway. 
1.4 Synapse 
In previous section 1.3.5.3, the excitatory circuits in the hippocampus are well-
illustrated. The neuronal circuits, at the cellular level, consist of connections 
between neurons. Neurons make contact with each other, and play essential 
roles in coordinating neural activities within neuronal circuits. A contact 
between neurons is termed as a ‘synapse’, which originates from ‘synaptein’, 
combining the Greek "syn-" ("together") and "haptein" ("to clasp"); this term was 
first applied by British neurophysiologist Charles Sherrington. The interactions 
among neurons at the synapse are conducted by transmitting electrical signals 
from one neuron to the other. Two main forms of synaptic transmission, 
electrical and chemical, are responsible for the connection within the synapse. 
1.4.1 Chemical synaptic transmission 
Chemical synaptic transmission is known as the classical synaptic transmission. It 
has four phases:     38 
1) The action potential initiated from the presynaptic neuron activates voltage-
dependent calcium channels located at the presynaptic terminal to allow the 
calcium influx. 
2) The elevation of calcium concentration triggers neurotransmitters to be 
released from the pre-synaptic terminal. 
3) Neurotransmitters cross the synaptic cleft, and then bind to neurotransmitter 
receptors on the postsynaptic neuron. 
4) After the neurotransmitters have acted on neurotransmitter receptors on the 
postsynaptic neuron, the neurotransmitter receptors generate a change of local 
resting membrane potential. 
It is also termed an electrical-chemical-electrical transmission, since the action 
potential is transferred into the “chemical” form when delivering from the 
presynaptic to the postsynaptic neuron, and is transferred back again to the 
“electrical” form at the postsynaptic terminal to be sent through the 
postsynaptic neuron. 
The critical phase of chemical synaptic transmission is the release of 
neurotransmitters. The release of neurotransmitters is characterised by a 
mechanism involving the exocytosis and the recycling of synaptic vesicles and 
can be divided into four steps as below, 
1) Docking. Vesicles containing neurotransmitters are tethered to the active 
zone of the pre-synaptic terminal.  
2) Priming. In this step, all the protein and lipid modification and rearrangement 
in the active zone has been done to make synaptic vesicles “readily releasable” 
and competent to fusion (Lloyd & Bellen, 2001).  
3) Fusion. The activation of calcium channel is triggered by the calcium influx, 
and then synaptic vesicles fuse with the pre-synaptic membrane, leading to the 
release of neurotransmitters into synaptic cleft. These three steps combine to 
from the process of “exocytosis”.     39 
4) Recycling. Vesicles have been are recycled back to the pre-synaptic terminal, 
reloaded with neurotransmitters, and transported to the releasable pool. 
1.4.2 Electrical synaptic transmission 
Unlike the electrical-chemical-electrical transduction in classical chemical 
synapses, the information flow between neurons can be passed through direct 
electrical coupling established by the electrical synapses in the brain (Eccles, 
1982; Jessell & Kandel, 1993). Electrical synapse, which is known as the gap 
junction, allows charged ions and transmitters to flow through the gap-junction 
channel connexons between adjacent neurons (Bennett, 1997; Bennett & Zukin, 
2004). Compared to the chemical synapse, most transmissions at electrical 
synapses are bidirectional. Electrical synapse and chemical synapse can coexist 
at one single synaptic formation (Shapovalov, 1980). Functionally, electrical 
synapses are particularly essential in local inhibitory circuits consisting of GABA-
releasing interneurons to generate gamma oscillation (Galarreta & Hestrin, 2001). 
1.4.3 Postsynaptic potential 
The neurotransmitter is released from the presynaptic terminal, diffused 
through the synaptic cleft, and bound with specific receptors on the 
postsynaptic membrane. The binding of the neurotransmitter to specific 
receptors induces conformation change of the receptor proteins, and 
subsequently leads the opening of ion channels to alter the permeability of 
certain ions. 
The permeability alteration generates the ion influx/efflux and further results in 
the membrane potential change, namely the postsynaptic potential. 
Postsynaptic potentials can be excitatory or inhibitory. The excitatory 
postsynaptic potential (EPSP) represents the postsynaptic response depolarising 
the membrane potential, while the inhibitory postsynaptic potential indicates a 
hyperpolarising response. Therefore, neurotransmitters are classified into two 
main groups: those that lead to EPSPs are termed as excitatory 
neurotransmitters, and those that lead to IPSPs are termed as inhibitory 
neurotransmitters. In the brain, the most common excitatory neurotransmitter is 
glutamate, and the most important inhibitory neurotransmitter is γ–aminobutyric     40 
acid (GABA). An EPSP is mainly mediated by the sodium and/or calcium influx 
through ligand-gated cation channels, such as α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors, N-methyl-D-aspartic acid (NMDA) 
receptors and kainate receptors. The fast form IPSP is primarily from the 
chloride influx through the opening of GABAA receptors. The opening of 
potassium channels by GABAB receptors, however, contributes to the slow form 
IPSP. 
1.4.4 Integration of synaptic inputs 
EPSPs and IPSPs are local electronic potentials, without a discrete nature, which 
can be summated. This process is named synaptic integration (London & Hausser, 
2005). A single EPSP or IPSP generally is about 1mV. To fire a neuronal action 
potential that can be transmitted throughout neurons, post-synaptic 
depolarisation must be strong enough to overcome the threshold, which is 
around 10mV. Therefore, spatial and temporal summation of EPSPs or IPSPs 
determine the magnitude and the time course of gross synaptic inputs, and in 
turn generate the output as an action potential firing. Two types of summations 
are observed, temporal and spatial summation (Bartos et al., 2007). In temporal 
summation, continual postsynaptic potentials come closely after each other 
before the last potential decays; thus, the amplitude of the potential will be 
added into the previous one. However, the spatial summation means that the 
postsynaptic potentials originate from multiple synapses and arrive 
simultaneously at a given neuron. Thus, in spatial summation, the membrane 
potential of postsynaptic neuron equals the sum of EPSPs and IPSPs. Both 
temporal summation and spatial summation coexist and function simultaneously 
to steer a particular neuron to fire APs or not in response to EPSPs and IPSPs in a 
neuronal circuit.  
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1.5 Synaptic plasticity 
The efficacy of synaptic transmission between neurons can be strengthened or 
weakened both in vitro and in vivo; this is called synaptic plasticity (Bliss & 
Collingridge, 1993; Bortolotto et al., 1999; Kemp & Bashir, 2001; Zucker & 
Regehr, 2002; Whitlock et al., 2006). Three types of synaptic plasticity are 
observed: short-term plasticity, long-term plasticity and long-term depression. 
Synaptic plasticity is regarded as the molecular and cellular basis for learning 
and memory, as information may be stored and retrieved by transforming 
differential spatiotemporal patterns of neural activity into synaptic changes in 
different locations, circuits and neurons in the brain (Bliss & Collingridge, 1993; 
Martin et al., 2000; Holtmaat & Svoboda, 2009; Wang & Morris, 2010). The term 
“synaptic plasticity” was first introduced by Dr. Jerzy Konorski in the late 1940s 
(Konorski, 1948). The concept was subsequently refined by Dr. Donald Hebb in 
1949 with a proposed mechanism known widely as Hebb’s postulate (Hebb, 1949): 
‘When an axon of cell A is near enough to excite a cell B and repeatedly or 
persistently takes part in firing it, some growth process or metabolic change 
takes place in one or both cells such that A’s efficiency, as one of the cell firing 
B, is increased’. 
In the following sections, the three types of synaptic plasticity are illustrated. 
1.5.1 Short-term plasticity 
Short-term plasticity means a short-term increase or decrease of synaptic 
strength that lasts at most a few minutes. Depending on the patterns of synaptic 
strength change, it could be divided into two groups, short-term facilitation (STF) 
or short-term depression (STD). 
In experiments, short-term facilitation (STF) has been observed upon application 
of a closely paired stimuli paradigm (paired pulse), with an interval of between 
10ms and 300ms. The synaptic response of the second pulse can be several times 
stronger than the first one and it has a presynaptic mechanism (Zucker & Regehr, 
2002). It originates from an increase in the release of readily releasable vesicles 
and the transient accumulation of presynaptic calcium, as calcium influx     42 
triggered by the second action potential is added into the residual calcium which 
has not been depleted after the first pulse (Wu & Saggau, 1994). 
Short-term depression (STD) also occurs in the paired pulse paradigm, and the 
most widely accepted mechanism for STD is the ‘depletion model’ (Zucker & 
Regehr, 2002). That means the STD is the result of a decrease in available 
vesicles in readily releasable pools in presynaptic terminals in response to 
closely paired stimuli. 
1.5.2 Long-term potentiation 
Long-term potentiation (LTP), a long-lasting form of synaptic strength increase, 
was first described in the perforant path from the entorhinal cortex into the 
dentate gyrus in an anaesthetised rabbit (Bliss & Gardner-Medwin, 1973; Bliss & 
Lomo, 1973). Subsequently, it is observed in all excitatory pathways into 
principal cells in the hippocampus, the neocortex, the striatum, and the 
cerebellum (Wilson & Racine, 1983; Calabresi et al., 1992; Shibuki & Okada, 
1992). LTP has also been discovered in excitatory synapses onto inhibitory 
interneurons in the hippocampus (Mahanty & Sah, 1998; Perez et al., 2001; 
Kullmann & Lamsa, 2007; Lamsa et al., 2007). 
LTP has three distinct properties: input-specificity, associativity, and 
cooperativity (Bliss & Collingridge, 1993). Input-specificity means that LTP does 
not spread and is only found within the pathway that has been activated to 
express LTP. Associativity indicates that a weak input may induce LTP as long as 
a separate strong input simultaneously stimulates the same target neuron. 
Cooperativity describes the existence of a threshold of input intensity for 
inducing LTP. LTP can be either induced by strong tetanus stimulation in a single 
pathway or by the summation of several small stimuli. 
In addition, LTP can be divided into NMDA receptor-dependent or NMDA 
receptor-independent groups, depending on whether or not the NMDA receptor 
antagonist can block its induction. In the hippocampus, the LTP in the Schaffer 
collateral-to-CA1 pyramidal cell synapses is the most studied type of the NMDA 
receptor-dependent group (Bliss & Collingridge, 1993). However, the LTP in the 
mossy fibre synapses onto CA3 pyramidal cells is representative of the NMDA     43 
receptor-independent group (Harris & Cotman, 1986; Nicoll & Schmitz, 2005). 
Schaffer collateral LTP can be induced either by tetanus stimulation or theta 
burst stimulation, and this induction follows Hebb’s postulate (Collingridge et al., 
1988; Kauer et al., 1988; Huang et al., 1992). The voltage dependent magnesium 
blockade of NMDA receptors in postsynaptic membrane sets the LTP threshold 
for cooperativity, and associativity is reflected by the requirement of removing 
the magnesium blockade of NMDA receptors by depolarising postsynaptic 
terminals by a voltage step or convergent excitatory inputs. The permeability to 
calcium is the key to Schaffer collateral LTP induction (Lynch et al., 1983). The 
time course of LTP can be divided into four phases: post-tetanus potentiation 
(PTP), short-term potentiation (STP), early-LTP, and late-LTP (Bliss & 
Collingridge, 1993; Malenka & Nicoll, 1999). Post-tetanus potentiation (PTP, 
immediately following the tetanus stimulation) is the response of enhanced 
neurotransmitter release corresponding to residual calcium accumulation 
presynaptically during the tetanus stimulation, and is NMDA receptor-
independent. Short-term potentiation (STP), which usually lasts 30-60 minutes 
after the tetanus stimulation, can be also acquired by a weak stimulation 
protocol. Early-LTP describes a synaptic strength increase that lasts under 3 
hours, and has been verified as protein kinase-dependent (Malinow et al., 1988; 
Malenka et al., 1989). Late-LTP, which normally lasts beyond 3 hours, however, 
has been shown to be protein synthesis-dependent (Frey et al., 1988). 
1.5.3 Long-term depression 
The opposing process to LTP, long term depression (LTD) is the long-lasting 
decrease of synaptic strength. This phenomenon was first reported in a 
hippocampal CA1 LTP study, a LTP induction unexpectedly resulted in a 
continuing depressed synaptic efficacy, a phenomenon later described as the 
“heterosynaptic LTD” by Lynch and co-workers in 1977 (Lynch et al., 1977). In 
1980, another report described that low frequency stimulation effectively 
reversed hippocampal LTP (Barrionuevo et al., 1980). Both phenomena were 
neglected until the early 1990s, when a new form of “homosynaptic LTD” was 
discovered by Mark Bear’s group, and this was supported by Robert Malenka’s 
group in 1992, who showed that low frequency stimulation (LFS) of 900 stimuli at 
1 Hz produced a prolonged reduction of synaptic transmission in the 
hippocampal CA1 region (Dudek & Bear, 1992; Mulkey & Malenka, 1992).     44 
Homosynaptic LTD is development-dependent. One study showed that the 
standard low frequency stimulation protocol, 900 stimuli at 1 Hz, routinely 
produced LTD in hippocampal CA1 regions from 2-week-old animals, whereas 
LTD magnitude decreased by half in 5-week-old animals (Dudek & Bear, 1993). 
LTDs are classified as NMDA receptor-dependent or mGlu receptor-dependent. 
The LTD induced by LFS (900 stimuli, 1Hz) in the CA1 region of hippocampus has 
been confirmed as NMDA receptor-dependent (Dudek & Bear, 1992; Mulkey & 
Malenka, 1992). NMDA receptor-dependent LTD was also found in the visual 
cortex (Kirkwood & Bear, 1994), the perirhinal cortex (Ziakopoulos et al., 1999), 
and the barrel cortex (Feldman et al., 1998). It has been confirmed that the 
induction of NMDA receptor-dependent LTD requires a rise of postsynaptic 
calcium concentration (Mulkey & Malenka, 1992). 
The LFS-induced LTD in the hippocampal CA1 region is NMDA receptor-dependent 
and was proved by one report, which discovered that overexpression of 
embryonic dominant NR2D subunit resulted in a loss of LTD in juvenile mice 
(Okabe et al., 1998). Also, functional knockout of the NR2B subunit in NMDA 
receptor prevented LFS-induced LTD, thus further supporting this hypothesis 
(Kutsuwada et al., 1996). 
The involvement of mGlu receptors in LTD was first evidenced by the discovery 
that the group I/II mGluR antagonist, MCPG, blocked the induction of 
depotentiation by the LFS protocol (900 stimuli, 1 Hz) in the CA1 region of the 
hippocampus (Bashir et al., 1993; Bashir & Collingridge, 1994). LTD induced by 
low-frequency stimulation of paired-pulse at 1Hz (PP-LFS) in adult (Kemp & 
Bashir, 1999) and juvenile animals (Huber et al., 2000) were shown to require 
mGluRs. Interestingly, NMDA receptor-dependent LTD induced by LFS is also 
present in the same synapses in the hippocampal CA1, but it has been suggested 
that these two forms of LTD utilise distinct induction pathways: mGluR-
dependent LTD requires the calcium influx from T-type calcium channel, and 
protein kinase C, whereas, NMDA receptor-dependent LTD requires calcium 
influx through NMDA receptors (Oliet et al., 1997). It has been further suggested 
that the requirement of NMDA receptors and mGlu receptors in induction of LTD 
may be mutually exclusive, as where there is a role for NMDA receptors, there is 
no role for mGluRs and vice versa (Bortolotto et al., 1999; Kemp & Bashir, 2001).     45 
1.5.4 Glutamate receptors and synaptic plasticity 
In the cortex of mammalian brain, excitatory synaptic transmission is mediated 
primarily by glutamate-gated ion channels embedded in the postsynaptic cell 
membrane. Glutamate receptors contribute to the fast excitatory postsynaptic 
response by allowing positively charged ions to flow into the postsynaptic 
compartment upon binding glutamate. Different classes of receptors are named 
for their most potent agonists, such as AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazole proprionate) receptors and NMDA (N-methyl-D-aspartate) receptors. In 
the mature brain, AMPA receptors primarily conduct sodium ions and mediate 
the initial and largest component of field excitatory postsynaptic potential 
(fEPSP), while NMDA receptors have the unique property of allowing calcium ions 
to flow into the postsynaptic cell in addition to sodium ions. The contribution of 
NMDA receptors to basal synaptic transmission is highly variable because, under 
resting physiological conditions, their ion pores are blocked by magnesium ions 
which prevent current flow. However, during periods of heightened stimulation, 
the amount of positive charge flowing in through AMPA receptors depolarises the 
postsynaptic spine sufficiently to remove the magnesium ion block and allow 
calcium ions to enter the postsynaptic terminal through the NMDA receptor (see 
figure 1.4A) (Mayer et al., 1984; Nowak et al., 1984). The NMDA receptor thus 
satisfies the requirement of Hebb's coincidence detector, with its activation 
requiring concurrent presynaptic glutamate release and postsynaptic 
depolarisation. The amount of calcium ions passing through the NMDA receptor 
varies depending on the magnitude of pre- and postsynaptic co-activation and 
ultimately determines whether synaptic connections will be strengthened or 
weakened (Lisman, 1985; Madison et al., 1991; Malenka & Nicoll, 1999). The 
most commonly studied forms of LTP and LTD are NMDA receptor-dependent 
synaptic plasticities. 
The induction of LTP requires large influxes of calcium ions in the postsynaptic 
terminal that trigger the activation of protein kinases, enzymes, and whose 
enzymatic activity can long outlast the changes in calcium ion concentration 
that triggered them (figure 1.4A and 1.4B). The phosphorylation of synaptic and 
structural substrates plays a critical role in the induction and expression of LTP 
(Soderling & Derkach, 2000). In addition to the phosphorylation of AMPA 
receptors at synapses, new AMPA receptors are also recruited to the     46 
postsynaptic membrane (Malinow et al., 2000), leading to larger amplitude 
fEPSPs with faster onsets, while on the presynaptic side more glutamate is 
released into the synaptic cleft (Bliss et al., 1990a; Bliss et al., 1990b; Dolphin 
et al., 1982). Structural changes, such as the growth of new spines and the 
enlargement or splitting of synapses in two, have also been observed following 
LTP induction (Yuste & Bonhoeffer, 2001). In LTD, small increases in calcium ions 
arising from weak synaptic stimulation favour the activation of protein 
phosphatases that dephosphorylate synaptic proteins including glutamate 
receptors (figure 1.4B) (Mulkey et al., 1994; Mulkey et al., 1993). Contrary to 
LTP, LTD results in the removal and eventual degradation of AMPA receptors, 
NMDA receptors, and structural synaptic proteins (Ehlers, 2000; Heynen et al., 
2000; Colledge et al., 2003). 
 
 
Figure 1.4 Glutamate receptors and synaptic plasticity. 
(A) The NMDA receptor is mediated and activated by coincident pre- and postsynaptic 
activities. (B) A large increase in postsynaptic calcium, induced by HFS, favours the 
activation of protein kinases and results in LTP, while small, sustained Ca
2+ elevations 
during LFS favour the activation of protein phosphatases, resulting in LTD. (C) Long-term     47 
changes in synaptic strength can be explained as a function of the amount of calcium ions 
flowing into the postsynaptic neuron via NMDA receptors. (Adopted and modified from M. 
Bear, B. Connors, & M. Paradiso, Neuroscience: Exploring the brain, 3rd edition, © 2007, 
Lippincott Williams & Wilkins.) 
Assessing synaptic plasticity deficits in disease animal models of 
neurodevelopmental disorders will be beneficial for understandings of the 
synaptic functional alterations in these disorders. Several synaptic plasticity 
studies in RTT animal models have been introduced in section 1.2.5 and were 
reviewed again in the introduction of Chapter 5. 
 
 
 
1.6 Aims 
There are still numerous limitations in the RTT research. Firstly, the genotype-
phenotype correlations differ from species to species, and the manner in which 
MeCP2 modulates the neuronal functions is still obscure. Secondly, at cellular 
level, MeCP2 dysfunctions induced an overall higher cell packing rate, smaller 
soma size and deficits in axon targeting and dendrite branching (see previous 
sections). However, few detailed studies have compared the cellular densities or 
the change in distribution patterns in distinct cell types. Since a recent study has 
already demonstrated that selective knock-out of MeCP2 in GABAergic neurons 
recapitulated nearly all RTT-like phenotypes in mouse (Chao et al., 2010), it is 
of interest to assess the alteration of cellular density and localisations in various 
neuronal subtypes. Thirdly, RTT can be classified as synaptopathy, and most 
symptoms are closely linked to synaptic dysfunction. Nevertheless, a recent 
electrophysiological report showed several discrepancies in the “phenotype-
synaptic functions” relationship (Dani & Nelson, 2009), and it is necessary to 
elucidate the precise mechanism underlying RTT synaptopathy by more sensitive 
experimental designs. Finally, the ultimate MeCP2 research aim is primarily 
focused on the clinical treatment of RTT. Numerous animal drug studies and 
clinical trials are already underway to further assist RTT patients.      48 
The understanding of MeCP2 molecular functions is the key to future RTT 
therapy development, and in this thesis, I have aimed to address three sets of 
principal questions relating to the effects of MeCP2 deficiency in the central 
nervous system, 
1. How do the gross signs of the Mecp2-stop phenotype develop postnatally? Do 
distinct symptoms progress in different ways from each other? 
2. How does the absence of functional MeCP2 affect neuronal density? Does the 
absence differentially affect different subtypes of neurons? 
3. How is synaptic plasticity affected in the Mecp2-stop brain? Is there a 
relationship between synaptic plasticity deficits and the progression of 
neurological signs? Can these synaptic plasticity deficits be amended or reversed 
by pharmacological modulations?     49 
2  Material and Methods 
2.1 The timeline of experiments 
All the studies in the current thesis used Mecp2
tm2bird mouse, in which the first 
generation was originally obtained from Prof. Adrian Bird’s laboratory at the 
University of Edinburgh as a gift. The original mouse at the University of 
Edinburgh was purchased from Jackson Laboratories (Maine, USA; stock number 
006849). In the following sections and chapters, Mecp2
tm2bird mice are referred 
to as Mecp2-stop mice. The Mecp2-stop mice were introduced from the 
University of Edinburgh, and the mouse colony was bred and maintained in the 
animal unit at the University of Glasgow. Figure 2.1 illustrates the timeline of all 
the experiments in this thesis. All the offspring from the Mecp2-stop mice colony 
were weaned at the age of 3 weeks and the genotyping was done at the same 
time (see results in Chapter 3). In order to maintain the Mecp2-stop mice colony, 
heterozygous females (Mecp2
stop/+) were preserved for further mating with wild 
type (WT) Balb/c mice introduced from Harlan Laboratories (Shardlow, UK). WT 
females from the Mecp2-stop colony were humanely culled, while both WT and 
hemizygous (Mecp2
stop/y) males were selected for future experimental use. The 
phenotyping was performed weekly for every hemizygous Mecp2-stop mouse 
from the time of weaning to death, as labelled in the yellow block in figure 2.1 
(see results in Chapter 3). 
For the immunohistochemistry studies (see results in Chapter 4), both 
“symptomatic” Mecp2
stop/y mice and their WT littermates were used. The 
definition of “symptomatic” mice refers to the fact that the sum symptom score 
reached 5 or above in the phenotyping test (see section 2.5 for detailed 
description). Generally, Mecp2
stop/y mice reached symptom scores of 5 at around 
10 to 15 weeks, as illustrated by the selection phase (the red block) in figure 2.1. 
With regard to the electrophysiology studies (see results in Chapter 5), synaptic 
plasticity (long-term potentiation) was assessed using the symptomatic 
Mecp2
stop/y mice and their WT littermates (as in the immunohistochemistry 
studies). However, synaptic plasticity saturation was evaluated in mild 
symptomatic (score 2-4) Mecp2
stop/y mice, symptomatic (score 5 or above) 
Mecp2
stop/y mice and their age-matched WT littermates. Finally, the in vivo     50 
chronic pharmacological treatment (Memantine treatment, see also section 2.8 
for detailed information) on both Mecp2
stop/y mice and WT littermates was 
applied from week 5 to week 8 (the blue block in figure 2.1). In later sections, 
all the detailed materials and methods are listed. 
 
 
 
 
Figure 2.1 Illustration of the timeline of experiments. 
After litters were weaned, ear samples were collected for genotyping (data shown in 
Chapter 3). Mecp2
stop/y and their littermates were paired for future experimental use, and 
Mecp2
stop/+ were selected for breeding. The yellow block represents the phenotype study 
(data shown in Chapter 3), which started immediately after genotyping as a weekly scoring 
assessment, and ended before mice were culled or death. For the immunohistochemistry 
study (data shown in Chapter 4), symptomatic mice were used after the symptom score 
reached five or more (represented as the selection phase in the red block), and their WT 
littermates were also used for comparison. For the synaptic plasticity study in acute brain 
slices (data shown in Chapter 5), symptomatic mice and their WT littermates were selected 
using the same criteria as above in the immunohistochemistry study, while in the in vivo 
chronic memantine treatment study (data shown in Chapter 5), Mecp2
stop/y and their 
littermates were treated with memantine from 5 to 8wks (represented by the blue block).    
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2.2 General materials 
All the chemicals below without specified origins were supplied from Merck Ltd. 
(BDH laboratories, UK) or Sigma-Aldrich Company Ltd. (Sigma, UK). 
2.2.1 Solutions 
0.1M PB: Solution A: NaH2PO(2H2O) 37.44 g in 1200 ml H2O; Solution B: Na2HPO4 
84.90 g in 3000 ml H2O; Add 1120 ml of solution A to 2880 ml of solution B and 
mix well. Adjust pH to 7.4 with either HCl or NaOH. Add 3000 ml distilled water 
to the final solution. 
0.3M PBS: 0.2 M phosphate buffer 100 ml, Distilled water 1900 ml & NaCl 36 g. 
1kb+ ladder: 60ng/μl 1kb ladder (Invitrogen, UK), 1x DNA loading dye in 1x TBE. 
1x Artificial cerebrospinal fluid (ACSF): NaCl 124mM (VWR International, UK), 
KCl 3mM (VWR International, UK), NaHCO3 26mM (Fischer Scientific, UK), 
NaH2PO4･2H2O 1.25mM (Sigma, UK), MgSO4･7H2O 1mM (VWR International, UK), 
CaCl2 2mM (BDH, UK), and D(+)-Glucose C6H12O8 10mM (VWR International, UK) 
dissolved in 1 litre distilled water. 
1x TBE: 90mM Trizma base, 90mM orthoboric acid, 2mM EDTA. 
5x DNA loading dye: 0.5% (w/v) SDS, 0.25% (w/v) xylene cyanol, 0.25% (w/v) 
bromophenol blue, 1.5% (w/v) Ficoll
○ R400, in 3x TBE. 
Ethidium Bromide: Stock solution: 10mg/ml in H2O. 
TE buffer: 10mM Tris-HCl pH 8.0, 1mM EDTA pH 8.0. 
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2.2.2 Enzymes 
Enzymes and suppliers are listed in Table 2.1 
Table 2.1 Enzymes 
Enzymes  Supplier  Remarks 
Dnareleasy
TM  Anachem, UK  Enzyme for cell 
digestion (DNA 
extraction) 
Thermostart high performance PCR 
mixture 
Fisher Scientific, UK  PCR reaction 
mixtures (ready-
mixed for PCR) 
 
2.2.3 Oligonucleotide primers 
All oligonucleotide primers were obtained from Sigma Genosys Ltd (Haverhill, 
UK). The primer sequence and the targeted alleles for each oligonucleotide are 
listed in Table 2.2 
Table 2.2 Oligonucleotide primers 
Primer 
name 
Nucleotide Sequence 5’-3’  For detection  Product size 
P5  TGGTAAAGACCCATGTGACCCAAG  WT Mecp2 allele  416bp 
P7  GGCTTGCCACATGACAAGAC  WT Mecp2 allele  416bp 
NeoF  GTCATCTCACCTTGCTCCTGCC  STOP Mecp2 allele  470bp 
NeoR  GAAGGCGATAGAAGGCGATGCG  STOP Mecp2 allele  470bp 
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2.2.4 Antibodies 
Primary antibodies used are listed in Table 2.3 
Table 2.3 Primary antibodies 
Antibodies  Species 
raised 
Working 
dilution 
Supplier  References 
Somatostatin  Rabbit  1:2000  Millipore, UK  Elde et al., 1978 
Parvalbumin  Mouse  1:5000  Swant, UK  Celio & Heizmann et al., 1981 
Calbindin  Mouse  1:5000  Swant, UK  Garcia-Segura et al., 1984 
Calretinin  Mouse  1:5000  Swant, UK  Rogers, 1987 
MeCP2  Rabbit  1:500  Millipore, UK  Guy et al., 2001 
NeuN  Mouse  1:500  Millipore, UK  Mullen et al., 1992 
 
Secondary antibodies used are listed in Table 2.4 
Table 2.4 Secondary antibodies 
Antibodies  Species against  Working dilution  Supplier 
Alexa-488  Mouse  1:500  Jackson Laboratories, USA 
Alexa-488  Rabbit  1:500  Jackson Laboratories, USA 
Alexa-546  Mouse  1:500  Jackson Laboratories, USA 
Alexa-546  Rabbit  1:500  Jackson Laboratories, USA 
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2.3 Mecp2-stop animal model 
2.3.1 Design of the Mecp2-stop model 
Originally, the Mecp2-stop mouse was designed by Prof Adrian Bird’s team at the 
University of Edinburgh, Edinburgh, UK. The endogenous Mecp2 allele was 
silenced by a targeted NEO-STOP cassette (Guy et al., 2007) as illustrated in 
figure 2.2. The NEO-STOP cassette was inserted inside intron 2 to generate 
truncated mRNA (or incomplete mRNA) during transcription. The truncated or 
incomplete mRNA was not then translated; therefore null production of MeCP2 
was observed in the Mecp2-stop model. The breeding strategy of the Mecp2-stop 
colony is described in later sections. 
 
III IV
NEOSTOP
 
 
Figure 2.2 Design of the Mecp2-stop model. 
In the Mecp2 allele, a NEO-STOP cassette was inserted inside intron 2. Incomplete or 
truncated Mecp2 mRNA was not then translated, and generated a functional knock-out 
phenotype by null production of the MeCP2. 
 
 
 
2.3.2 Breeding strategy and animal husbandry of the Mecp2-stop 
colony 
A local Mecp2-stop colony at University of Glasgow was established by breeding 
heterozygous Mecp2
stop/+ females (C57BL/6 background, fully congenic) with WT 
males (Balb/c background) purchased from Harlan laboratories (Shardlow, UK). 
The reason for back-cross with Balb/c background was because Mecp2
stop/+ 
females of C57BL/6 background normally neglected to feed offspring and had a 
smaller litter size. After back-cross with WT males of Balb/c background, this 
concern was largely improved. All mice used in the current experiments were 
hemizygous Mecp2
stop/y males and WT male littermates resulting from a breeding     55 
scheme involving at least 6 generations of back-cross from a congenic C57BL/6 
background onto a BALB/c background. Figure 2.3 shows all the possible 
genotypes of the Mecp2-stop offspring. Four distinct combinations of genotypes 
and genders were observed, heterozygous Mecp2
stop/+ females, hemizygous 
Mecp2
stop/y males, WT females and WT males. The offspring genotype was 
determined by PCR reactions (see results in Chapter 3). Mice were housed in 
groups of 1-3, maintained on a 12-hour light/dark cycle and provided with food 
and water ad libitum. Experiments were carried out in accordance with the 
European Communities Council Directive (86/609/EEC) and a project license 
with local ethical approval under the UK Scientific Procedures Act (1986). 
 
BALB/c Male 
(WT, Mecp2+/y)
C57BL/6 Female 
(HET, Mecp2stop/+ )
Mecp2stop/+
female 
(HET)
Mecp2+/+
female 
(WT)
Mecp2+/y
male   
(WT)
Mecp2stop/y
male 
(HEMI)
 
Figure 2.3 Breeding scheme of the Mecp2-stop colony. 
The Mecp2-stop colony was established by breeding heterozygous (HET) Mecp2
stop/+ 
females (C57BL/6 background) with WT males (Balb/c background). Four distinct 
combinations of genotypes and genders were observed, heterozygous Mecp2
stop/+ females, 
hemizygous Mecp2
stop/y males (HEMI), WT females (Mecp2
+/+) and WT males (Mecp2
+/y). The 
heterozygous females (Mecp2
stop/+) were preserved for further breeding, WT females 
(Mecp2
+/+) were culled humanely, while hemizygous males (Mecp2
stop/y) and WT males 
(Mecp2
+/y) were selected for experimental use. 
     56 
2.4 Genotyping 
2.4.1 PCR protocols for genotyping of the Mecp2-stop mice 
Standard PCR reactions were carried out in a volume of 25μl using 1x 
Thermostart PCR mixture (Epsom, UK) with each primer at a concentration of 
1μM. The primer set P5/P7 was designed to detect the WT Mecp2 allele, and the 
primer set NeoF/NeoR was designed to detect the STOP Mecp2 allele (see table 
2.3). The template concentration varied between 20-100ng of extracted mouse 
genomic DNA. The mouse genomic DNA was extracted using the Dnareleasy
TM 
(Anachem, UK) to digest ear/tail samples at 75
oC for 5 minutes followed by 96
oC 
for 2 minutes. All PCR amplifications were carried out in a GeneAmp thermal 
cycler (PCR system 9700; Applied Biosystems, UK). The reaction had an initial 
heating step at 95
oC to activate the polymerase in the Thermostart PCR mixture 
and a post cycling extension step at 72
oC for 10 minutes. Reactions were 
thermally cycled as follows: 
Thermostart Taq polymerase activation: 94
oC for 15 minutes 
35 cycles: 94
oC for 45sec 
       61
oC for 1 minute 
       72
oC for 1 minute 
Final extension: 72
oC for 10 minutes 
PCR products were separated according to their size by agarose gel 
electrophoresis. Solutions of 0.8% (w/v) agarose in 200ml of TBE were prepared 
in a microwave. When the TBE solution had cooled to approximately 40
oC, 
ethidium bromide was added to a final concentration of 200ng/ml. Gels were 
cast in a horizontal tray. DNA samples were mixed with 1x DNA loading dye and 
electrophoresed for periods of time from 45 minutes to one hour at 120V. An 
aliquot of a DNA size ladder (around 500ng) was also electrophoresed and used 
as a size marker. Separated DNA samples were visualised using an UV 
transilluminator (UV-TM-40; Upland, USA; wavelength 254nm) and photographed     57 
by Canon digital camera (PC1192; Japan). PCR products for the P5/P7 primer set 
are 416bp, and PCR products for the NeoF/NeoR primer set are 470bp. 
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2.5 Phenotyping 
2.5.1 Phenotyping protocols of the Mecp2-stop mice 
After weaning, Mecp2-stop mice were scored weekly for a number of RTT-like 
signs as described by Guy et al. 2007 (Guy et al., 2007). A comparison of human 
RTT signs and RTT-like phenotypes in Mecp2-null mouse models are listed in 
table 2.5. In Guy et al. 2007’s report, they selected six cardinal RTT-like 
features for assessment of symptoms progress and the assessment was carried 
out weekly to generate a semi-quantitative measure of phenotype status (Guy et 
al., 2007). Each of six observable features including mobility, gait, hindlimb 
clasping, tremor*, breathing* and general condition* were scored on a 0 (no 
signs), 1 (mild signs) or 2 (severe signs) scale, and scores for each feature were 
added to yield a composite symptom score between 0 and 12. The detailed 
information of each scoring category is listed in section 2.5.2. This score was 
also used to determine when animals should be subjected to humane culling. 
Any animal scoring 2 for any of the categories indicated* were routinely culled. 
 
Table 2.5 Comparisons of human RTT symptoms and RTT-like phenotypes in Mecp2-null 
mice models 
Symptoms  Human  Mecp2-null models 
Early normal development  √ (infant stage)  √ (before adult stage) 
Motor defects  √  √ 
Ataxia  √  √ 
Hypoactivity  √  √ 
Hand stereotypies  √  √ 
Breathing dysrhythmias  √  √ 
Reduced social reactions  √  √ 
Impaired learning  √  √ 
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2.5.2 Detailed information of each scoring category 
Scoring descriptions are as below, and all the scorings were performed every 
Friday morning (9-10AM) under room temperature in the animal procedure room 
(on the laboratory bench) within the animal unit at the University of Glasgow. 
1. Mobility: The mouse was observed on bench and when handled gently. 
Score 0 = as wild-type. 
Score 1 = reduced movement, extended freezing periods. 
Score 2 = no spontaneous movement. 
2. Gait:  
Score 0 = as wild-type. 
Score 1 = hind legs are spread wider than wild-type when walking or running 
with reduced pelvic elevation, resulting in a “waddling” gait. 
Score 2 = more severe abnormalities: tremor when feet are lifted, walks 
backwards or 'bunny hops' by lifting both rear feet at once. 
3. Hindlimb clasping: The mouse was observed when suspended by base of the 
tail. The hindlimb clasping representative pictures are illustrated in figure 2.4. 
Score 0 = legs splayed outwards. 
Score 1 = hindlimbs are drawn into the midline (without touching trunk) or one 
leg is drawn into the trunk. 
Score 2 = both legs are pulled into the midline tightly or touching body. 
4. Tremor: Mouse observed while standing. 
Score 0 = no tremor.     60 
Score 1 = intermittent mild tremor. 
Score 2 = continuous or violent tremor. 
5. Breathing: Observed while animal is standing still. 
Score 0 = normal breathing. 
Score 1 = short periods of rapid breathing or pauses in breathing. 
Score 2 = very irregular breathing - gasping or panting. 
6. General condition: Mouse observed for indicators of general well-being such 
as coat condition, eyes, body stance. 
Score 0 = clean shiny coat, clear eyes, normal stance. 
Score 1 = eyes dull, coat dull/ungroomed, somewhat hunched stance. 
Score 2 = eyes crusted or narrowed, piloerection, hunched posture. 
(A)                       (B) 
 
Figure 2.4 Representative pictures of the hindlimb clasping scoring. 
For the hindlimb clasping scoring, the mouse was observed when suspended by the tip of 
the tail. (A) At early stages (normally less than five weeks), the hindlimbs stretched out 
widely during observations, and the reaction was similar to that of WT littermates (score=0). 
(B) However, at later stages (normally after ten weeks), the hindlimbs were found to be 
withdrawn, and constantly in contact with the body (score=2). Adopted and modified from 
Guy et al., 2001 (Guy et al., 2001).     61 
2.5.3 The selection of symptomatic Mecp2
stop/y mice 
In this thesis, “symptomatic” Mecp2
stop/y mice were widely used in various 
experiments. The hemizygous male mice (Mecp2
stop/y genotype) used in the 
current study developed overt RTT-like signs during postnatal development that 
mirrored those reported by Guy et al. 2007 (Guy et al., 2007). In order to select 
appropriate time points for the immunohistochemistry (see Chapter 4) and 
electrophysiological experiments (see Chapter 5), the onset and the progression 
of observable phenotypes were monitored by adopting the semi-quantitative 
scoring system described in section 2.5.1. Once the sum symptom score reached 
5 or above, Mecp2
stop/y mice were considered to be sufficiently “symptomatic” 
and selected with the age-matched WT littermates for further experimental use 
(see “selection phase” in figure 2.1). 
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2.6 Immunohistochemistry methods 
2.6.1 Preparation of immunohistochemistry experiments 
A range of neurochemical markers that enable discrimination between discrete 
populations of cortical interneurons, including somatostatin (SOM), parvalbumin 
(PV), calbindin (CB) and calretinin (CR), were examined in the hippocampus and 
neocortex (see primary antibodies and secondary antibodies in table 2.3 and 
table 2.4). NeuN was also examined to evaluate the neuronal density change in 
the neocortex of hemizygous Mecp2-stop mice (Herculano-Houzel & Lent, 2005). 
The animals were deeply anaesthetised with sodium pentobarbital at 100 mg/kg 
body weight (Merial Animal Health Ltd., Harlow, UK). After animals were fully 
anesthetised, all four limbs were fixed with No.23G needles (BD Microlance, UK) 
on a wood or a polystyrene plate. The chest was opened immediately with 
dissecting scissors. Superior and inferior vena cava were clamped by a 
haemostatic forceps and a No.19G needle (BD Microlance, UK) was inserted into 
the right atrium of heart. After the No.19G needle was fixed by another 
haemostatic forceps and connected to a 100ml syringe setting on the syringe 
pump (BD Microlance, UK), the mouse was perfused transcardially with 5-10ml 
normal saline, followed by 60ml 4.0% paraformaldehyde in the 0.1M PB at a rate 
of 5-6 ml/min continuously. When mice were completely fixed (which was 
recognised by the rigid state of the tail and four limbs), brains were removed 
using a No.22 scalpel (Swann Morton Ltd., Sheffield, UK) from the skull. Brains 
were then immersed in 4.0% paraformaldehyde in 0.1M PB at room temperature 
for three hours and transferred to 0.1M PB overnight at 4
oC. On the second day, 
brains were embedded in 3% agarose (w/v) and cut coronally into 50m-thick 
serial sections on a Vibratome (Series 1000; Technical Products International, St. 
Louis, MO). Serial sections were collected and stored in 0.1 M PB. After rinsing 
three times in 0.3M PBS, for ten minutes each, the brain sections were 
incubated with primary antibodies that contained 0.3% Triton X-100 in 0.1M PB 
for 3 days at 4
oC. The sections were again rinsed three times, for ten minutes 
each, in 0.3M PBS, to wash out excess primary antibodies. Sections were then 
incubated with secondary antibodies that contained 0.3% Triton X-100 in 0.1M PB 
for three hours at room temperature. Finally, they were rinsed three times in 
0.3M PBS, mounted on glass slides, covered by coverslips in an anti-fade medium     63 
containing DAPI (Vectashield; Vector Laboratories, Burlingame, CA, USA) and 
stored at -20ºC. All the brain sections were then examined with a confocal laser-
scanning microscope (CLSM; MRC-1000; Bio-Rad, Herts, UK). 
All the brain coronary sections were scanned with a confocal laser scanning 
microscope equipped with a Krypton-Argon laser (Bio-Rad, UK) through an oil-
immersion 40x lens with a zoom of 1 and a z-separation of 0.5µm or 1µm. Scans 
were saved in the format of raw images (Bio-Rad PIC files) and viewed using 
Image J software (version 1.44; National Institutes of Health, USA). Maximum 
intensity projections were made from these image stacks and saved in TIFF 
format. 
2.6.2 Quantification of cortical cells 
For cortical cell counting, the primary somatosensory cortex of a hemizygous 
Mecp2-stop mouse was selected. After they were immunostained with 
neurochemical markers (see section 2.6.1), coronal brain sections located at 
Bregma -2.80mm to -3.60mm were chosen. As illustrated in figure 2.5, for each 
of the selected brain section, the intermediodorsal thalamic nucleus (IMD) was 
regarded as the central point, and an oblique line (35-40
o deviation from the 
vertical axis) was drawn from this centre. The line normally crossed through the 
hippocampal CA2 and CA3 regions and reached the somatosensory cortex area at 
the outer surface of brain section. As described in Chapter 1, the somatosensory 
cortex is layered from I to VI (from the outermost to the innermost layers). 
Under microscopic examination, layer V of the somatosensory cortex was 
identified, and the image stack was obtained by using a confocal laser-scanning 
microscope (Bio-Rad, UK) through an oil-immersion 40x lens with a zoom of 1 
and a z-separation of 1 µm. For either side of the coronal brain section, one to 
three adjacent areas located at the somatosensory cortex layer V were selected 
for the confocal scanning (see figure 2.5). Generally, one image stack contained 
21 to 31 images (20 to 30µm thickness). 
Image stacks were saved in the format of raw images (Bio-Rad PIC files) and 
analysed using Image J software (National Institutes of Health, USA). The 
cortical cell counting was performed by using the disector method. First, the 
probe that is used to count is called the counting frame (see figure 2.6(A)). The     64 
counting frame is an interesting probe since it is asymmetrical and extends to 
infinity. The red lines border the rejection region and are known as the rejection 
lines. The green lines pass through the acceptance region and are the 
acceptance lines. The rejection and acceptance regions cover everywhere. The 
border between these two regions extends to infinity. 
The disector method is used to count objects in three dimensions. The disector 
method uses the counting frame to count objects in two adjacent sections. In 
fact, the term disector comes from the composition of the terms di for two and 
section. The two sections must be close enough so that it is possible to infer 
what lies between the two sections. This makes it possible to use the disector 
method to sample volume. 
The two sections are referred to by unique terms. One is called the reference 
section and the other is called the lookup section. Particles are selected in the 
reference section and counting is done in the lookup section. If a particle 
appears in the reference section but not the lookup section, then the particle is 
counted. This ensures that a unique point, i.e., the top, of the particle is 
counted. Therefore, the disector method results in unbiased estimates of cell 
number in a fixed volume built by adjacent image stacks. (Sterio, 1984) 
As illustrated in figure 2.6(B)&(C), incomplete or partial cells attached to the 
border of the image stack were counted at one end but not the other, and this 
principle was applied to the x, y and z axes. The image stack was opened in 
Image J (National Institutes of Health, USA) and the counting was completed 
manually to avoid overlapped counting of the same cell in adjacent planes of 
image stacks. For cell density measurement, the density was generated by 
dividing the cell count of the image stack by its own volume. 
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Figure 2.5 Localisation of the somatosensory cortex. 
In the coronal brain sections at Bregma -3.30mm, an oblique line (35-40
o deviation from the 
vertical axis) was drawn from the intermediodorsal thalamic nucleus (IMD). This line 
normally passed through hippocampal CA1 and CA2 regions and reached somatosensory 
cortex at the superficial region of brain section. The blue square boxes indicate the selected 
areas for the cortical cell counting studies. 
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(A) 
 
(B)                                                                  (C) 
 
Figure 2.6 Disector counting method.  
(A) The counting frame, showing acceptance (green lines) and rejection regions (red lines). 
The confocal image stack (B) consisted of several two-dimensional images (C). The disector 
counting method was applied when incomplete or partial cells (labelled as circles) attached 
to the border of the image stack; cells were counted at one end but not the other. As 
illustrated here, incomplete or partial cells attached the red border were excluded for 
counting, while those attached the black border were considered as one intact cell. 
Following the same principle, incomplete or partial cells at the top plane were counted while 
those at the bottom plane were excluded.  
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2.7 Electrophysiology methods 
2.7.1 Preparation of brain slices 
Symptomatic hemizygous (Mecp2
stop/y genotype) male (see section 2.5.3 for the 
selection criteria) and their WT littermates were culled by cervical dislocation, 
followed by decapitation in accordance with UK Home Office Schedule 1 
guidelines. After decapitation, the brain was removed quickly from the skull and 
immersed in ice-cold (0-4
oC) oxygenated (95% O2, 5% CO2) 1x artificial 
cerebrospinal fluid (ACSF) solution. The brain was further hemisected and each 
part was glued to the stage of a vibrating microtome (see figure 2.7; Campden 
Instruments Ltd., UK). 
As illustrated in figure 2.7, parasagittal hippocampal slices (400μm thick) were 
prepared and transferred to an interface holding chamber in a humidified and 
oxygen-enriched (95% O2, 5% CO2, maintained at 32°C) atmosphere for at least 
one hour to enable recording, as described (McNair et al., 2006). 
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Figure 2.7 Parasagittal brain slicing. 
(A) After removal of the brain from the skull, the cerebellum was separated from the 
cerebrum (as shown in “1”) using a scalpel blade. Secondly, the cerebrum was divided into 
two hemispheres (as shown in “2”). (B) A portion of the lateral side of each hemisphere was 
cut (as shown in “3”) to allow the hemisphere to be glued onto the plastic board (coloured 
grey in (C)). (C) The parasagittal brain slicing started from the medial side of the hemisphere 
to the lateral side and the thickness setting on the vibrating microtome (Campden 
Instruments Ltd., UK) was 400μm. 
 
2.7.2 Equipment used for extracellular recording 
Transverse brain slices were transferred into a humidified and oxygen-enriched 
(95% O2, 5% CO2) atmosphere interface recording chamber maintained at 32°C 
and perfused by 1x ACSF oxygenated by 95% O2 and 5% CO2 at a rate of 6-8 
ml/min powered by a peristaltic pump (Minipuls 3; Gilson, France). Figure 2.8 
shows the equipment used for the extracellular recording. An interface 
recording chamber (HAAS-type; Berlin), a binocular dissecting microscope (Zeiss, 
Germany), a stimulating micromanipulator (Narishige, Japan), a recording 
micromanipulator (Leica, Germany) and a lamp were secured on an anti-
vibration table (Intracel, UK). Moreover, an amplifier (AxoClamp 2B; Axon 
instruments, USA), a digitizer (Digidata 1320A; Axon instruments), a 50Hz line 
noise eliminator (Hum Bug; Quest Scientific), an instrumental amplifier (model     69 
440; Brown precision) and a desktop were secured into a rig. Stimulating current 
was delivered through a bipolar tungsten stimulating electrode of 3.5MΩ 
resistance (World Precision Instruments, USA) using an isolated constant current 
stimulator (model D52A; Digitimer Ltd., UK). The current range was 0-30mA and 
the pulse duration was 0.1ms. Recording electrodes were made from standard 
walled (1.2mm O.D. x 0.69mm I.D.) borosilicate glass capillaries (Harvard 
Apparatus, UK) pulled on a Flaming/Brown micropipette puller (model P-87; 
Sutter Instrument Co., USA). The electrodes (1-5MΩ) were filled with ACSF 
solution and were connected via a silver chloride pellet-containing electrode 
holder to a headstage (HS2A; Axon Instruments). 
 
 
Figure 2.8 Image of the electrophysiology experimental setup. 
The electrophysiology experiments were performed using this setup. The equipment has 
been labelled in the figure. This image was taken by a previous PhD student, Jian Gan. 
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Pre-amplification (x100) was carried out by an AxoClamp 2B amplifier (Axon 
instruments, USA) set to current clamp mode. Further amplification (x20) and 
filtering (1Hz HP-1KHz LP) was carried out using a Brownlee instrumentation 
amplifier (model 440; Brownlee Precision, USA), giving a total amplification of 
x2000. A Hum Bug 50/60Hz noise eliminator (Quest Scientific, UK) was used to 
eliminate 50Hz line frequency noise where necessary. Data were captured by 
Digidata 1320A analogue-to-digital acquisition board (Axon Instruments) and 
transferred directly to the desktop (Viglen Pentium 4) at a sampling rate of 10 
KHz. 
 
2.7.3 Extracellular recording protocols 
After at least one hour equilibration time for hippocampal slices, a single 
stimulating electrode and a single recording electrode were placed on either 
side of the stratum radiatum in the CA1 region of hippocampal slice to stimulate 
the Schaffer collateral pathway (see figure 2.9). Small stimulating current pulses 
(current range 0-30mA; pulse duration 0.5ms) were administered to test for the 
presence of field excitatory postsynaptic potentials (fEPSP) responses. Once 
synaptic potentials were observed, input-output (I/O) curve was obtained by 
gradually increasing stimulating current and monitoring fEPSP responses. The 
stimulating current which gave half the maximum fEPSP response was then 
applied for the remainder of experiment. Measurements of synaptic responses 
were monitored in terms of the initial slope of fEPSP (Figure 2.10). The window 
for slope measurement was typically in the range of 2 to 6 ms following 
stimulation. 
Field EPSPs were evoked at the frequency of 0.05 Hz in the stratum radiatum of 
the hippocampal CA1 region. Paired-pulse facilitation (PPF) was investigated 
using a 50ms intersimulus interval. A high-frequency stimulation paradigm of 
100Hz high frequency stimulation (HFS) for one second was used to induce long-
term potentiation (LTP). Synaptic efficacy was monitored for at least 20 minutes 
before LTP induction by recording fEPSP responses every 20s (traces were 
averaged for every minute interval). Slices that did not exhibit stable fEPSP     71 
slopes (more than 5% amplitude change) during the initial 20 minutes baseline 
recording were excluded from the study. 
 
(A) 
 
(B) 
Stimulating
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Recording
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Figure 2.9 Extracellular recording at the hippocampal CA1 region. 
(A) For extracellular recording at the hippocampal CA1 region, acute hippocampal slices 
were used. (B) Illustration of a hippocampal slice from (A). On the hippocampal CA1 region, 
stimulating and recording electrodes were placed at either side of the CA1 region to 
stimulate the Schaffer collateral (Sch) pathway. Abbreviations: commissure (comm), fimbria 
(fim), dentate gyrus (DG), Mossy fibre (mf), perforant path (pp). Source: 
http://graulab.tamu.edu/J-Grau/Psyc606/Outlines/ComplexStim-Neurobio.html  
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Figure 2.10 Recording of the field excitatory postsynaptic potential (fEPSP). 
Example of a fEPSP recorded in the stratum radiatum of the mouse hippocampal CA1 
region. The arrow indicates the time of stimulation for fEPSP. The red dashed line indicates 
slope measurement for the fEPSP trace. 
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2.7.4 Electrophysiology data analysis 
All data from extracellular recordings in acute hippocampal slices were analysed 
online and fEPSP slopes re-analysed offline using the software packages WinLTP 
(Anderson & Collingridge, 2007) and Excel 2003 (Microsoft, USA). Paired-pulse 
facilitation (PPF) was calculated as the amplitude ratio of second to first 
response for each paired stimulation event (see figure 2.11). Post-tetanic 
potentiation (PTP) was calculated as the mean of the first three slope data 
points following HFS. LTP was measured at 40-60 minutes post-HFS in the one-
hour LTP experiments, and at 12-15 minutes post-HFS in the LTP saturation 
experiments. Data were gathered from recordings made from 1-3 slices per 
mouse brain and were expressed as mean±SEM of all the slices. All data were 
graphically illustrated using GraphPad Prism 5.0 (GraphPad Software, USA). WT 
mice used as controls were age-matched to their respective experimental (i.e. 
symptomatic or pre-symptomatic) groups. 
 
Figure 2.11 Measurement of the pair-pulse facilitation (PPF). 
As illustrated, paired stimulations (50ms interval) were applied for the generation of paired 
fEPSPs. The second fEPSP had a higher response (amplitude) than the first one due to 
elevated presynaptic calcium concentrations. Paired-pulse facilitation (PPF) was calculated 
as the amplitude ratio of second to first response for each paired stimulation event. 
2.7.5 Statistical analysis of electrophysiological data 
Data from the PPF, PTP and LTP experiments were compared by repeated-
measures ANOVA with Tukey’s post-hoc analysis (Minitab version 10) and a p 
value of less than 0.05 was taken as indicating statistical significance. 
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2.8 Drug application in Mecp2-stop mice 
2.8.1 Memantine application 
For the memantine treatment experiment in acute slices (see Chapter 5), 
1mg/ml memantine stock was made by dissolving memantine hydrochloride 
(Tocris Bioscience, Bristol, UK) in 1x ACSF. This was subsequently added to the 
slice perfusion medium (ACSF) at 1μM final concentration and pumped into the 
bath containing the slices being recorded. Recordings were commenced 30–60 
min after the slices first became exposed to memantine. For the chronic in vivo 
memantine treatment study (see results in Chapter 5), memantine hydrochloride 
was dissolved in sterile water at a final perfusate concentration of 3mg/ml 
(Diehl et al., 2001). Dosing was administered orally by gavage at a dose of 
30mg/kg. Mice were dosed daily over a four-week period. The choice of doses 
for the drug was based on those found to be effective in previous studies, with 
in vitro at 1μM (Frankiewicz & Parsons, 1999), in vivo at 30mg/kg/day 
(Minkeviciene et al., 2004).     75 
3  Genotype phenotype correlations in Mecp2-stop 
mice 
3.1 Introduction 
Over 95% of the classical RTT pathogenesis originates from MECP2 mutations 
(Neul et al., 2008), and the Mecp2-mutant mouse model recapitulates most RTT 
symptoms and serves as a good model for investigating MeCP2 functions (Calfa et 
al., 2011) (see table 2.5 in chapter 2). Mecp2-mutant mouse has a late onset of 
phenotypes (as in RTT patients), and it is generally not possible to differentiate 
them from their WT littermates based on gross phenotypic assessments at early 
postnatal stages (Calfa et al., 2011). In this thesis, I used the Mecp2-stop model, 
and three possible genotypes (WT, Mecp2
stop/+ and Mecp2
stop/y) of offspring were 
generated (Guy et al., 2007). In order to set breeding colonies and select 
animals for further experimental use, it was essential to identify genotypes. 
Therefore, the aim in this chapter was to confirm the genotypes of the Mecp2-
stop mouse colony established in Glasgow. This was done by applying two sets of 
PCR reactions (one for detection of the WT allele, and the other for detection of 
the mutant allele). The second aim was to map out the progression of symptoms 
as the RTT-like phenotype developed. For this, I adopted the scoring system that 
was published by Guy et al., 2007 for the phenotype recording of the Mecp2-stop 
mice (Guy et al., 2007). Since the progression of symptoms has never been 
analysed in detail in hemizygous Mecp2-stop mice, both the sum symptom score 
and the score of each subcategory (mobility, gait disturbance, hindlimb clasping, 
tremor, breathing abnormality, and general conditions) were recorded and 
analysed. 
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3.2 Confirmation of genotypes in Mecp2-stop mouse 
colony 
3.2.1 Confirmation of genotypes in Mecp2-stop mouse colony by 
PCR 
The Mecp2-stop mouse model was designed by Prof. Adrian Bird’s team at the 
University of Edinburgh with a STOP cassette inserted into intron 2 (see Chapter 
2 for the detailed design). This design led to a truncated mRNA production and 
generated a MeCP2 protein-null phenotype. In order to detect both the WT and 
mutant alleles in the Mecp2-stop mice, the primers designed by Guy et al. 2007 
were adopted to generate and amplify a 416bp product (from primers P5/P7 
reaction; to detect the WT allele) and a 470bp product (from primers 
NeoF/NeoR reaction; to detect the mutant allele), respectively (Guy et al., 2007) 
(see figure 3.1). Tissue samples were collected from Mecp2-stop mice and the 
DNA from each sample was extracted. The extracted DNA was diluted and 
prepared for PCR reactions. PCR products were loaded onto an agarose gel for 
electrophoreses. The scheme for interpretation of genotype results is given in 
table 3.1. Representative PCR results are shown in figure 3.2. For each DNA 
sample, two PCR reactions were performed; the first lane was loaded with the 
PCR product from P5/P7 primers reaction and the second lane was loaded with 
the PCR product from NeoF/NeoR primers reaction. As illustrated in figure 3.2, 
the tenth and eleventh lanes were typically representative of the WT genotype 
result (positive only in the primers P5/P7 reaction), and the sixteenth and 
seventeenth lanes were from the hemizygous Mecp2
stop/y DNA sample, only 
presenting positive in the primers NeoF/NeoR reaction. Once genotypes had 
been confirmed, heterozygous females were preserved for breeding and 
maintenance of the Mecp2-stop colony, and WT females were culled humanely. 
Both WT and hemizygous males, were selected for further experimental use 
(immunohistochemistry or electrophysiology studies) and were recorded weekly 
for symptom progression. In later sections, the observation of symptom progress 
of the Mecp2
stop/y mice is illustrated. 
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Figure 3.1 Illustration of the Mecp2-stop mice design 
The upper diagram shows the Mecp2 gene of the WT allele, and the lower diagram shows 
the insertion of a neo-stop cassette into intron 2 of the Mecp2 gene of the STOP allele. The 
primer set P5/P7 was designed to amplify a 416bp PCR product in the WT allele, while the 
primer set NeoF/NeoR was designed to amplify a 470bp PCR product in the STOP allele. 
 
Table 3.1 Mecp2-stop mice genotype patterns 
  Genotype  P5/P7  NeoF/NeoR  Lanes in fig. 3.2 
Heterozygous female  Mecp2
stop/+  Positive  Positive  6/7, 8/9,12/13, 
26/27, 28/29  
WT female  Mecp2
+/+  Positive  Negative  10/11, 14/15 
Hemizygous male  Mecp2
stop/y  Negative  Positive  16/17, 18/19 
WT male  Mecp2
+/y  Positive  Negative  20/21, 22/23, 24/25 
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(A) 
 
Figure 3.2 Genotyping data of the Mecp2-stop mouse model 
(A) Three different genotypes (WT, Mecp2
stop/+ and Mecp2
stop/y) were distinguished by the 
PCR test. 1kb+ DNA ladder was loaded in lane 1 and lane 30. For each animal DNA sample, 
the first lane was for the WT allele detection (416bp), and the second lane was for the 
mutant allele detection (470bp). Lanes 2 and 3 were no DNA controls, and lanes 4 and 5 
were positive controls (previously confirmed heterozygous female DNA in the PCR reaction). 
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3.2.2 Western blot and immunohistochemistry verifications of 
lack of MeCP2 production in the hemizygous Mecp2-stop 
mice 
In the Mecp2-stop model design, a STOP cassette was inserted into intron 2 
leading to a functional knock-out of Mecp2. In order to confirm that MeCP2 has 
not been generated in detectable amounts in hemizygous Mecp2-stop brains, 
tissues from hemizygous Mecp2-stop mice were assessed by western blot and 
immunohistochemistry. Coronal brain slices from one-month-old Mecp2
stop/y mice 
and their age-matched WT littermates were used in both types of experiments. 
As shown in figure 3.3, western blot analysis (performed by Ms Faye McLeod; WT: 
n=2, Mecp2-stop: n=2) confirmed the absence of a detectable 75kDa MeCP2 band 
in protein extracts from the brains of hemizygous Mecp2
stop/y mice. This 
conclusion was in line with the absence of detectable MeCP2 within the 
hippocampus as revealed by immunohistochemistry studies (performed by myself; 
WT: n=2, Mecp2-stop: n=2; see figure 3.3). In contrast, in WT mice a strong 
MeCP2 signal was detected from a similar amount of protein in the western 
analysis and strong expression was apparent in the cell nuclei in the 
hippocampal formation including all principal cells of the hippocampus (not 
shown) and dentate gyrus. Therefore, the functional silencing of MeCP2 in the 
Mecp2-stop model was proved to be robust. 
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Figure 3.3 Robust silencing of MeCP2 expression in the Mecp2-stop mouse model 
(A) Genotyping results from two WT and two hemizygous Mecp2-stop mice used in the 
western blot and immunohistochemistry experiments. (B) Western blot of protein extract 
from hippocampus of WT and hemizygous male mice. Samples from each of two mice were 
loaded in adjacent lanes. GAPDH (37 kDa) detection was carried out as a loading control. 
(Data collected and provided by Ms Faye McLeod) (C) Fluorescence micrographs of dentate 
gyrus from WT (I, II) and from hemizygous (III, IV) male mice immunostained for MeCP2 (II, 
IV) and co-stained with DAPI (I, III) to reveal nuclei. In the Mecp2-stop model, only DAPI 
stained nuclei were identified, while no signals were detected in the MeCP2 staining. 
 
 
 
 
 
 
 
 
 
     81 
3.3 Phenotype scoring of Mecp2-stop mice 
3.3.1 Progression of sum symptom score in hemizygous Mecp2-
stop mice 
The phenotype progression of hemizygous Mecp2-stop mice was recorded by 
adopting the scoring method described by Guy et al. 2007 (Guy et al., 2007). Six 
categories of symptoms were scored (mobility, gait, hindlimb clasping, tremor, 
breathing, and general condition) using a semi-quantitative method (see Chapter 
2 for detailed methods). All the Mecp2-stop mice and their WT littermates were 
documented weekly for symptom scoring, and once the symptom score reached 
five or more, the Mecp2-stop animal and its age-matched WT littermate were 
selected and processed for immunohistochemistry (see in Chapter 4) or 
electrophysiological (see in Chapter 5) experiments. Figure 3.4 presents the 
progression of sum symptom score in hemizygous Mecp2-stop mice and their WT 
littermates. Symptom onset was generally recorded from the fifth week to the 
seventh week, and always before the tenth week. After the tenth postnatal 
week, symptoms progressed rapidly to reach a score of five or more (as the 
defined as “symptomatic” in this thesis).  
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Figure 3.4 Symptoms progression in Mecp2-stop mice 
(A) Time plot showing onset and progression of phenotypic signs in Mecp2-stop mice 
(n=15). Scores for WT mice (n=10) were also plotted for comparison. The curve for the 
hemizygous mice was censored at the top end due to the humane culling policy in operation. 
The red semi-transparent block indicates the selection phase (symptomatic animals) for 
immunohistochemistry or electrophysiological experiments. (B) Using nonlinear regression 
method, the symptoms versus age plot fits a one-phase exponential curve. 
 
 WT   Mecp2
stop/y
 
r
2
=0.998     82 
3.3.2 Progression of symptom score in each specific category of 
hemizygous Mecp2-stop mice 
As mentioned in previous sections, the sum score system consisted of six distinct 
categories: motor dysfunction, gait disturbance, hindlimb clasping, tremor, 
breathing abnormality, and abnormal general conditions. These categories 
represent key aspects of the RTT-like phenotype and the scoring system was 
tailored to the specific constellations of features and was adopted in order to 
give a score that encompassed the key salient features, that characterise the 
Mecp2-stop phenotype. However, I also went on to assess each of the observed 
measures individually. The symptom progression of each distinct category was 
documented weekly. 
The progression of symptom scores in each individual category of hemizygous 
Mecp2-stop mice were plotted in figure 3.5. As illustrated in figure 3.5, the 
mobility score of Mecp2-stop mice (n=7) had a mean onset of 7.58 ± 0.36 weeks 
and mean maximal score of 1.67 ± 0.33 units. The gait score of Mecp2-stop mice 
had a mean onset of 7.87 ± 0.68 weeks and mean maximal score of 1.33 ± 0.33 
units. The hindlimb clasping score of Mecp2-stop mice had a mean onset of 8.58 
± 0.81 weeks, and the mean maximal score was 1 ± 0 units. The tremor score of 
Mecp2-stop mice had a mean onset of 8.01 ± 0.68 weeks, and the mean maximal 
score was 1 ± 0 units. The breathing score of Mecp2-stop mice had a mean onset 
of 11.58 ± 0.52 weeks, and the mean maximal score was 0.33 ± 0.33 units. The 
last was the general condition score; the mean onset was 10.72 ± 0.72 weeks, 
and the mean maximal score was 0.67 ± 0.67 units. The tremor, breathing and 
general condition data never reached a score of two due to the censoring 
criteria (indicated by  sign in figure 3.5). In summary, motor dysfunction, gait 
disturbance, hindlimb clasping, and tremor all had an earlier onset, while 
breathing abnormality and abnormal general conditions occurred later with 
severer phenotypes developed (see figure 3.6 & 3.7). 
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Figure 3.5 The progression of symptom score in each individual category. 
(A)-(F) The progression of symptom score in each individual category was plotted as mean 
± SEM units. The star sign () indicates the criterion that an Mecp2-stop mouse was 
selected for experiments or culled once score reached two in any of the tremor, breathing or 
general condition groups. 
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Figure 3.6 The onset of symptom score in each individual category. 
The symptom onset of each individual category was plotted as mean ± SEM wks. 
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Figure 3.7 Summary of score progression for each symptom measure. 
All symptom score data were plotted as weekly score means. 
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3.4 Survival analysis of hemizygous Mecp2-stop mice 
Both progression of symptoms and the shortened period of survival were 
characteristic features of phenotypes in MeCP2 functional knock-out mice. A 
previous study (Guy et al., 2001) reported that MeCP2 functional knock-out mice 
had a shorter life span compared to WT mice. Reactivation of MeCP2 in MeCP2 
functional knock-out mice was proved to be capable of prolonging the life span 
and alleviating symptoms at adult stages (Guy et al., 2007). The aim here was to 
assess the normal life span of Mecp2-stop mice. Mecp2-stop mice (n=10) and 
their WT littermates (n=8) were caged under identical conditions in the Animal 
Unit at the University of Glasgow (see Chapter 2) The incidence of sudden or 
unexpected death before 2 month old was low (less than 1%) under the care of 
experienced animal unit staff. Animals were monitored on a daily basis for 
obvious signs of distress. Symptom scores were recorded at weekly intervals, and 
any Mecp2-stop mouse that scored two in the tremor, breathing or the general 
condition category was humanely culled and reported as death. As presented in 
figure 3.8, the distribution of Mecp2-stop mice survival ranged from 70 days 
(10wk) to 110 days (15.7wk). 
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Figure 3.8 Survival of hemizygous Mecp2-stop mice 
Mecp2-stop mice (n=10) and their WT littermates (n=8) were assessed for the normal life 
span. Both groups were caged under identical conditions described in chapter 2. Survival 
was recorded on a daily basis for obvious signs of distress. Any Mecp2-stop mouse that 
was given a score of two in any of the tremor, breathing or general condition categories was 
humanely culled and reported as death. The distribution of Mecp2-stop mice survival 
ranged from 70 days (10wk) to 110 days (15.7wk). 
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3.5 Discussion 
Before the application of Mecp2-stop animals in immunohistochemistry (see 
Chapter 4) or electrophysiological experiments (see Chapter 5), it was essential 
to confirm the genotypes of the colony we established in Glasgow. The primers 
designed by Guy et al. 2007 (Guy et al., 2007) were adopted in the PCR 
experiments to confirm the genotypes of Mecp2-stop animals. The PCR results 
showed unambiguous evidence of all three different genotypes (WT, Mecp2
stop/+ 
and Mecp2
stop/y). However, the PCR results were solely the functional knock-out 
evidence at the gene level, the null production of MeCP2 still needed to be 
verified at the protein level. The western blot and immunostaining assessments 
for brain slices from Mecp2-stop
 mice
 provided further robust evidence and 
confirmed the functional knock-out of MeCP2 in hemizygous Mecp2
stop/y mice. 
RTT-like phenotype development serves as a feature of the Mecp2-stop mouse 
model. On average, Mecp2
stop/y mice began to display symptoms around week 7, 
and the severity increased gradually. After postnatal week 10, symptoms 
aggravated rapidly and induced inevitable death at around week 12 to 15, while 
their WT littermates always scored zero all the time. The symptom score system 
was adopted from Guy et al. (Guy et al., 2007). Previous study has described the 
sum symptom score as a good indicator for categorising suitable Mecp2-stop 
animals into mild symptomatic (score= 2-4) and symptomatic (score= 5 or more) 
groups (Guy et al., 2007). In this thesis, I adopted an identical symptom score 
system for the selection of Mecp2-stop mice for experimental use. 
The individual category of the symptom score represented key aspects of the 
RTT-like phenotype and the score system was tailored to the specific 
constellations of features. The analyses from distinct symptom categories 
showed that impaired mobility and gait disturbance consistently occurred earlier 
(the mean onset of impaired mobility was 7.58 ± 0.36 weeks and the mean onset 
of gait disturbance was 7.87 ± 0.68 weeks), followed by tremor (8.01 ± 0.68 
weeks) and hindlimb clasping (8.58 ± 0.81 weeks), and the last two to occur 
were abnormal general conditions (10.72 ± 0.72 weeks) and irregular breathing 
(11.58 ± 0.52 weeks). Regarding the maximal score of each category, the highest 
was the impaired mobility (1.67 ± 0.33 units) and the lowest was the breathing 
(0.33 ± 0.33 units). From the analyses of individual symptom progression, the 
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mobility score appeared to be the best indicator since it always started earliest 
and reached the highest maximal score when Mecp2-stop mice became 
symptomatic. In contrast, both the breathing and general condition scores 
seemed to contribute less to the sum symptom score. In RTT patients, the 
clinical signs begin with hypotonia, microcephaly, and later develop into 
respiratory abnormalities (Chahrour & Zoghbi, 2007). Therefore, it is not 
surprising that the breathing score in Mecp2-stop mice always had a late onset. 
Both the breathing and general condition scores may not be the most suitable 
indicators of the phenotype development and the experimental animal selection 
of Mecp2-stop mice. However, the order of symptom onsets in Mecp2-stop mice 
was similar to that of human RTT patients, and this indicated the Mecp2-stop 
animal was a good model for investigating the pathogenesis of Rett syndrome by 
recapitulating most of the clinical features of RTT. 
During weeks 12 to 15, the variance in the progression of each distinct symptom 
score showed huge differences. The breathing and the general condition scores 
showed great standard errors while in the hindlimb clasping and the tremor 
scores, no standard errors were shown. This was possibly due to the diminished 
number of Mecps2-stop mice since some died or were culled.     89 
4  Immunohistochemistry 
4.1 Introduction 
RTT mouse models provide potent resources for investigating the genotype– 
phenotype pathway. In Chapter 3, I examined the phenotype progression in the 
Mecp2-stop male mice. However, the underlying alterations to neuronal network 
behaviour that lead to the clinical symptoms are still poorly 
understood. Amongst the prominent clinical features of RTT are abnormal EEG 
patterns and a predisposition to epilepsy (Chahrour & Zoghbi, 2007). Most RTT 
patients have seizures, ranging from benign focal partial convulsions to 
generalised intractable epilepsies (Jian et al., 2006). Molecular changes that 
occur during epileptogenesis are not yet clarified and could be attributed to cell 
death, reorganisation of neural networks, alterations in the release of 
neurotransmitters, etc (Herman, 2006). These changes cause neuronal networks 
to become hyperexcitable, and may lead to seizures. 
Recent laboratory studies have observed the hyperexcitable state within cortical 
and hippocampal circuits in RTT mouse models (Dani et al., 2005; Nelson et al., 
2006; Zhang et al., 2008; Wood & Shepherd, 2010). The crucial mechanism that 
underlies hyperexcitability might be due to the loss or dysfunction of inhibitory 
neurons. Interestingly, one recent report showed that functional knock-out of 
MeCP2 selectively in inhibitory neurons could recapitulate most of the RTT-like 
symptoms in mice, including seizure disorder and hyperexcitable discharging 
patterns in EEG recordings (Chao et al., 2010). A previous study has also 
demonstrated that lack of MeCP2 disrupted the development and function of 
inhibitory neuronal circuits (Zhang et al., 2010). In summary, MeCP2 is regarded 
as critical to the development and functions of inhibitory neuronal networks. 
In the mammalian brain, inhibitory neurons can be further classified into distinct 
subgroups by various protein markers (Druga, 2009). Although the pivotal 
function of inhibitory neurons may underlie the pathogenesis of seizures in RTT 
patients, few studies have focused on the role of MeCP2 in the development and 
functioning of inhibitory neurons, and they have particularly rarely focused on 
the alterations of distinct subgroups of inhibitory neurons.     90 
The aim of the work presented in this chapter was to assess the possible 
alterations in cell density and distribution pattern of each subtype of inhibitory 
neurons. In this chapter, I first assessed the cell densities of the cortex in both 
symptomatic Mecp2-stop and WT brains to obtain the correcting factor for the 
standardisation of cell density of each subtype of inhibitory neurons. Secondly, 
the cell density of each subgroup of inhibitory neurons in the symptomatic 
Mecp2-stop and WT cortices was assessed and standardised by the correcting 
factor. Thirdly, the distribution pattern of distinct neuronal subtypes in the 
symptomatic Mecp2-stop hippocampus was characterised and compared with 
that of the WT hippocampus. 
4.2 Macroscopic structure of the symptomatic Mecp2-
stop mouse cortex 
The cortical thickness of both symptomatic Mecp2-stop (score 5 or more) and WT 
mice were assessed microscopically. The cortical thickness measurement was 
accomplished in the primary motor cortex (coronal section ranges from Bregma -
0.1 to 0.74mm) and primary somatosensory cortex (coronal section ranges from 
Bregma 2.8 to 3.6mm) in both symptomatic Mecp2-stop and WT brains. Figure 
4.1(A) presents the measurement of cortical thickness in the primary motor 
cortex at Bregma 0.2mm. As shown in figure 4.1(B)&(C), the cortical thickness of 
primary motor cortex in symptomatic Mecp2-stop mouse was significantly 
thinner than that of age-matched WT mouse (data was shown as mean ± SEM; 
WT= 1493 ± 58.58 µm, n=4 animals; symptomatic Mecp2-stop= 1292 ± 72.47 µm, 
n=4 animals; p<0.001; data collected and analysed by Dr Rosie Spike). This data 
was comparable with the cortical thickness data of the primary somatosensory 
cortex of symptomatic Mecp2-stop mice. As illustrated in figure 4.1(D), the 
cortical thickness of the primary somatosensory cortex in symptomatic Mecp2-
stop mice was also significantly thinner than that of WT mice (data was shown as 
mean ± SEM; WT= 1189 ± 53.3 µm, n=5 animals; symptomatic Mecp2-stop= 1062 
± 68.33 µm, n=4 animals; p<0.001; data collected and analysed by myself). All 
these data together indicated that the cortex of symptomatic Mecp2-stop mouse 
is thinner than that of WT mouse.  
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Figure 4.1 The cortical thickness of symptomatic Mecp2-stop mice was thinner in WT mice. 
(A) Illustration of measurement of cortical thickness in primary motor cortex of mouse. (B) 
Representative micrographs for cortical thickness measurement of primary motor cortex in 
both symptomatic Mecp2-stop and WT brains. (C) Comparison of cortical thickness of 
primary motor cortex in both symptomatic Mecp2-stop and WT brains. (D) Comparison of 
cortical thickness of primary somatosensory cortex in both symptomatic Mecp2-stop and 
WT brains. All data presented as mean ± SEM. 
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4.3 Cortical cell density quantifications in the 
somatosensory cortex in Mecp2-stop mice 
4.3.1 Cell densities in layer five of the somatosensory cortex in 
symptomatic Mecp2-stop mice 
As detailed in chapter 2, the cell quantification work in the following sections 
was carried out on brains from symptomatic Mecp2-stop mice and their WT 
littermates. The brains were fixed with paraformaldehyde prior to 
immunostaining and image analysis. In order to assess the cortical cell density, 
DAPI-positive cell densities in the somatosensory cortex layer five of both 
symptomatic Mecp2-stop mice and age-matched WT littermates were examined. 
The cortical layer five was chosen because it is the main output layer of the 
cortex, and because it is easy to recognise even without counterstaining. In 
particular, the large pyramidal cells in cortical layer five of the primary 
somatosensory cortex in Mecp2-null mice have been reported to have reduced 
spontaneous firing at both early postnatal developmental stages by using whole-
cell patch-clamp recordings (Dani et al., 2005).  
As presented in figure 4.2(A)-(C), all the brain sections used in this chapter were 
co-stained with DAPI and NeuN markers. The cell density quantification was 
carried out in image stacks by applying disector methods manually (see details in 
Chapter 2). As shown in figure 4.2(D), the DAPI positive cell density in 
somatosensory cortex layer five of symptomatic Mecp2-stop mice was 1.28 times 
greater than that of WT littermates (data shown as mean ± SEM; WT= 271851.3 ± 
6845.7 cells/mm
3, n=10 from 5 animals; Mecp2-stop= 348671.6 ± 9014.2 
cells/mm
3, n=10 from 4 animals; p<0.0001). 
In the rodent cortical layer five, neurons constitute 70-80% of the cell population 
(Bass et al., 1971). In order to evaluate whether neuronal density was also 
different in the symptomatic Mecp2-stop mouse brain, NeuN-positive cell 
densities in the somatosensory cortex layer five of both symptomatic Mecp2-stop 
and WT mice were analysed. NeuN is a neuronal nuclear antigen and was 
detected in most neuronal types within the mouse brain; therefore NeuN is 
recognised as a neuronal marker (Herculano-Houzel & Lent, 2005). As shown in 
figure 4.2(D), NeuN-positive cell density was 1.41 times greater than that of WT     94 
(data shown as mean ± SEM; WT= 206620.2 ± 7254.2 cells/mm
3, n=10 from 5 
animals; Mecp2-stop= 290504.5 ± 9600.8 cells/mm
3, n=10 from 4 animals; 
p<0.0001). 
Since the DAPI and NeuN positive cell count were quantified from the same 
regions of brain sections, NeuN-positive cell percentage of the total cortical 
population in layer five of somatosensory cortex was calculated. As illustrated in 
figure 4.2(E)&(F), NeuN-positive percentage in layer five of somatosensory 
cortex had no statistical difference between Mecp2-stop and WT groups (data 
shown as mean ± SEM; WT(NeuN)= 76 ± 2.67%, WT(non-NeuN)=24 ± 2.43%, n=10 
from 5 animals; Mecp2-stop(NeuN)= 83.3 ± 2.75%, Mecp2-stop(non-NeuN)=16.7 ± 
2.53%, n=10 from 4 animals; Chi-Square test, p=0.0726). Although a trend 
towards a higher proportion of neurons in symptomatic Mecp2-stop mice existed, 
these results have demonstrated that the NeuN-positive cell density in the 
symptomatic Mecp2-stop mouse brain is elevated, compared to WT mice, and is 
roughly proportional to the total cortical cell density alteration. 
 
 
 
 
 
 
 
 
 
     95 
  (A)                                       (B)                                       (C) 
50µm 50µm 50µm Mecp2stop/y Mecp2stop/y Mecp2 stop/y 50µm 50µm 50µm 50µm 50µm 50µm 50µm 50µm 50µm Mecp2stop/y Mecp2stop/y Mecp2 stop/y
 
(D)                                                   (E) 
     
       
ns ns ns ns ns ns
 
(F) 
ns ns ns
 
Figure 4.2 Cell densities elevated with remaining NeuN-positive percentage in layer five of 
somatosensory cortex in symptomatic Mecp2-stop mice. 
(A)-(C) Confocal images of DAPI-positive and NeuN-positive cells. DAPI is coloured blue 
while NeuN is coloured red. High power insets from (A)-(C) are shown at upper left corners. 
(D) DAPI-positive and NeuN-positive cortical cell densities in symptomatic Mecp2-stop mice 
and their WT littermates. (D)&(E) The percentage of NeuN-positive and NeuN-negative cells 
in layer five of somatosensory cortex in both symptomatic Mecp2-stop and WT cortices.     96 
4.3.2 Categorisation of inhibitory interneurons in the 
somatosensory cortex layer V by the expression of calcium-
binding proteins  
Neurons releasing excitatory neurotransmitters are regarded as excitatory 
neurons and neurons releasing inhibitory neurotransmitters are regarded as 
inhibitory neurons. Recently, functional knock-out of MeCP2 selectively in 
inhibitory neurons was reported to recapitulate most of the RTT-like symptoms 
in mice (Chao et al., 2010). Inhibitory neurons comprise subgroups of neurons 
with distinct electrical and anatomical properties. In the mammalian cortex, 
inhibitory neurons can be further classified into distinct subtypes on the basis of 
protein markers; parvalbumin (PV), somatostatin (SOM), calretinin (CR) and 
calbindin (CB). In the following sections, these protein markers (as illustrated in 
figure 4.3) were examined to assess whether the cell density of different 
inhibitory neuron subtypes was altered in the somatosensory cortex of 
symptomatic Mecp2-stop mice. 
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Figure 4.3 The percentage of distinct inhibitory neurons in rodent cortical layers V & VI. 
In order to discriminate distinct subtypes of inhibitory neurons (GABAergic neurons), 
different protein markers were applied. In rodent cortical layers V & VI, PV positive cells 
comprise ~50% of all inhibitory neurons, while SOM positive cells comprise ~30%, CR 
positive cells comprise ~15%, and CB positive cells comprise ~30% (most CB positive cells 
were recognised by more than one protein marker). Therefore, more than 95% of inhibitory 
neurons could be recognised by staining with one or more of these four markers (PV, SOM, 
CR and CR). Adopted and modified from Kubota et al., 1994 (Kubota et al., 1994).     97 
4.3.3 Parvalbumin (PV) positive cell density in layer five of the 
somatosensory cortex in symptomatic Mecp2-stop mice 
The cell density of PV positive neurons in layer five of the somatosensory cortex 
was quantified in confocal image stacks by manual counting with the disector 
principle (see Chapter 2). As shown in figure 4.4(B), the raw PV positive cell 
density in the somatosensory cortex layer five of symptomatic Mecp2-stop mice 
was significantly increased compared to WT mice (data shown as mean ± SEM; 
WT= 38516.3 ± 1497.5 cells/mm
3, n=30 regions from 5 animals; Mecp2-stop= 
51756.9 ± 2791.3 cells/mm
3, n=24 regions from 4 animals; p<0.0001). In section 
4.3.1, the total cortical cell density (DAPI-positive cell density) in layer five of 
somatosensory cortex in symptomatic Mecp2-stop mice was shown to be 1.28 
times greater than that of WT mice (the Mecp2-stop/WT DAPI correcting factor= 
1.28). In order to calibrate the effect of higher cell density in the Mecp2-stop 
mouse brain, the raw PV positive density was standardised by the Mecp2-
stop/WT DAPI correcting factor. The DAPI-standardised PV positive cell density 
equals to the raw PV positive cell density divided by the Mecp2-stop/WT DAPI 
correcting factor. As presented in figure 4.4(B), after calibration with the 
Mecp2-stop/WT DAPI correcting factor, there was no difference between Mecp2-
stop and WT groups (data shown as mean ± SEM; WT= 38516.3 ± 1497.5 
cells/mm
3, n=30 regions from 5 animals; Mecp2-stop= 40353.7 ± 2176.3 
cells/mm
3, n=24 regions from 4 animals; p=0.48). 
In this chapter, I also applied the Mecp2-stop/WT NeuN correcting factor to 
calibrate the raw cell density. In section 4.3.1, the total neuronal cell density 
(NeuN-positive cell density) in layer five of the somatosensory cortex in 
symptomatic Mecp2-stop mice was shown to be 1.41 times greater than that of 
WT mice (the Mecp2-stop/WT NeuN correcting factor = 1.41). The NeuN-
standardised PV positive cell density is equal to the raw PV positive cell density 
divided by the Mecp2-stop/WT NeuN correcting factor. As shown in figure 4.4(B), 
after calibration with the Mecp2-stop/WT NeuN correcting factor, there was no 
difference between Mecp2-stop and WT groups (data shown as mean ± SEM; WT= 
38516.3 ± 1497.5 cells/mm
3, n=30 regions from 5 animals; Mecp2-stop= 36811.9 
± 1985.3 cells/mm
3, n=24 regions from 4 animals; p=0.49). 
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Figure 4.4 Parvalbumin (PV)-positive cell density in layer five of the somatosensory cortex 
layer five in symptomatic Mecp2-stop mice. 
(A) Representative micrograph of PV-positive cells in layer five of the somatosensory cortex 
in symptomatic Mecp2-stop brains. PV-positive cells are coloured red. (B) The PV-positive 
cell density in symptomatic Mecp2-stop (raw data and after calibrations) and WT mice. All 
data shown as mean ± SEM. 
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4.3.4 Somatostatin (SOM) positive cell density in layer five of the 
somatosensory cortex in symptomatic Mecp2-stop mice 
I next examined the cell density of SOM immunopositive neurons in layer five of 
the somatosensory cortex in symptomatic Mecp2-stop mice. As shown in figure 
4.5(B), the raw SOM positive cell density in layer five of the somatosensory 
cortex showed no difference between Mecp2-stop and WT groups (data shown as 
mean ± SEM; WT= 20381.3 ± 1381.7 cells/mm
3, n=30 regions from 5 animals; 
Mecp2-stop = 23559.1 ± 1018.6 cells/mm
3, n=24 regions from 4 animals; p=0.08). 
After calibration with the Mecp2-stop/WT DAPI correcting factor, there was no 
difference between Mecp2-stop and WT groups (data shown as mean ± SEM; WT= 
20381.3 ± 1381.7 cells/mm
3, n=30 regions from 5 animals; Mecp2-stop= 18368.5 
± 794.2 cells/mm
3, n=24 regions from 4 animals; p=0.2544). Interestingly, after 
calibration with the Mecp2-stop/WT NeuN correcting factor, the NeuN-
standardised SOM positive cell density in layer five of the somatosensory cortex 
in symptomatic Mecp2-stop mice was significantly decreased compared to that 
of WT mice (data shown as mean ± SEM; WT= 20381.3 ± 1381.7 cells/mm
3, n=30 
regions from 5 animals; Mecp2-stop= 16756.3 ± 724.5 cells/mm
3, n=24 regions 
from 4 animals; p=0.04). 
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Figure 4.5 Altered cell density of somatostatin (SOM) positive neurons in the 
somatosensory cortex in symptomatic Mecp2-stop after the NeuN correcting factor 
calibration. 
(A) Representative micrograph of SOM-positive cells in layer five of the somatosensory 
cortex in symptomatic Mecp2-stop brains. SOM-positive cells are coloured green. (B) The 
SOM-positive cell density in symptomatic Mecp2-stop (raw data and after calibrations) and 
WT mice. All data shown as mean ± SEM.     100 
4.3.5 Calretinin (CR) positive cell density in layer five of the 
somatosensory cortex in symptomatic Mecp2-stop mice 
The cell density of CR immunopositive neurons in layer five of the somatosensory 
cortex in symptomatic Mecp2-stop mice was also assessed. As shown in figure 
4.6(B), the raw CR positive cell density in layer five of the somatosensory cortex 
showed no difference between Mecp2-stop and WT groups (data shown as mean 
± SEM; WT= 9944.1 ± 978.5 cells/mm
3, n=30 regions from 5 animals; Mecp2-stop 
= 9971.5 ± 687.4 cells/mm
3, n=24 regions from 4 animals; p=0.98). After 
calibration with the Mecp2-stop/WT DAPI correcting factor, the DAPI-
standardised CR positive cell density in layer five of the somatosensory cortex in 
symptomatic Mecp2-stop mice was significantly decreased compared to that of 
WT mice (data shown as mean ± SEM; WT= 9944.1 ± 978.5 cells/mm
3, n=30 
regions from 5 animals; Mecp2-stop= 7774.6 ± 535.9 cells/mm
3, n=24 regions 
from 4 animals; p=0.04). The same decrease was also observed after calibration 
with the Mecp2-stop/WT NeuN correcting factor. The NeuN-standardised CR 
positive cell density in layer five of the somatosensory cortex in symptomatic 
Mecp2-stop mice was significantly decreased compared to that of WT mice (data 
shown as mean ± SEM; WT= 9944.1 ± 978.5 cells/mm
3, n=30 regions from 5 
animals; Mecp2-stop= 7092.2 ± 488.9 cells/mm
3, n=24 regions from 4 animals; 
p=0.02). 
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Figure 4.6 Altered cell densities of calretinin (CR) positive neurons in symptomatic Mecp2-
stop somatosensory cortex after DAPI or NeuN correcting factor calibrations. 
(A) Representative micrograph of CR-positive cells in layer five of the somatosensory cortex 
in symptomatic Mecp2-stop brains. CR-positive cells are coloured green. (B) The CR-    101 
positive cell density in symptomatic Mecp2-stop (raw data and after calibrations) and WT 
mice. All data shown as mean ± SEM. 
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4.3.6 Calbindin (CB) positive cell density in layer five of the 
somatosensory cortex in symptomatic Mecp2-stop mice 
The cell density of CB immunopositive neurons in layer five of the somatosensory 
cortex in symptomatic Mecp2-stop mice was assessed. As shown in figure 4.7(B), 
the raw CB positive cell density in layer five of the somatosensory cortex showed 
no difference between Mecp2-stop and WT groups (data shown as mean ± SEM; 
WT= 26435.5 ± 1632.2 cells/mm
3, n=30 regions from 5 animals; Mecp2-stop = 
31010.3 ±1829.9 cells/mm
3, n=24 regions from 4 animals; p=0.07). After 
standardisation with the Mecp2-stop/WT DAPI correcting factor, the DAPI-
standardised CB positive cell density in layer five of the somatosensory cortex 
showed no difference between symptomatic Mecp2-stop and WT groups (data 
shown as mean ± SEM; WT= 26435.5 ± 1632.2 cells/mm
3, n=30 regions from 5 
animals; Mecp2-stop= 24178 ±1426.7 cells/mm
3, n=24 regions from 4 animals; 
p=0.32). After calibration with the Mecp2-stop/WT NeuN correcting factor, the 
NeuN-standardised CB positive cell density in layer five of the somatosensory 
cortex showed no difference between Mecp2-stop and WT groups (data shown as 
mean ± SEM; WT= 26435.5 ± 1632.2 cells/mm
3, n=30 regions from 5 animals; 
Mecp2-stop= 22056 ±1301.5 cells/mm
3, n=24 regions from 4 animals; p=0.053). 
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Figure 4.7 The cell density of calbindin (CB) positive neurons remained no change in layer 
five of somatosensory cortex in symptomatic Mecp2-stop mice. 
(A) Representative micrograph of CB-positive cells in layer five of the somatosensory cortex 
in symptomatic Mecp2-stop brains. CB-positive cells are coloured green. (B) The CB-
positive cell density in symptomatic Mecp2-stop (raw data and after calibrations) and WT 
mice. All data shown as mean ± SEM. 
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4.4 Morphological analyses in the hippocampus in 
symptomatic Mecp2-stop mice 
After assessing the cell density change of inhibitory neuronal subtypes in layer 
five of the somatosensory cortex in symptomatic Mecp2-stop mice, I further 
examined the distribution pattern of inhibitory neuronal subtypes in the 
hippocampus. The hippocampus was chosen because its structure and neuronal 
circuits are already well-investigated and can provide an excellent platform for 
recognising alterations in distribution pattern of distinct neuronal subtypes (see 
section 1.3.4). 
4.4.1 PV and SOM positive cell distribution patterns in the 
hippocampus in symptomatic Mecp2-stop mice 
As detailed in Chapter 2, the morphological work in the following sections was 
carried out on brains from symptomatic Mecp2-stop mice and their WT 
littermates. The brains were fixed with paraformaldehyde prior to 
immunostaining and image analysis. First I examined brain sections co-stained 
with both parvalbumin (PV) and somatostatin (SOM) protein markers. 
As illustrated in figure 4.8, brain sections from both symptomatic Mecp2-stop 
and WT mice revealed identical distribution patterns in hippocampal CA1 regions 
under microscopic examinations. Since most hippocampal PV positive cells are 
inhibitory neurons which directly target to the pyramidal cells located at the 
stratum pyramidale layer (sp), one obvious red band  that represented PV 
positive neuronal innervations was clearly detected in the sp layers in both 
images (see in figure 4.8(B)-(G)). 
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Figure 4.8 PV-positive cells in the hippocampal CA1 region of symptomatic Mecp2-Stop 
mice had an identical distribution pattern to that of WT mice. 
(A) Illustration of demonstrative areas in (B)-(G) in hippocampal CA1 regions. (B),(D)&(F) 
Under confocal microscopic examinations, PV positive cells were stained red while SOM 
positive cells were stained green. The figure represents the PV positive distribution pattern 
in the WT CA1 region. Most PV positive cells were located in the stratum pyramidale (sp) 
and targeted pyramidal cells in the same sp layer (red band). (C),(E)&(G) Confocal images 
show identical distribution patterns in symptomatic Mecp2-stop mice brains. Similarly, PV 
positive innervations are visible in the sp layer and show the same distribution pattern.     105 
Figure 4.9 further reveals the innervation pattern of PV positive cells in the sp 
layer of CA1 region in the hippocampus. In both symptomatic Mecp2-stop and 
WT hippocampi, PV positive cells (coloured red) project axons to form string-like 
innervations around proximal pyramidal cells (coloured blue with DAPI stain). 
With regard to the SOM immunopositive neurons, shown in figure 4.10, these 
cells in the hippocampal CA1 region of symptomatic Mecp2-stop mice were 
located in the stratum oriens layer (so) and sent out innervations through the 
stratum radiatum layer (sr) to reach the stratum lacunosum-moleculare layer 
(slm) and form a green band in the slm layer. This identical distribution pattern 
has been reported previously in normal WT rodents (Jinno & Kosaka, 2006). 
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Figure 4.9 PV positive cells in stratum pyramidale at CA1 regions of symptomatic Mecp2-
stop and WT mice showed an identical distribution pattern.  
Under the confocal microscopic examinations, PV positive cells are coloured red while DAPI 
positive cells are coloured blue. The white boxes in (A)&(C) label the same regions which     106 
are further magnified to be micrographs as (B)&(D) to show more detailed PV positive cell 
distribution pattern. 
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Figure 4.10 SOM positive cells in hippocampal CA1 regions of symptomatic Mecp2-stop 
mice had an identical distribution pattern as that of WT mice. 
(A) Illustration of demonstrative areas in (B),(C)&(D) in hippocampal CA1 regions. Under the 
confocal microscopic examinations, SOM positive areas are coloured green. Figure (B) 
shows the SOM positive distribution pattern of symptomatic Mecp2-stop mice in the 
hippocampal CA1 region at lower magnification. Demonstrating the same distribution 
pattern as that of WT mice, most SOM positive cells were located at the stratum oriens layer 
(so) and sent out innervations through the stratum radiatum layer (sr) to reach the stratum 
lacunosum-moleculare layer (slm). Figure (C) was magnified from figure (B) and several 
string-like projections (as indicated by arrows) were visible inside the sr layer and linked 
from the so layer to the slm layer. Figure (D) shows that the green band formed by SOM 
positive projections was limited in the slm layer and not beyond the molecular layer (ml) of 
dentate gyrus. 
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4.4.2 CR positive cell distribution pattern in the hippocampus in 
symptomatic Mecp2-stop mice 
I next examined the cell distribution pattern of calretinin (CR) immunopositive 
neurons in the hippocampus. Under the confocal microscopic examination, the 
CR positive cell (mossy cells) displayed green colour and was clearly recognised 
at the hippocampal dentate gyrus region (DG). As shown in (B), (C) of figure 4.11, 
the mossy cell at the hippocampal DG region was CR positive and located inside 
the hilus of dentate gyrus. Mossy cells projected innervations to pass through the 
granule cell layer and form a visible green band in the inner molecular layer. An 
identical distribution pattern of mossy cells was observed in the hippocampi in 
both symptomatic Mecp2-stop and WT mice. The confocal images at 
hippocampal DG regions were further magnified as (D), (E) of figure 4.11. In 
these higher power magnified images, the projections which connected the hilus 
and the inner molecular layer of DG were observed clearly in both the 
symptomatic Mecp2-stop and WT groups. 
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Figure 4.11 CR positive cells in the hippocampal dentate gyrus of the symptomatic Mecp2-
stop mouse has an identical distribution pattern to that of WT mice. 
(A) Illustration of demonstrative areas in (B)&(C) in hippocampal DG regions. Under 
confocal microscopic examinations, CR positive areas are coloured green. (B) At low power 
magnification, CR positive cells (mossy cells) were located in the hilus of dentate gyrus (DG) 
in WT mice brains. Mossy cells inside the DG hilus sent out projections through the 
granular cell layer (gcl) to reach the inner molecular layer (iml) and form a bright green band 
in the inner granular cell layer (iml). (C) In the hippocampus of symptomatic Mecp2-stop 
mice, the distribution pattern was the same as that of WT mice. At higher power 
magnification (D&E), the connections between the DG hilus and the iml layer were observed 
clearly in both genotype groups. 
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4.4.3 CB positive cell distribution pattern in the hippocampus in 
symptomatic Mecp2-stop mice 
The distribution pattern of the calbindin (CB) immunopositive neurons in the 
hippocampus was also assessed. The CB positive cells showed a green colour 
under the confocal microscopic examination. A subpopulation of hippocampal 
pyramidal cell shares the CB antigen (the signal is weaker than that of CB 
positive inhibitory neurons) with CB positive inhibitory neurons. As illustrated in 
figure 4.12(B), a green band in the stratum pyramidale layer (sp) of WT 
hippocampal CA1 region was observed. The hippocampus of symptomatic Mecp2-
stop mouse correspondingly presented an identical distribution pattern (see 
figure 4.12(C)). In the layer of stratum lacunosum-moleculare (under the 
stratum radiatum layer), CB positive cells were mainly inhibitory neurons and 
the cell density was rather lower. In the stratum lacunosum-moleculare layer of 
hippocampal CA1 regions from both genotype groups, CB positive neurons were 
observed (indicated by arrows in figure 4.12 (D)&(E)). 
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Figure 4.12 CB-positive cell in the hippocampal CA1 region of the symptomatic Mecp2-stop 
mouse has an identical distribution pattern to that of WT mice. 
(A) Illustration of demonstrative areas in (B)-(E) in hippocampal CA1 regions. Under the 
confocal microscopic examinations, CB positive areas are coloured green. The CB marker 
was shared by a subpopulation of pyramidal cells (the signal is weaker than that of CB 
positive inhibitory neurons) and CB positive inhibitory neurons. Figure (B) was 
photographed at the stratum pyramidale layer of WT hippocampal CA1 region and showed 
that a subgroup of the pyramidal cells were weakly immunopositive. Under the stratum 
pyramidale layer, few scattered green cells were the CB positive inhibitory neurons (as 
indicated by arrows in D). Figure (C) was photographed at the stratum pyramidale layer of 
hippocampal CA1 region from symptomatic Mecp2-stop mice and showed an identical 
distribution pattern to that of WT mice. (D)&(E) Under higher power magnification, a 
subgroup of pyramidal cells was weakly stained in the sp layer and few CB positive     111 
inhibitory neurons were scattered in the slm layer of the CA1 region from both symptomatic 
Mecp2-stop and WT mice hippocampi. 
4.5 Discussion 
In this chapter, all the results can be grouped into three main parts. First, in the 
cortical thickness measurement, the symptomatic Mecp2-stop mouse had a 
reduced cortical thickness in the primary somatosensory cortex, approximately 
89% of the WT cortex. The cortical thickness serves as a one-dimensional 
indicator, while the change of brain volume needs to be assessed by a three-
dimensional measurement. If the reduced percentage was equal in all the three 
dimensions, the brain volume of symptomatic Mecp2-stop mice would have 
shrunk to 70.4% (89%x89%x89%) of that of WT mice. This prediction was later 
verified by the DAPI density change in symptomatic Mecp2-stop mice brains. The 
Mecp2/WT DAPI correcting factor was 1.28; if there was no cell loss in the 
symptomatic Mecp2-stop cortex, this higher cell density might be due to the 
smaller volume (1/1.28= 78%). Both the assumptions of the brain volume change 
were quite close (70.4% vs. 78%), and were in line with previous reports showing 
that Mecp2-null mice had a smaller brain volume (Reiss et al., 1993). 
The smaller brain volume was not only restricted in the Mecp2-null models, but 
was also observed in RTT patients. In previous clinical reports of RTT patients, 
the head circumference growth pattern differed from that of normal children 
(Hagberg et al., 2000). Within the first six months, RTT patients had a normal 
head circumference growth speed. However, the head circumference growth 
speed decelerated from around eight to ten months old, and eventually RTT 
patients had a smaller brain compared to that of age-matched children. 
The second part of the results was the altered cell density in the symptomatic 
Mecp2-stop cortex. The total cortical cell density in the somatosensory cortex of 
Mecp2-stop mice was elevated (the Mecp2/WT DAPI correcting factor was 1.28). 
Previous reports have shown no obvious cell loss or death in the Mecp2-null 
models or RTT brains (Chen et al., 2001; Armstrong, 2005; Taneja et al., 2009). 
The reduced cortical thickness proved in this chapter also suggested 
symptomatic Mecp2-stop mice had a smaller brain volume. Therefore, the 
elevated total cortical cell density may be due to the brain volume effect. This 
conclusion was further supported by the increased neuronal density in the     112 
symptomatic Mecp2-stop cortex (the Mecp2/WT NeuN correcting factor was 1.41) 
without significant shifting of the neuron/non-neuron ratio in symptomatic 
Mecp2-stop mice brains. 
One of the aims of Chapter 4 was to assess the alteration of inhibitory cortical 
neurons in the symptomatic Mecp2-stop brain, since recent study has shown that 
functional knock-out of MeCP2 selectively in inhibitory neurons recapitulated 
most RTT-like symptoms in mice, particularly the hyperexcitable state of 
neuronal networks. In this chapter, four protein markers (PV, SOM, CR, and CB) 
were applied to discriminate distinct subtypes of inhibitory neurons. As 
illustrated in figure 4.3, in the rodent cortical layer five, more than 95% of 
inhibitory neurons can be recognised by labelling with one or more of these 
markers (Kubota et al., 1994). Therefore, the immunolabelling method was 
adopted to quantify the cell density alteration of distinct subtypes of inhibitory 
neurons in the symptomatic Mecp2-stop cortex. 
Since both the DAPI and NeuN positive cell densities of the symptomatic Mecp2-
stop cortex increased without significant shifting of the neuron/non-neuron ratio, 
the raw density of distinct subtypes of inhibitory neurons in symptomatic Mecp2-
stop mice was standardised for further comparison to that in WT mice. After 
calibration with the Mecp2/WT NeuN correcting, all the four subtypes had a 
lower cellular density (see figure 4.13). However, only CR and SOM positive cell 
densities of symptomatic Mecp2-stop mice were significantly different from that 
of WT mice, while the change in both PV and CB positive cell densities showed 
no statistical difference. This data indicated certain inhibitory neuron reduced 
in symptomatic Mecp2-stop mouse brains, but the mechanism by which this 
occurred is unclear, and requires further investigation. However, the density 
change of inhibitory neurons can still serve as an indicator of MeCP2 dysfunction 
in various RTT animal studies. 
With regard to the symptomatic (score 5 or more) heterozygous (Mecp2
stop/+ 
genotype) females, different subtypes of inhibitory neurons seemed to have 
significant skewing in the lack of MeCP2. As shown in figure 4.14 (data collected 
and analysed by Dr Rosie Spike), the skewing phenomenon of subtypes of 
inhibitory neurons was observed in symptomatic Mecp2
stop/+ brains. Theoretically, 
all cells in the heterozygous brain have an equal possibility of being either     113 
MeCP2 positive or negative. Half of the cortical neurons (NeuN positive cells) 
were MeCP2 negative, while less than 50% of cells in each subtype of inhibitory 
neuron were MeCP2 negative (skewing phenomenon). The reason may be either 
because MeCP2 is essential for inhibitory neuronal development process (lack of 
MeCP2 hinders the neurogenesis of inhibitory neurons) or because MeCP2 is 
critical in maintaining inhibitory neuronal populations (lack of MeCP2 makes 
inhibitory neurons more vulnerable). What role MeCP2 plays in inhibitory neurons 
is still not yet clarified; however, this result supported our conclusion that 
MeCP2 is important to inhibitory neurons. 
The third part of the results was generated from the morphological work in the 
hippocampus of symptomatic Mecp2-stop mice. Four protein markers (PV, SOM, 
CR, and CB) were applied in the morphological work for detecting the 
distribution patterns of distinct subtypes of cortical neurons in the hippocampus 
in symptomatic Mecp2-stop mice. Interestingly, no obvious difference was 
observed in the distribution pattern of four distinct subtypes of neurons in the 
symptomatic Mecp2-stop hippocampus. The hippocampus serves as an excellent 
platform for anatomical studies since the neuronal circuits and structures are 
already well-investigated. However, the results of the morphological work could 
only provide limited information since the distribution patterns might be altered 
in other regions of the symptomatic Mecp2-stop brain. Therefore, more future 
anatomical studies are still required to investigate the influence of MeCP2 on 
distribution patterns of distinct subtypes of cortical neurons in the brain. 
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Figure 4.13 Altered interneuronal percentages in symptomatic Mecp2-stop mice cortex. 
The CR and SOM positive cell densities were significantly reduced after calibrations by the 
Mecp2/WT NeuN correcting factor while the PV and CB positive cell densities were not 
significantly altered in the symptomatic Mecp2-stop mouse brain. 
 
 
Figure 4.14 Skewing of interneuronal MeCP2 expression in symptomatic heterozygous 
Mecp2
Stop/+ mice cortex. 
Theoretically, all cells in the heterozygous (Mecp2
stop/+) brain have an equal possibility to be 
either MeCP2 positive or negative. Half of the cortical neurons (NeuN+) were MeCP2 
negative; however, all four subtypes of interneurons had a skewing effect, causing there to 
be more MeCP2 positive neurons than MeCP2 negative ones. (Data collected and provided 
by Dr Rosie Spike) 
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5  Electrophysiology 
5.1 Introduction 
In Chapter 3, the symptom progression in Mecp2-stop mice was investigated and 
characterised. The severity of Mecp2-stop mice phenotype was found to steadily 
increase in an age-dependent manner. It thus appeared that the neurological 
deficits may accumulate throughout postnatal developmental stages. In order to 
assess possible modifiers in the neuroanatomical differences between 
symptomatic Mecp2-stop mice and their WT littermates, the distribution 
patterns and cell density of distinct neuron subtypes were investigated in the 
hippocampus and somatosensory cortex. The results of experiments in Chapter 4 
showed that distribution patterns of neuronal subtypes and their patterns of 
connectivity were not visibly changed, but the neuronal density of specific 
subtypes was altered. To probe potential changes of the synaptic level, I 
switched from an anatomical to physiological approach and focused my studies 
on the hippocampus. 
In previous studies, subtle changes have been reported in neuronal electrical 
properties at the cellular level (Dani et al., 2005; Taneja et al., 2009; Kline et 
al., 2010) but more overt changes in synaptic levels have been reported, 
including reduced synaptic plasticity (Asaka et al., 2006; Moretti et al., 2006; 
Guy et al., 2007; Nelson et al., 2008) and changes in basal inhibitory and 
excitatory synaptic transmission (Dani et al., 2005; Medrihan et al., 2008; Nelson 
et al., 2008; D'Cruz et al., 2010; Kline et al., 2010; Maliszewska-Cyna et al., 
2010). Anatomical studies have also shown changes in synaptic connectivity and 
neuronal structure (Armstrong et al., 1995; Belichenko et al., 1997; Armstrong 
et al., 1998; Armstrong, 2005; Chao et al., 2007), whilst at the network level 
there were changes in network excitability (Zhang et al., 2008; D'Cruz et al., 
2010). There is increasing evidence that MeCP2 is an important regulator of 
neuronal plasticity and that synaptopathy is a major component of the Rett 
phenotype (Gadalla et al., 2011). 
The aim of this chapter was to characterise hippocampal synaptic plasticity in 
the Mecp2-stop mouse model of RTT and to investigate the potential for 
pharmacological manipulation of plasticity deficits. In order to assess the     116 
possible deficits at synaptic levels in symptomatic Mecp2-stop mice, different 
aspects of synaptic plasticity were investigated in this chapter. These include 
short-term plasticity, long-term plasticity and the saturation properties of 
synaptic plasticity. In addition, I also assessed the effectiveness of the Alzheimer 
disease drug memantine in reversing potential Mecp2-stop related plasticity 
deficits. 
5.2 Assessment of the basal synaptic transmission in 
Mecp2-stop hippocampus 
In the synaptic plasticity assessment, I focused on the Schaffer collateral to CA1 
synapse. Evoked fEPSPs were recorded using extracellular field potentiation 
recording electrodes in the CA1 region of the hippocampus. At the beginning of 
the long-term potentiation (LTP) experiments, the input-output (I/O) curve was 
generated by increasing stimulus intensity and recording the respective field 
excitatory post-synaptic potential (fEPSP) magnitude to assess whether any 
difference existed in the basal synaptic transmission. Brain slices were obtained 
from four different mouse groups for comparison, including the symptomatic 
Mecp2-stop group, the pre-symptomatic Mecp2-stop group, and their age-
matched WT control groups. 
The comparison of the I/O curves between two different age WT mouse groups 
was plotted as shown in figure 5.1. The two WT groups were selected as the age-
matched littermates of either symptomatic Mecp2-stop mice (age ranging from 
12 to 15 weeks) or pre-symptomatic Mecp2-stop mice (age ranging from 4-5 
weeks). As illustrated in figure 5.1, the stimulus intensity plot shows the fEPSP 
slope (mean ± SEM; WT at 4-5 wks= 6 slices from 4 animals; WT at 12-15 wks= 10 
slices from 9 animals) in response to increasing stimulus strength for two WT 
group samples. No difference was observed in the I/O curves from two distinct 
age WT groups (p= 0.89, repeated-measures ANOVA). Therefore, there was no 
age-dependent difference in the basal synaptic transmission of WT brain slices. 
As illustrated in figure 5.2, the stimulus intensity plot shows the fEPSP slope 
(mean ± SEM; WT= 16 slices from 13 animals; pre-symptomatic Mecp2-stop= 6 
slices from 4 animals; symptomatic Mecp2-stop= 10 slices from 8 animals) in 
response to increasing stimulus strength for wild-type and Mecp2-stop samples.     117 
Hemizygous males were used at two developmental time points, pre-
symptomatic (severity score below two, blue symbols), and symptomatic (mean 
severity score 5.3 ± 0.2; generally at between 12 and 15 wk of age, orange 
symbols). Assessment of evoked synaptic transmission at the Schaffer-collateral-
to-CA1 pyramidal cell synapse using conventional field recording revealed no 
significant differences between genotype or phenotype groups with respect to 
the baseline fEPSP slope (p= 0.42, repeated-measures ANOVA). 
Multiple factors should be considered before making any comparison between 
brain slices from different animals, such as differences in the preparation 
process, differences in the electrode placement, the slice thickness, the slice 
cutting angle, etc. Before the comparison of fEPSPs from different brain slices, 
the pre-synaptic fibre volley assessment was generally adopted to evaluate 
whether this variability existed. As illustrated in figure 5.3, immediately after 
the stimulus (indicated by the arrows), a small field response that precedes the 
post-synaptic potential and correlates with the number of pre-synaptic afferents 
activated by the stimulation pulse is the pre-synaptic fibre volley. In my study, I 
also applied the pre-synaptic fibre volley assessment to investigate the possible 
difference originating from distinct brain slices. Since the pre-synaptic fibre 
volley response is proportional to the stimulation strength, the input current was 
always set to induce the half-maximum amplitude recorded in the previous I/O 
curve test of each brain slice. As shown in figure 5.3, two groups of brain slices 
were used in the pre-synaptic fibre volley experiment, one was from WT mice 
and the other from Mecp2-stop mice (all age ranged from 12 to 15 weeks). The 
pre-synaptic fibre volley data showed no difference in brain slices of WT and 
Mecp2-stop mice (WT= 0.028 ± 0.009mV, n=30 slices from 13 animals; Mecp2-
stop= 0.033 ± 0.003mV, n=30 slices from 12 animals; p= 0.61). 
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Figure 5.1 Comparison of Input-output curves between two different age WT mice groups. 
Stimulus intensity plot showing fEPSP slope (mean±SEM; WT at 4-5 wks= 6 slices from 4 
animals; WT at 12-15 wks= 10 slices from 9 animals) in response to increasing stimulus 
strength for two different age WT mice samples. Males were used at two developmental time 
points, one matched the age of pre-symptomatic Mecp2-stop mice (generally range between 
4 and 5wk of age, black symbols), and the other matched age of symptomatic Mecp2-stop 
mice (generally range between 12 and 15wk of age, grey symbols). No difference was 
observed between two different age WT mice groups (p= 0.89). All data is shown as mean ± 
SEM. 
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Figure 5.2 Comparison of Input-output curves between Mecp2-stop and WT mice. 
Stimulus intensity plot showing fEPSP slope (mean±SEM; WT= 16 slices from 13 animals; 
pre-symptomatic Mecp2-stop= 6 slices from 4 animals; symptomatic Mecp2-stop= 10 slices 
from 8 animals) in response to increasing stimulus strength for WT and Mecp2-stop 
samples. Mecp2-stop males were used at two developmental time points, pre-symptomatic 
(severity score <2, blue symbols), and symptomatic (mean severity score 5.3±0.2; generally 
at between 12 and 15wk of age, orange symbols). No difference was observed in all three 
mice groups (p= 0.42). All data is shown as mean ± SEM. 
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Figure 5.3 Comparison of pre-synaptic fibre volley between Mecp2-stop and WT mice 
groups. 
(A) Illustration of measurement of the pre-synaptic fibre volley. In an EPSP trace, 
immediately after the stimulus (removed and replaced with arrows for clarity), a small field 
response that precedes the postsynaptic potential and correlates with the number of pre-
synaptic afferents activated by the stimulation pulse is the pre-synaptic fibre volley. 
Adopted and modified from Bortolotto et al., 2011 (Bortolotto et al., 2011). (B) The amplitude 
of pre-synaptic fibre volley (from baseline) showed no difference between Mecp2-stop and 
WT mice (WT= 0.028 ± 0.009mV, n=30 slices from 13 animals; Mecp2-stop = 0.033 ± 0.003mV, 
n=30 slices from 12 animals; p= 0.61). All data is shown as mean ± SEM. 
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5.3 LTP in the Mecp2-stop hippocampus 
5.3.1  HFS-induced LTP was induced in the Mecp2-stop 
hippocampus 
Synaptic plasticity was investigated in acute hippocampal slices from hemizygous 
male Mecp2-stop mice and WT littermates as described in Chapter 2. All brain 
slices used in one-hour LTP experiments were first recorded for least half hour 
to assure a stable fEPSP baseline. The stable fEPSP baseline was defined as less 
than 5% amplitude change for at least 30 minutes recording.  
Representative fEPSPs of four different mouse groups are shown in figure 5.4. 
Field EPSPs recorded for the baseline evaluation were plotted as dotted lines, 
while the fEPSPs recorded at time 41 to 60 min were plotted as continual lines. 
Noticeably, all the traces from WT and the pre-symptomatic Mecp2-stop groups 
showed a significant increase before and after HFS; however, the increase in the 
symptomatic Mecp2-stop group was not obvious. 
As illustrated in figure 5.5, assessment of LTP revealed that high frequency 
stimulation (HFS) produced a robust and enduring potentiation of the fEPSP 
slope in slices from WT mice (WT at 4-5 weeks= 153.1 ± 12.0 % of baseline 
measured at 41 to 60 min following HFS; n=6 slices from 4 mice; WT at 12-15 
weeks= 146.2 ± 3.5 % of baseline measured at 41 to 60 min following HFS; n=10 
slices from 9 mice). No difference was observed in the two distinct age WT 
groups (p= 0.45, repeated-measures ANOVA). Therefore, in the following one-
hour LTP experiments, both WT groups’ data were pooled. 
In figure 5.6, pre-symptomatic Mecp2-stop mice showed a robust LTP (155.2 ± 
10.4 % of baseline at 41 to 60 min, n= 6 slices from 4 mice) that was similar in 
magnitude to that evoked in WT controls (p= 0.35, repeated-measures ANOVA). 
In contrast, brain slices obtained from symptomatic Mecp2-stop mice (mean 
severity score 5.3 ± 0.2) showed a significantly lower LTP (115.7 ± 3.2 % of 
baseline at 41 to 60 min, n= 10 slices from 8 mice), which represented 
approximately 40% of the wild-type value, than both the WT and pre-
symptomatic groups (F (2, 28) = 12.14; p< 0.001 for both post hoc pairwise 
comparisons).     121 
(A) Age-matched controls of (B)      (B) Pre-symptomatic group 
 
(C) Age-matched controls of (D)      (D) Symptomatic group 
 
Figure 5.4 Representative fEPSPs for all four groups pre- and post-HFS.  
Representative fEPSPs before (dotted lines, obtained from the pre-HFS stage; as indicated 
as “1” in figure 5.6) and following (continual lines, obtained from the post-HFS stage; as 
indicated as “2” in figure 5.6) HFS stimulation for each of the four comparison groups. 
Arrowheads indicate point of stimulus. Scale bars: vertical, 0.2mV; horizontal, 10ms. 
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Figure 5.5 HFS-induced LTP experiments in different age WT mice. 
EPSP slope was plotted against time after HFS stimulation (large arrow; time 0), as a 
percentage of the averaged pre-HFS baseline slope for each slice used. The pooled LTP 
data from 41 to 60 min showed no difference between two different age WT mouse groups 
(WT at 4-5 weeks= 153.1 ± 12.0 %, n= 6 slices from 4 animals; WT at 12-15 weeks= 146.2 ± 3.5 
%, n= 10 slices from 9 animals; p= 0.45, repeated-measures ANOVA). All data is shown as 
mean ± SEM. 
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Figure 5.6 HFS-induced LTP experiments in Mecp2-stop mice. 
EPSP slope was plotted against time after HFS stimulation (large arrow; time 0), as a 
percentage of the averaged pre-HFS baseline slope for each slice used. The pooled LTP 
data from 41 to 60 min showed no difference between pre-symptomatic Mecp2-stop and WT 
mice (WT= 152.7 ± 5.3 %, n=16 slices from 13 animals; pre-symptomatic Mecp2-stop = 155.2 
± 10.4 %, n=6 slices from 4 animals; p= 0.35), while significant reduction was observed in 
the symptomatic Mecp2-stop mice compared to the WT or pre-symptomatic mice 
(symptomatic Mecp2-stop = 115.7 ± 3.2 %, n=10 slices from 8 animals; p< 0.001 for post hoc 
pairwise comparisons). All data is shown as mean ± SEM. 
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5.3.2 Post-tetanic potentiation (PTP) was altered in the 
symptomatic Mecp2-stop hippocampus 
In one-hour LTP experiments of Mecp2-stop mice, the post-tetanic potentiation 
(PTP) could be further analysed. The PTP value in this chapter was averaged 
from the first three fEPSP slope data following HFS (the fEPSP was measured for 
every 20 seconds, and the first three fEPSPs were within the first minute after 
HFS). PTP is regarded to be related to the calcium concentration at the pre-
synaptic locus of synapses (Zucker & Regehr, 2002). 
As illustrated in figure 5.7, the PTP from two distinct age WT groups were 
compared and no significant difference was noted (WT at 4-5 weeks= 225.1 ± 
41.0 % of baseline measured at 1
st min following HFS; n=6 slices from 4 mice; WT 
at 12-15 weeks= 208.6 ± 51.4 % of baseline measured at 1
st min following HFS; 
n=10 slices from 9 mice; p= 0.62). Since there was no age-dependent difference 
in the PTP data between both WT groups, the PTP data were pooled for further 
analyses. 
In the same one-hour LTP experiments, PTP were analysed for the pre-
symptomatic Mecp2-stop group, the symptomatic Mecp2-stop group and the WT 
group. As illustrated in figure 5.8, PTP differed between groups (F (2, 25) = 
3.492; p= 0.046), with symptomatic Mecp2-stop mice exhibiting PTP values that 
were 45 ± 18% of those observed in WT mice (WT= 216 ± 46.2 % of baseline, 
symptomatic Mecp2-stop= 97.8 ± 40.8 %; post hoc Tukey test, p= 0.036), while 
pre-symptomatic mice did not differ from wild-type (WT= 216 ± 46.2 % of 
baseline, pre-symptomatic Mecp2-stop= 204.3 ± 18.1 %; p= 0.73). 
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Figure 5.7 PTP comparison between both two different age WT groups. 
The amplitude of PTP (compared to baseline) showed no difference between two different 
aged WT mice groups (WT at 4-5 weeks= 225.1 ± 41.0 %, n=6 slices from 4 animals; WT at 
12-15 weeks= 208.6 ± 51.4 %, n=10 slices from 9 animals; p= 0.62). All data is shown as 
mean ± SEM. 
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Figure 5.8 PTP analyses of Mecp2-stop mice. 
The amplitude of PTP (compared to baseline) showed no difference between pre-
symptomatic Mecp2-stop and WT mice (WT= 216 ± 46.2 %, n=13 slices from 16 animals; pre-
symptomatic Mecp2-stop = 204.3 ± 18.1 %, n= 6 slices from 4 animals; p= 0.73), while 
significant reduction was observed in the symptomatic Mecp2-stop mice compared to the 
WT mice (WT= 216 ± 46.2 %, n=13 slices from 16 animals; symptomatic Mecp2-stop = 97.8 ± 
40.8 %, n= 10 slices from 8 animals; post hoc Tukey test, p= 0.036). All data is shown as 
mean ± SEM. 
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5.3.3 Paired-pulse facilitation (PPF) ratio analyses from one-hour 
LTP experiments 
Paired-pulse facilitation (PPF) is the increased amplitude of a second synaptic 
response when triggering stimuli are delivered in pairs. The phenomenon is 
considered to be mediated by residual calcium accumulation in the axonal 
terminal and is generally regarded as a pre-synaptic functional assessment 
(Zucker & Regehr, 2002). Paired pulses with 50ms interval were delivered every 
20 seconds. In figure 5.9, two representative traces from pre-symptomatic and 
symptomatic Mecp2-stop mice were demonstrated. As described in Chapter 2, 
the PPF ratio was calculated as the amplitude of the second fEPSP divided by the 
amplitude of the first fEPSP. The PPF ratio of the representative trace in the 
pre-symptomatic Mecp2-stop mice was significantly higher than that of the 
symptomatic Mecp2-stop mice. 
As illustrated in figure 5.10, PPF ratios were compared in two different age WT 
groups. No age-dependent difference was observed between these two WT 
groups (WT at 4-5 weeks= 1.85 ± 0.05; n=6 slices from 4 mice; WT at 12-15 
weeks= 1.82 ± 0.08; n=10 slices from 9 mice; p= 0.71). Therefore, data from two 
WT groups were pooled for further analyses. 
Tested by repeated-measures ANOVA, there were significant differences 
between the symptomatic Mecp2-stop group and the other two (WT and pre-
symptomatic Mecp2-stop) groups (F (2, 29) = 16.978; p< 0.001). As shown in 
figure 5.11, the paired-pulse ratio was observed to be of similar magnitude in 
pre-symptomatic Mecp2-stop mice (1.85 ± 0.04) and WT controls (1.84 ± 0.02) 
(p= 0.89). In contrast, symptomatic Mecp2-stop mice showed a significant 
reduction in baseline paired pulse ratio (ratio=1.43 ± 0.02; post hoc Tukey test 
p< 0.001) compared to age-matched WT controls. PPF analysis over the duration 
of the LTP experiments revealed that the symptomatic mice showed a consistent 
deficit relative to both other groups (before and after the induction of LTP), 
with the exception of a brief period immediately following high-frequency 
stimuli (coinciding with the peak of the PTP) during which all groups showed a 
similar reduced peak ratio. 
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Figure 5.9 Representative fEPSPs in response to paired stimuli of pre-symptomatic and 
symptomatic Mecp2-stop mice.  
Representative EPSPs observed in response to paired stimuli (arrowheads) from the pre-
symptomatic (blue) and symptomatic Mecp2-stop (orange) mice groups. The interval 
between the paired stimuli was set as 50ms. Scale bars: vertical, 0.2mV; horizontal, 10ms. 
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Figure 5.10 Pair-pulse facilitation (PPF) ratio comparison between both two different age WT 
groups. 
(A) Paired-pulse facilitation (PPF) ratios were plotted as mean±SEM (WT at 4-5 wks= 6 slices 
from 4 animals; WT at 12-15 wks= 9 slices from 10 animals). The slope ratio time course was 
plotted relative to the delivery of HFS stimulation (time= 0). (B) The mean PPF data at 
baseline recording showed no age-dependent changes between two different age WT mice 
groups (WT at 4-5 wks= 1.85 ± 0.05; WT at 12-15 wks= 1.82 ± 0.08; p= 0.71). All data is shown 
as mean ± SEM. 
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Figure 5.11 Paired-pulse facilitation (PPF) ratios of Mecp2-stop mice. 
(A) Paired-pulse facilitation (PPF) ratios were plotted as mean±SEM (n= 6–10 slices, four to 
nine mice per group). The slope ratio time course was plotted relative to the delivery of HFS 
stimulation (time= 0). (B) The mean PPF data at baseline recording showed no difference 
between pre-symptomatic Mecp2-stop and WT mice (WT= 1.84 ± 0.02; pre-symptomatic 
Mecp2-stop= 1.85 ± 0.04; p= 0.89), while significant reduction was observed in the 
symptomatic Mecp2-stop mice compared to the WT mice (WT= 1.84 ± 0.02; symptomatic 
Mecp2-stop= 1.43 ± 0.02; p< 0.001). All data is shown as mean ± SEM. 
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5.4 LTP saturation experiments 
5.4.1 LTP saturation experiments in Mecp2-stop brain slices 
After analysing the LTP, PTP, and PPF results of Mecp2-stop mice, we concluded 
that functional knock-out of MeCP2 is characterised by both the pre-synaptic and 
the post-synaptic deficits in symptomatic Mecp2-stop mice. Here we introduced 
another experimental design in order to further assess how the LTP is 
compromised in the Mecp2-stop brain. The principle was to deliver repetitive 
high-frequency stimuli (HFS) at regular intervals (for example 15-20 minutes), 
and the fEPSP amplitude gradually reached the plateau after repetitive 
inductions. Multiple HFS induced a cumulated form LTP rather than a single 
potentiated event following a single HFS. This scheme was adopted in an 
attempt to detect more subtle deficits in synaptic plasticity. Therefore, not only 
the symptomatic Mecp2-stop and their WT littermates were assessed in the LTP 
saturation experiments, but also the mild symptomatic Mecp2-stop mice (score 
ranged from 2 to 4). The results were beneficial for further analysing the effect 
of symptom progression on the alteration of synaptic plasticity in Mecp2-stop 
brains. 
In figure 5.12, the representative fEPSP traces from the symptomatic Mecp2-stop 
and WT brain slices were plotted. The letter “b” labels the initial baseline trace 
before HFS, and the numbers label traces five minutes after each HFS 
stimulation. In the WT brain slices, the amplitude of LTP increased after each 
HFS stimulation towards a “saturated” or “plateau” state, while in the 
symptomatic Mecp2-stop brain slices, the amplitude of LTP did not increase but 
decreased back to the baseline level after multiple HFS inductions. 
As illustrated in figure 5.13(A), the assessment of plasticity defects in Mecp2-
stop mice was conducted by delivering repeated episodes of HFS (see methods 
detailed in Chapter 2) to investigate possible saturation effects. In WT mice 
synaptic tone increased over four successive rounds of HFS at fifteen-minute 
intervals, each successive increase in fEPSP slope being smaller than the 
previous one such that a plateau was being approached at around the one-hour 
mark. In contrast, strongly symptomatic Mecp2-stop mice showed, in addition to 
their deficit in the response to the initial HFS, a profound inability to generate     129 
further LTP following subsequent HFS episodes and even a modest depression in 
the most symptomatic mice. Slices obtained from mildly symptomatic 
(phenotype score of 2-4) mice, which did not display overt LTP deficits after the 
first HFS over fifteen minutes, did reveal intermediate but significant additional 
LTP deficits in response to subsequent episodes of HFS. As the quantification 
analyses of 15 min LTPs following each consecutive HFS in figure 5.13(B) show, 
in the WT brain slices, the increase of LTPs after each HFS stimulations was 
smaller compared to the previous one; however, in the symptomatic Mecp2-stop 
brain slices, a reduced propensity to produce further LTP enhancement was 
observed. 
 
 
Figure 5.12 Representative EPSP traces after each HFS in the LTP saturation experiments of 
symptomatic Mecp2-stop and WT mice groups. 
Representative traces from a WT (top, black) and symptomatic Mecp2-stop (bottom, orange) 
mice. The letter “b” labels the initial baseline trace before HFS, and the numbers label 
traces five minutes after each HFS stimulation. Scale bar 0.25mV, 5ms. Stimulus (artefact 
removed for clarity) is indicated by the inverted arrow head. 
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Figure 5.13 LTP showed pronounced saturated phenomenon in symptomatic Mecp2-stop 
mice. 
(A) Time plot shows mean fEPSP slope upon repeated high frequency stimulation of 
afferents in hippocampal slices prepared from WT (score 0) and increasingly symptomatic 
(symptom score range 2–6) Mecp2-stop mice. (B) Bar plot shows 15 min LTPs (mean±SEM, 
n=7–10 slices, four to eight mice from each symptom-scored group) following each 
consecutive HFS, normalised to the preceding pre-HFS baseline. Note that fEPSP slope 
shows a robust further LTP enhancement in response to second and subsequent HFS in WT 
mice but a reduced propensity to produce further LTP enhancement in brain slices from 
symptomatic Mecp2-stop mice. All data is shown as mean ± SEM. 
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5.4.2 PTP was induced in mild symptomatic and symptomatic 
Mecp2-stop mice 
In section 5.3.2, the PTP was analysed and the results indicated potential pre-
synaptic deficits in symptomatic Mecp2-stop mice brains. In order to further 
characterise short-term plasticity, brain slices from a range of mildly to severely 
symptomatic Mecp2-stop mice were assessed for post-tetanic potentiation. 
Analysis of PTPs in LTP saturation experiments (figure 5.14) revealed a similar 
impairment in symptomatic Mecp2-stop mice that tended to increase with 
increasing symptom score (R
2= 0.074 in a linear regression of PTP versus 
aggregate symptom score, n= 29; WT mice were treated as having a symptom 
score of 1 for this test to mimic linearity, pre-symptomatic Mecp2-stop mice 
were with scores of 2 to 4, and symptomatic Mecp2-stop mice were with scores 
of 5 to 6). 
The PTP amplitude had a negative correlation with the symptom progress. As 
illustrated in figure 5.14, when plotting PTP levels versus symptoms scoring, the 
PTP decreased as the scoring increased. This was an essential finding as previous 
reports described the pre-synaptic deficit only in symptomatic RTT mice brains; 
however, it appeared to be that the PTP deficit was accumulated throughout the 
developing process and eventually became significant at the severe symptomatic 
stage. The result was in line with previous sections that the pre-synaptic and 
post-synaptic deficits co-existed in RTT mouse brains. 
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Figure 5.14 Quantification analyses of initial PTP in the LTP saturation experiments of 
Mecp2-stop mice. 
Bar plot shows level of post-tetanic potentiation (PTP; mean±SEM, n=7–10 slices, four to 
eight mice from each symptom-scored group) following HFS in WT littermate controls 
(score 0) and progressively more symptomatic Mecp2-stop mice (score range 5-6). The PTP 
is presented as the percentage of baseline level (100%). All data is shown as mean ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     133 
5.5 Effects of memantine on synaptic plasticity deficits in 
symptomatic Mecp2-stop mice 
5.5.1 In vitro memantine treatment on Mecp2-stop brain slices 
In previous sections, LTP deficits were observed in the Mecp2-stop hippocampus 
and these deficits were shown to be associated with an aspect of LTP-saturation-
like effect. Interestingly, identical LTP saturation has been reported in 
Alzheimer disease models and models of NMDA receptor hyper-stimulation 
(Frankiewicz & Parsons, 1999). Furthermore, these reports indicated that such 
abnormalities can be reversed by the Alzheimer disease drug memantine 
(Frankiewicz & Parsons, 1999). Memantine, a weak NMDA receptor antagonist, is 
thought to bind the NMDA receptor on the post-synaptic terminus to prevent 
excessive basal stimulation whilst at the same time allowing NMDA receptor 
activation upon appropriate plasticity-producing stimulus. Clinically memantine 
was reported to slow down the progression of memory dysfunction in Alzheimer 
disease. Since the synaptic plasticity defects were similar in nature to those 
reported due to NMDA over-stimulation, memantine was applied to symptomatic 
Mecp2-stop brain slices to further assess the potential for reversing the LTP 
saturation deficits in the Mecp2-stop brain. 
LTP saturation experiments were repeated (as in previous sections) in brain 
slices pre-incubated for one hour and bathed for the recording duration in 1μM 
memantine (dissolved in 1x ACSF). As shown in figure 5.15, memantine was 
assessed on control brain slices from WT mice and showed no significant 
alterations in LTP, PTP or LTP saturation. In contrast, as illustrated in figure 
5.16, in brain slices from symptomatic (mean score =5.3 ± 0.2, n=7) Mecp2-stop 
mice, memantine produced a significant enhancement of both PTP and the first 
15-minute LTP, restoring these parameters to WT levels (+memantine: 100% of 
WT first 15-minute LTP, 104% of WT PTP; untreated: 69% of WT first 15-minute 
LTP and 61% of WT PTP). In response to subsequent episodes of HFS, memantine-
treated brain slices from symptomatic Mecp2-stop mice showed enhanced PTP 
and short-term plasticity, but the potentiation rapidly decayed to the preceding 
baseline level within the 15-minute inter-HFS period. 
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Figure 5.15 Partial reversal of plasticity deficits in symptomatic Mecp2-stop mice by 
memantine.  
Time plot shows that memantine did not affect LTP, PTP or LTP saturation in brain slices 
obtained from WT memantine-treated mice (black empty dots, eight slices from five mice) to 
WT age-matched controls (black dots, 10 slices from eight mice). Arrows indicate points of 
afferent HFS every 15 minutes for four instances. All data is shown as mean ± SEM. 
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Figure 5.16 Partial reversal of plasticity deficits in symptomatic Mecp2-stop mice by 
memantine. 
Time plot shows reduced hippocampal LTP and PTP and elevated synaptic saturation in 
brain slices from symptomatic Mecp2-stop mice (orange dots, seven slices from four mice) 
compared to WT littermate controls (black dots, 10 slices from eight mice). LTP/PTP 
reduction and LTP saturation were partially reversed in Mecp2-stop slices incubated in 1 μM 
memantine (orange empty dots, 10 slices from five mice). In contrast, memantine did not 
affect LTP, PTP or LTP saturation in slices obtained from wild-type mice (black empty dots, 
eight slices from five mice). Arrows indicate points of afferent HFS every 15 minutes for four 
instances. The dotted line indicates the mean LTP level 15 min after the first HFS in 
memantine-treated Mecp2-stop mice for easier comparison with subsequent 15min post-
HFS time points. All data is shown as mean ± SEM. 
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5.5.2 In vivo memantine treatment on Mecp2-stop mice 
In section 5.5.1, memantine restored the first 15-minute LTP and PTP in the 
symptomatic Mecps2-stop hippocampus. In order to further evaluate the in vivo 
effects of memantine, Mecp2-stop mice and their WT littermates were dosed 
daily from five to eight weeks old with a dose (30mg/Kg) shown previously to 
achieve the therapeutic serum level of memantine in mice (Minkeviciene et al., 
2004). Control groups consisted of age-matched Mecp2-stop and WT mice and 
were also administrated with vehicles (normal saline) daily for four weeks (5 to 8 
weeks old). The symptom progress and the life span of all four groups were 
recorded for further analyses and comparisons. 
As shown in figure 5.17, memantine administered daily from five weeks old in 
Mecp2-stop mice (n= 7) for a four-week period revealed no significant difference 
in severity or progression of RTT-like signs from vehicle-treated Mecp2-stop mice 
(n= 8). As expected, WT mice scored 0 throughout the study and memantine 
administration did not affect this score. With regard to the survival plot in figure 
5.18, Mecp2-stop mice had a reduced survival, but again this was not altered by 
the memantine treatment. 
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Figure 5.17 Memantine did not affect progression of Mecp2-stop mice phenotypes. 
Plot shows phenotypic severity progression in WT (mice treated with memantine, grey 
symbols, n=7 animals; mice treated with vehicle, black symbols, n=8 animals) and Mecp2-
stop
 (orange symbols) mice treated with memantine (oral dosing 30 mg/kg, open symbols, 
n=7 animals) or vehicle (closed symbols, n=8 animals). The treatment was administered 
between 5 and 8 weeks of age, continually for 28 days with a daily dose (shown as black 
bar). All data is shown as mean ± SEM. 
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Figure 5.18 Memantine did not affect survival of Mecp2-stop mice. 
Survival curves plotted for the same four groups of mice as indicated in figure 5.18 (WT 
mice treated with memantine, grey symbols, n=7 animals; WT mice treated with vehicle, 
black symbols, n=8 animals; Mecp2-stop mice treated with memantine, orange open 
symbols, n=7 animals; mice treated with vehicle, orange closed symbols, n=8 animals). Note 
that vertical steps indicate deaths due to culling under the humane culling policy (see 
Chapter 2, determined by symptom scores) rather than natural lifespan of Mecp2-stop mice. 
 
     138 
5.6 Discussion 
The major finding in this chapter is that both short-term and long-term plasticity 
deficits were detected in symptomatic Mecp2-stop brains. In addition, in the LTP 
saturation experiment, both short-term and long-term plasticity were observed 
to be connected to the progression of RTT-like symptoms. Furthermore, the 
effectiveness of memantine on the symptomatic Mecp2-stop brain was assessed 
and it was concluded that memantine can partially restore synaptic plasticity 
deficits, particularly the short-term plasticity deficit. 
An important observation is that classic LTP was not impaired in Mecp2-stop 
mice during the first postnatal weeks, but rather the deficits appeared with the 
onset of overt RTT-like symptoms. These data mirrored earlier studies conducted 
in male Mecp2-null mice (Asaka et al., 2006) as well as with studies in 
symptomatic female Mecp2-stop mice which developed symptoms later (the 
symptom onset was around 6 to 9 months) (Guy et al., 2007). In contrast, those 
studies reporting the absence of deficits have mainly been limited to 
experiments conducted using relatively immature brain tissues from presumably 
asymptomatic mice (Dani & Nelson, 2009). 
In addition to long-term potentiation, the PTP and PPF analyses showed that 
short-term forms of plasticity were impaired in symptomatic Mecp2-stop mice. 
Whilst this was the first report addressing short-term plasticity in the Mecp2-
stop mouse, similar observations have been made in Mecp2-null mice (Asaka et 
al., 2006) and the Mecp2
308 line (Moretti et al., 2006). Both PTP and PPF are 
believed to represent plasticity processes with largely pre-synaptic loci of 
expression (Zucker & Regehr, 2002). In contrast, sustained LTP at 41 to 60 
minutes following HFS has been shown to be mainly of post-synaptic origin at the 
Schaffer collateral-to-CA1 pyramidal cell synapse (Nicoll, 2003). It is obvious 
that the deficits in the two forms of plasticity (LTP and PTP) showed strong 
parallelism. However, it was unclear from the extracellular recording data 
whether this relationship could be explained by some overlap in the underlying 
mechanisms or whether the reduction in LTP is a direct consequence of reduced 
PTP mediated via a predominantly pre-synaptic dysfunction. In summary, it 
appeared that both pre-synaptic and post-synaptic elements contributed to the 
deficits in hippocampal synaptic plasticity in symptomatic Mecp2-stop mice.     139 
In the LTP saturation experiments, the inability to produce cumulative LTP in 
response to repeated HFS in hippocampal slices from symptomatic Mecp2-stop 
mice was observed. Another important finding of the LTP saturation experiment 
was that deficits in synaptic plasticity could be revealed in very mildly 
symptomatic male mice (from around five weeks old) by adopting appropriate 
plasticity induction paradigms which assess cumulative synaptic potentiation 
(see section 5.4). With symptom progression, these subtle abnormalities in 
synaptic plasticity became more overt and could be detected by a single HFS 
protocol for LTP induction. These findings indicated synaptic plasticity deficits 
as an early indicator of the disease process, although the precise cellular and 
synaptic dysfunctions and their mechanistic link with MeCP2 deficiency remain 
obscure. 
The PTP analyses suggested pre-synaptic deficits in symptomatic Mecp2-stop 
hippocampal slices, and the PTP analyses from the LTP saturation experiments 
showed similar results. As with LTP analyses in the LTP saturation experiments, 
the PTP deficits became more pronounced with symptom progression. From the 
extracellular recording data, it was difficult to determine the exact mechanism 
underlying the synaptopathy occurring in RTT mice brains; however, both pre-
synaptic and post-synaptic deficits in the Mecp2-stop hippocampus seemed to be 
consistent with the symptom progression and severity. Our result was the first to 
report this conclusion in an experimental animal model of RTT. 
One possibility for the LTP deficits detected in the Mecp2-stop mice was that an 
overall reduction in plasticity existed, or that the apparent reduced LTP was due 
to synapses operating close to a maximal “ceiling”. The latter hypothesis was 
supported by the fact that repeated HFS stimuli in hippocampal slices from 
symptomatic Mecp2-stop mice could not induce cumulative LTPs. This 
phenomenon further supported the hypothesis that neurotransmission at the 
Schaffer collateral-to-CA1 pyramidal cell synapses in symptomatic Mecp2-stop 
mice operated in a state that was closer to saturation than in pre-symptomatic 
or WT mice. 
A previous study showed that LTP saturation effects could be overcome by 
memantine, a drug prescribed to Alzheimer’s disease patients (Frankiewicz & 
Parsons, 1999); therefore memantine was applied in both in vitro and in vivo     140 
experiments to assess the therapeutic potential for amending synaptic plasticity 
deficits in symptomatic Mecp2-stop mice. The results of this chapter showed 
that memantine applied to the symptomatic Mecp2-stop hippocampal slices at 
clinically-relevant concentrations (Frankiewicz & Parsons, 1999; Minkeviciene et 
al., 2004) induced a heightened synaptic potentiation following HFS. In 
particular, memantine had a marked effect on the response to the first HFS 
(elevated LTP). However, the effect of memantine on the subsequent episodes 
of HFS was limited to a transient boost of short-term plasticity which typically 
decayed to baseline within a 15 minute period. This was a specific action 
targeting the MeCP2-related pathophysiology, as memantine had no effect on 
basal evoked synaptic transmission or control hippocampal slices from WT 
littermates subjected to the LTP saturation paradigm. 
In contrast to the clear actions of memantine on hippocampal synaptic 
transmission in vitro under the disease state, the long-term daily dosing of 
Mecp2-stop mice with memantine did not change either the progression of 
symptoms or affect the survival profile. Memantine has been used successfully to 
amend aspects of hippocampus-dependent dysfunction in a transgenic model of 
Alzheimer disease (Minkeviciene et al., 2004) and has been shown recently to 
normalise cognitive functions and synaptic marker levels in a mouse model of 
Down syndrome (Rueda et al., 2010). The absence of any detectable 
improvement in RTT-like phenotypes suggested that this drug may not hold 
promise in treating the full range of symptoms of RTT. However, Mecp2-stop 
males were very severely affected by loss of MeCP2, and it remains to be tested 
whether memantine could be beneficial in heterozygous Mecp2-stop females, 
which display a milder and more stable phenotype. In addition, the plasticity 
impairments demonstrated here ex vivo may manifest in a range of subtle 
cognitive and behavioural aspects of the Rett-like phenotype rather than 
affecting the observable signs and lethality. Thus, assessing the potential for 
memantine to improve the phenotype in vivo may require appropriate 
behavioural assays to evaluate the outcome after memantine treatment. 
However, male Mecp2-stop mice have severe motor deficits and were difficult to 
screen in most cognitive assays. The phenotypic assessment adopted in this 
thesis did not involve a specific measure of hippocampal dysfunction and it was     141 
therefore difficult to draw comparisons between the data obtained here in vitro 
and in vivo.     142 
6  General discussion 
6.1 Major findings 
The major findings of this study are as follows: 
Firstly, from the electrophysiology experiments, I report for the first time, 
pronounced hippocampal synaptic plasticity in the hemizygous Mecp2-stop brain. 
Moreover, I show a strong relationship between the degree of synaptic plasticity 
impairment and the overt neurological phenotype as assessed by observational 
signs at the whole animal level. Further analysis revealed significant deficits in 
both long-term (LTP) and short-term (PTP, PPF) forms of synaptic plasticity. In 
addition, the Alzheimer drug, Memantine, partially ameliorated synaptic 
plasticity deficits in symptomatic hemizygous Mecp2-stop hippocampi, 
particularly the short-term plasticity deficits.  
Clinically, reports suggested RTT to be associated with a reduced head size and 
an increase in neuronal density. In the current study, I showed several findings in 
the immunohistochemistry experiments; firstly, cell density alteration in the 
somatosensory cortex was associated with volume change in symptomatic 
hemizygous Mecp2-stop mice. Besides this, a decrease in density of calretinin- 
(CR) and somatostatin- (SOM) positive inhibitory neurons was observed in the 
somatosensory cortex of symptomatic hemizygous Mecp2-stop mice. 
Furthermore, the gross distribution patterns of inhibitory neuron subtypes in the 
hippocampus of symptomatic Mecp2-stop mice were not significantly altered.     143 
6.1.1 Synaptic plasticity deficits in Mecp2-stop mice 
In Chapter five, synaptic plasticity deficits were reported in the Mecp2-stop 
mouse brain. In the HFS-induced LTP experiments, LTP deficit was observed in 
symptomatic Mecp2-stop hippocampi. LTP deficits shown here were in line with 
previous reports in various Mecp2-mutant models (Asaka et al., 2006; Moretti et 
al., 2006; Guy et al., 2007). In a different Mecp2 knock-out model, LTP deficits 
were detected under either HFS or theta burst LTP induction schemes in 
symptomatic mice (Asaka et al., 2006). In the Mecp2
308/y animal model, in which 
a truncated MeCP2 protein is expressed, LTP deficits were observed in 
hippocampal and cortical regions (Moretti et al., 2006). Previously, Guy et al. 
demonstrated LTP deficits in HFS-induced LTP experiments in “symptomatic” 
(the same symptom scoring system was adopted; score=5 or more) heterozygous 
Mecp2
stop/+ mice brains (Guy et al., 2007). In summary, MeCP2 obviously plays an 
important role in the mechanism of long-term plasticity.  
In the HFS-induced LTP experiments of this thesis, not only the long-term 
plasticity but also the short-term plasticity was observed when MeCP2 was 
functionally knocked-out. The PTP analyses showed a reduced PTP in 
symptomatic Mecp2-stop mouse brains. Furthermore, the PPF analyses in the 
same experiments also revealed a decreased ratio in symptomatic Mecp2-stop 
mice brains. PTP and PPF are the representative assessment for short-term 
plasticity (Zucker & Regehr, 2002), and both results were consistent with the 
conclusion that short-term plasticity deficits exist in symptomatic Mecp2-stop 
mice brains. However, Asaka et al. reported that no significant reduced 
potentiation in the PTP assessment at Schaffer collateral but only a reduced PPF 
ratio was detected in symptomatic Mecp2 knock-out mice (Asaka et al., 2006). 
One difference between Asaka et al. and my studies was the age; most 
“symptomatic” mice used in Asaka’s study were over 6wks of age, while in this 
thesis “symptomatic” (score=5 or more) Mecp2-stop mice referred to 12-15wk 
old mice. The discrepancy between Asaka and my studies may be due to the fact 
that PTP deficits developed later, or due to the basic differences between these 
two model designs. 
The LTP saturation experiment, whereby repeated HFS stimuli led to a “plateau” 
or “saturation” state, proved a valuable means of further investigating plasticity     144 
deficits in the Mecp2-stop mice. Specifically, it revealed that synaptic plasticity 
deficits occurred very early in the disease phenotype (mice scoring only 2 or 
more on the phenotype severity scale). Under this experimental scheme, more 
subtle alterations in the LTP could be revealed. In chapter 5, not only 
symptomatic but also very mildly symptomatic (score 2-4) Mecp2-stop mice were 
used in LTP saturation experiments. My data showed that mild symptomatic 
Mecp2-stop mice demonstrated a significant reduction of LTP after the second or 
third repetitive stimulus. Most synaptic plasticity studies of the Mecp2-mutant 
mice reported that LTP deficits only existed in “symptomatic” mutant mice 
(Asaka et al., 2006; Moretti et al., 2006; Guy et al., 2007). However, in this 
thesis, LTP deficits were shown in mildly symptomatic (score=2-4) Mecp2-stop 
mice under the LTP saturation experimental paradigm. This is an important and 
novel finding since it indicated LTP alterations may accumulate through 
neurodevelopmental stages.  
PTP was also analysed in the LTP saturation experiments. My data showed that 
symptomatic Mecp2-stop mice had a significant reduction in the initial PTP 
amplitude. Generally, the age of “symptomatic” (score=5 or more) mice in this 
thesis ranged from 12-15wks old. In the synaptic plasticity study of Asaka et al., 
“symptomatic” mice referred to those with ages ranged above 6wks old (Asaka 
et al., 2006), and there was no difference in the PTP amplitude between 
symptomatic and WT groups in their study. Once again, PTP deficits in Mecp2-
null mouse models might occur rather late after symptoms develop and this is 
proved by the finding of no significant alteration to PTP at earlier stages in both 
Asaka’s and my studies. 
To conclude, the synaptic plasticity results observed in both classical HFS-
induced LTP and LTP saturation experiments verified that RTT animal models 
display deficits in both short-term and long-term synaptic plasticity. This adds to 
the prevalent finding of plasticity deficits in various neurodevelopmental 
disorder models, such as Down’s syndrome, Fragile-X syndrome, etc (Yun & 
Trommer, ; Rueda et al., 2010). The exact mechanism underlying the 
synaptopathy of RTT needs to be further addressed to clarify the role MeCP2 
plays in hippocampal neuronal circuits.      145 
6.1.2 Memantine partially improved synaptic plasticity deficits in 
symptomatic Mecp2-stop mice 
Memantine is classified as a weak NMDA receptor antagonist and has been widely 
used for treating Alzheimer’s disease clinically (Rammes et al., 2008). In an 
Alzheimer’s animal model, a previous study reported that Memantine has been 
used successfully to amend aspects of hippocampus-dependent dysfunction 
(Minkeviciene et al., 2004). 
In the results shown in Chapter 5, memantine was applied in the LTP saturation 
experiments at the therapeutic level. The LTP of the WT hippocampus was not 
significantly altered after memantine treatment. In contrast, the LTP of the 
hemizygous symptomatic Mecp2-stop hippocampus was partially restored in the 
LTP saturation experiments. The improvement was significant, particularly after 
the first HFS stimulus and the LTP of symptomatic Mecp2-stop mice showed no 
difference compared to the initial LTP of WT littermates. However, repeated 
HFS stimuli on memantine-treated symptomatic Mecp2-stop brain slices showed 
that only the short-term plasticity was restored. It was difficult to determine the 
mechanism by which memantine ameliorates short-term synaptic plasticity 
deficits by analysis of extracellular recordings; however, this mechanism was 
associated with the pathophysiology of RTT, since the LTP of WT brain slices was 
not altered but only effective on Mecp2-stop brain slices. It will be worth 
assessing whether memantine is beneficial in the heterozygous Mecp2-stop brain, 
since both WT and mutant cells co-exist in the heterozygous brain and the 
genotype is identical to that of human RTT patients.   
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6.1.3 Alterations of cell densities in the somatosensory cortex but 
preserved distribution patterns in the hippocampus in 
symptomatic Mecp2-stop mice 
Previous reports have shown a reduced brain volume in RTT patients (Reiss et al., 
1993). In Mecp2-mutant models, anatomical studies also revealed that brain 
cells had a higher packing rate (Chen et al., 2001; Taneja et al., 2009). Since 
autopsy analyses showed there was no significant apoptosis or necrosis in RTT 
brains (Armstrong, 2005), the higher cell packing rate may originate solely from 
the volume change in RTT brains. In order to confirm this hypothesis, both DAPI- 
and NeuN- positive cell densities were quantified in the somatosensory cortex of 
symptomatic Mecp2-stop and WT mice. The DAPI- and NeuN- positive cell 
densities were elevated in the symptomatic Mecp2-stop brain, and the chi-
square analysis showed no significant difference in the ratios of both DAPI- and 
NeuN- positive cells. This conclusion is in line with previous observations that no 
significant cell death had occurred in a rather smaller RTT brain (Armstrong, 
2005). 
One of the characteristic features of RTT is the development of seizure disorders. 
Previous report showed that an excitatory/inhibitory (E/I) imbalance existed in 
the Mecp2-mutant brains and served as the pathology of seizure disorders in RTT 
(Dani et al., 2005; Zhang et al., 2008; Wood & Shepherd, 2010). The E/I 
imbalance may be due to the dysfunctions of excitatory, inhibitory, or both 
neuronal cell types. Recently, the functional knock-out of MeCP2 selectively in 
inhibitory neurons has been shown to recapitulate most RTT-like symptoms in 
mice, including seizure disorders (Chao et al., 2010). Therefore, the dysfunction 
of inhibitory neurons may directly contribute to the mechanism underling seizure 
disorders in RTT. In mammalian brains, inhibitory cortical neurons can be further 
classified into distinct populations by protein markers, and it was of interest to 
investigate the alteration of different inhibitory neuron subtypes in Mecp2-stop 
brains. In Chapter 4, cell densities of four different inhibitory neuron 
populations (PV, SOM, CR, and CR) were quantified. Since the NeuN-positive 
(neuronal) density was elevated in the Mecp2-stop brain, the raw cell density 
data of each inhibitory neuron subtype was further standardised by the 
Mecp2/WT NeuN correcting factor. The results showed that CR- and SOM-positive 
neuronal densities in symptomatic Mecp2-stop mice were decreased compared     147 
to those of WT mice. However, both PV- and CB-positive cell densities remained 
unchanged in the symptomatic Mecp2-stop brain. This is the first report showing 
the decrease in cell density of specific inhibitory neurons in Mecp2-null animals. 
This decrease may be associated with deficits in the neurogenesis stage or, it 
may be that specific neuronal subtypes were more vulnerable in the 
symptomatic Mecp2-stop brain. This finding indicated that the dysfunction of 
inhibitory neurons in RTT brains may originate directly or indirectly from the 
alteration of specific inhibitory neuron populations. 
Regarding the distribution patterns of distinct neuronal subtypes, I assessed four 
neuronal subtypes (PV, SOM, CR and CB) in the hippocampus in the symptomatic 
Mecp2-stop mice under microscopic examinations, and the results showed a 
grossly similar distribution pattern to that of WT mice. To conclude, the 
distribution patterns of these four neuronal subtypes in the hippocampus of 
symptomatic Mecp2-stop mice were not altered; however, since this work was 
only performed in the hippocampal region, it is not possible to draw any 
conclusion about whether the lack of MeCP2 influences the distribution patterns 
of cortical neuronal subtypes or not. 
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6.2 Significance of this study 
The importance of this investigation is outlined in the following key points. 
1. In my thesis, both short-term and long-term synaptic plasticity were shown in 
“symptomatic” Mecp2-stop mouse brain. The long-term synaptic plasticity 
deficit of “symptomatic” Mecp2-stop mice was in line with previous reports 
demonstrating LTP deficits in Mecp2-mutant mice (Asaka et al., 2006; Moretti et 
al., 2006; Guy et al., 2007). Regarding the short-term plasticity deficit, my 
thesis was the first to report a reduction of both PTP and PPF in “symptomatic” 
Mecp2-mutant mice. 
2. In my thesis, the PTP and LTP deficits were examined both in “symptomatic” 
(age range 12-15wks) and “mild symptomatic” (age range 6-10wks) Mecp2-stop 
mice hippocampi. The LTP deficit was observed in “mild symptomatic” under 
the LTP saturation experimental scheme. The PTP deficit was only shown in 
“symptomatic” group, however, PTP analyses from “mild symptomatic” groups 
showed no significant difference to that of WT littermates, but a decreasing 
trend of PTP amplitude as symptoms progressed. The studies reported here are 
the first to link the symptom score progression to both short-term and long-term 
plasticity deficits in Mecp2-mutant mice. Moreover, it may suggest that subtle 
deficits in synaptic signalling may occur very early in disease pathogenesis but 
may be undetected by classical assays (for example, the one-hour HFS-induced 
LTP assessment). 
3. The Alzheimer’s drug memantine was applied in the current study and my 
thesis was the first to assess the therapeutic potential of memantine on Mecp2-
mutant animal models. The results in Chapter 5 showed that memantine 
partially amended synaptic plasticity deficits, particularly regarding short-term 
plasticity, while the WT littermates were not altered by memantine 
administration. My data also demonstrated that memantine was not beneficial to 
symptom progression or survival in hemizygous Mecp2-stop mice. All the three 
significant findings above have already been published in my recent paper (Weng 
et al., 2011).     149 
4. In the immunohistochemistry experiments on symptomatic Mecp2-stop brains, 
my thesis was the first to identify specific inhibitory neuronal loss in the Mecp2-
mutant brain. Both CR- and SOM-positive cells in the somatosensory cortex had a 
reduced cellular density compared to those of WT littermates. However, this 
was carried out only in a single region of the brain and it may or may not be 
representative.  
5. In my thesis, I examined the distribution patterns of four neuronal populations 
(PV, SOM, CB and CR) in symptomatic Mecp2-stop mice brains, and there was no 
significant difference from that of WT mice. The preserved targeting pattern 
may be directly or indirectly linked to the pathophysiology of RTT.  
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6.3 Technical considerations 
In the immunohistochemistry experiments, the cell density quantification inside 
image stacks was carried out by manual counting. The disector principle (see 
Chapter 2 for details) was applied to avoid overlapped counting. Several types of 
software, such as Image J or Image Pro Plus, have been used in the past for 
automated counting in this study; however, my experience was that manual 
counting was more reliable. The first reason for this is that any one cell can 
exist in adjacent image planes of the image stack. It was difficult to avoid 
repeated counting solely by the parameter adjustment of the software settings. 
The second reason is that manual counting was beneficial in differentiating real 
cells from artefacts by recognising the characteristics of cells. Cells containing 
identical markers may have varying shapes or sizes. It was difficult to set the 
parameters in automated cell counting for discriminating cells and artefacts in 
commercialised software. Therefore, the most reliable method was still manual 
counting, although it was a time-consuming experimental design. The cell 
density results in this thesis were further verified by comparing with previous 
studies quantifying the neuronal cell density in rodent neocortex layer five (Bass 
et al., 1971), and with reports of the percentage of distinct cortical inhibitory 
neuronal subtypes (Wonders & Anderson, 2006). To conclude, manual counting 
was regarded as the most reliable and accurate method in a cell density 
quantification experiment from 3D image stacks.  
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6.4 Future studies 
The results in this thesis have initiated the prelude for a full investigation of 
MeCP2 involvement in modulating synaptic plasticity and regulating inhibitory 
neuron subtype development. These pioneering experiments have laid the 
groundwork for more detailed future studies. Several further experiments 
emerging from this thesis have been highlighted in previous discussion. There are 
many unresolved questions that are worthy of further investigation: 
1. How are the pre-synaptic and post-synaptic deficits related in Mecp2-stop 
models? In Chapter 5, both the short-term and long-term plasticity deficits were 
observed in symptomatic Mecp2-stop mice. Since short-term plasticity is 
generally linked to the pre-synaptic mechanism while the long-term plasticity is 
principally mediated by the post-synaptic mechanism, the conclusion in this 
thesis supported the hypothesis that both short- and long-term plasticity deficits 
co-existed in symptomatic Mecp2-stop brains. The two forms of synaptic 
plasticity deficits showed strong parallelism (Zucker & Regehr, 2002), and it was 
difficult to determine how they are related solely from the extracellular 
recording data. Single-cell recording could be applied to assess the relationship 
between the two forms of synaptic plasticity in the lack of MeCP2. 
2. The memantine treatment in symptomatic Mecp2-stop hippocampi seemed to 
partially restore the synaptic plasticity deficit, particularly in the short-term 
plasticity. When it applied to the WT groups, no obvious alteration was observed. 
The improvement of memantine on short-term plasticity deficits in symptomatic 
Mecp2-stop brain slices may be directly connected to the RTT pathophysiology, 
and this will be worthy for further investigation. Whole cell recording could be 
applied to assess how memantine improves the synaptic plasticity of MeCP2-null 
cells. The answer will provide further information for treating human RTT in 
which both the mutant and WT cells co-exist as a mosaic pattern in the brain, 
and this information will be beneficial for exploring more suitable drugs for 
future treatment of RTT. 
3. In Chapter 4, a decrease in density of calretinin- (CR) and somatostatin- (SOM) 
positive inhibitory neurons was observed in the somatosensory cortex of 
symptomatic hemizygous Mecp2-stop mice. However, further investigation     152 
addressing the underlying mechanism of the decrease of specific neuronal 
subtype in the symptomatic Mecp2-stop brain needs to be assessed to clarify the 
MeCP2 role in the whole neurodevelopment from embryonic to adult stages. In 
addition, it will be essential to investigate the cell density alteration in the 
heterozygous Mecp2-stop mice, in which the genotype is identical to human RTT 
patients, since the answer will provide further understanding of the 
development of inhibitory neurons in RTT patients (this project has already been 
initiated in Dr Stuart Cobb’s lab at the University of Glasgow). 
4. Since the hippocampus laminar structure is well-investigated, it provides an 
excellent platform for assessing the distribution pattern of specific neuronal 
subtypes. However, the distribution pattern could be normal in the hippocampus 
but abnormal in other regions of the symptomatic Mecp2-stop brain. It is worth 
further characterising the distribution patterns of specific neuronal subtypes in 
distinct regions of the symptomatic Mecp2-stop brain. 
5. The phenotype score system of Mecp2-stop mice served as an excellent 
indicator for selecting animals for different experimental use. However, the 
phenotype score system could be further expanded from the original one 
adopted from Guy et al. (Guy et al., 2007), and might provide more subtle 
behavioural information for the interpretation of the role that MeCP2 plays in 
the RTT-like phenotype progression.   
To conclude, it is clear that the current study has commenced a new area of 
research that MeCP2 has an overt action on synaptic plasticity and specific 
neuronal subtype development. Clearly, this research has laid a strong 
foundation for a number of other important questions which are necessary to 
solve in the future for further understanding the role which MeCP2 plays in both 
normal and diseased brains. 153 
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